0001213900-20-021755.txt : 20200813 0001213900-20-021755.hdr.sgml : 20200813 20200813090038 ACCESSION NUMBER: 0001213900-20-021755 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200813 DATE AS OF CHANGE: 20200813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: My Size, Inc. CENTRAL INDEX KEY: 0001211805 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37370 FILM NUMBER: 201097437 BUSINESS ADDRESS: STREET 1: HAYARDEN 4 CITY: AIRPORT CITY STATE: L3 ZIP: 7010000 BUSINESS PHONE: 972-36009030 MAIL ADDRESS: STREET 1: HAYARDEN 4 CITY: AIRPORT CITY STATE: L3 ZIP: 7010000 FORMER COMPANY: FORMER CONFORMED NAME: Mysize Inc. DATE OF NAME CHANGE: 20150317 FORMER COMPANY: FORMER CONFORMED NAME: TOPSPIN MEDICAL INC DATE OF NAME CHANGE: 20021226 10-Q 1 f10q0620_mysizeinc.htm QUARTERLY REPORT

U. S. Securities and Exchange Commission

Washington, D. C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File No. 001-37370

MY SIZE, INC.

(Exact name of registrant as specified in its charter)

Delaware		51-0394637
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer I.D. No.)

HaYarden 4, POB 1026, Airport City, Israel, 7010000

(Address of principal executive offices)

+972-3-600-9030

Registrant’s telephone number, including area code:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		MYSZ		Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: as of August 4, 2020, 7,232,836 shares of common stock, par value $0.001 per share were issued and outstanding.

MY SIZE, INC.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED June 30, 2020

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION		1

Item 1.	Condensed Consolidated Interim Financial Statements (Unaudited)	1
	Condensed Consolidated Interim Balance Sheets	3
	Condensed Consolidated Interim Statements of Comprehensive Loss	4
	Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity	5
	Condensed Consolidated Interim Statements of Cash Flows	6
	Notes to Condensed Consolidated Interim Financial Statements	7
Item 2.	Management’s Discussion & Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	26
Item 4.	Controls and Procedures	26

PART II - OTHER INFORMATION		27

Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.	Defaults Upon Senior Securities	27
Item 4.	Mine Safety Disclosures	27
Item 5	Other information	27
Item 6.	Exhibits	28

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements.

My Size Inc. and Subsidiaries

Condensed Consolidated

Interim

Financial Statements

As of June 30, 2020

(unaudited)

U.S. Dollars in Thousands

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Financial Statements as of June 30, 2020 (Unaudited)

Contents

		Page

Condensed Consolidated Interim Balance Sheets		3

Condensed Consolidated Interim Statements of Comprehensive Loss		4

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity		5

Condensed Consolidated Interim Statements of Cash flows		6

Notes to Condensed Consolidated Interim Financial Statements		7-13

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Balance Sheets

U.S. dollars in thousands (except share data and per share data)

	June 30,			December 31,
	2020			2019
	(Unaudited)			(Audited)
Assets
Current Assets:
Cash and cash equivalents		4,549			1,203
Restricted cash		93			263
Restricted deposits		182			-
Accounts receivable		27			38
Other receivables and prepaid expenses		274			321
Total current assets		5,125			1,825

Property and equipment, net		128			141
Right-of-use assets		921			966
Investment in marketable securities		41			26
Total non-current assets		1,090			1,133

Total assets		6,215			2,958

Liabilities and stockholders’ equity

Current liabilities:
Operating lease liability		115			102
Trade payables		348			440
Accounts payable		361			378
Warrants and derivatives		-			328
Total current liabilities		824			1,248

Operating lease liabilities		598			659
Total non-current liabilities		598			659

Total liabilities		1,422			1,907

COMMITMENTS AND CONTINGENCIES

Stockholders’ equity:
Stock Capital -
Common stock of $ 0.001 par value - Authorized: 100,000,000 shares; Issued and outstanding: 7,157,836 and 2,085,900 as of June 30, 2020 and December 31, 2019, respectively		7			2
Additional paid-in capital		36,599			30,102
Accumulated other comprehensive loss		(536	)		(539	)
Accumulated deficit		(31,277	)		(28,514	)
Total stockholders’ equity		4,793			1,051
Total liabilities and stockholders’ equity		6,215			2,958

The accompanying notes are an integral part of the condensed consolidated interim financial statements.

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Statements of Comprehensive Loss

U.S. dollars in thousands (except share data and per share data)

	Six-Months Ended June 30,						Three-Months Ended June 30,
	2020			2019			2020			2019
	$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)			$ thousands (Unaudited)

Revenues		51			25			21			5
Cost of revenues		(1	)		(1	)		-			-
Gross profit		50			24			21			5

Operating expenses
Research and development		(688	)		(671	)		(340	)		(379	)
Sales and marketing		(1,077	)		(861	)		(452	)		(479	)
General and administrative		(1,078	)		(1,318	)		(562	)		(710	)

Total operating expenses		(2,843	)		(2,850	)		(1,354	)		(1,568	)
Operating loss		(2,793	)		(2,826	)		(1,333	)		(1,563	)
Financial income (expenses), net		30			(67	)		29			197
Net loss		(2,763	)		(2,893	)		(1,304	)		(1,366	)

Other comprehensive income (loss):

Foreign currency translation differences		3			234			4			70

Total comprehensive income (loss)		(2,760	)		(2,659	)		(1,300	)		(1,296	)

Basic and diluted loss per share		(0.72	)		(1.5	)		(0.25	)		(0.75	)
Basic and diluted weighted average number of shares outstanding		3,835,651			1,991,161			5,166,772			1,992,151

The accompanying notes are an integral part of the interim condensed consolidated financial statements

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity

U.S. dollars in thousands (except share data and per share data)

	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Number		Amount		capital		loss			deficit			equity

Balance as of January 1, 2020		2,085,900		2		30,102		(539	)		(28,514	)		1,051

Stock-based compensation related to options granted to employees and consultants		-		-		163		-			-			163
Issuance of shares, net of issuance cost of $1,160		2,439,802		3		5,992		-			-			5,995
Exercise of warrants and pre funded warrants		2,632,134		2		14								16
Liability reclassified to equity (*)		-		-		328		-			-			328
Total comprehensive loss		-		-		-		3			(2,763	)		(2,760	)
Balance as of June 30, 2020		7,157,836		7		36,599		(536	)		(31,277	)		4,793

(*)

See note 2 c.

	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Number		Amount		capital		loss			deficit			equity

Balance as of January 1, 2019		1,990,159		2		29,144		(835	)		(23,017	)		5,294

Stock-based compensation related to options granted to employees and consultants		-		-		374		-			-			374
Issuance of shares to consultants		2,084		(**)		48		-			-			48
Total comprehensive loss		-		-		-		234			(2,893	)		(2,659	)
Balance as of June 30, 2019		1,992,243		2		29,566		(601	)		(25,910	)		3,057

(**)

Represents an amount less than $1

	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Number		Amount		capital		loss			deficit			equity

Balance as of April 1, 2020		2,600,701		3		32,193		(540	)		(29,973	)		1,683

Stock-based compensation related to options granted to employees and consultants		-		-		93		-			-			93
Issuance of shares, net of issuance cost of $848		1,925,001		2		4,299		-			-			4,301
Exercise of warrants and pre funded warrants		2,632,134		2		14		-			-			16
Total comprehensive loss		-		-		-		4			(1,304	)		(1,300	)
Balance as of June 30, 2020		7,157,836		7		36,599		(536	)		(31,277	)		4,793

	Common stock				Additional paid-in		Accumulated other comprehensive			Accumulated			Total stockholders’
	Number		Amount		capital		loss			deficit			equity

Balance as of April 1, 2019		1,990,159		2		29,244		(671	)		(24,544	)		4,031

Stock-based compensation related to options granted to employees and consultants		-		-		274		-			-			274
Issuance of shares to consultants		2,084		(**)		48								48
Total comprehensive loss		-		-		-		70			(1,366	)		(1,296	)
Balance as of June 30, 2019		1,992,243		2		29,566		(601	)		(25,910	)		3,057

(**)

Represents an amount less than $1

The accompanying notes are an integral part of the interim condensed consolidated financial statements

MY SIZE, INC. AND ITS SUBSIDIARIES

Condensed Consolidated Interim Statements of Cash Flows

U.S. dollars in thousands

	Six-Months Ended June 30,
	2020			2019
	(Unaudited)			(Unaudited)
Cash flows from operating activities:
Net loss		(2,763	)		(2,893	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		19			13
Amortization of operating lease right-of-use asset		21			-
Revaluation of warrants and derivatives		(19	)		(269	)
Interest and revaluation of short-term deposit		-			54
Interest received from short-term deposit		-			16
Revaluation of investment in marketable securities		(15	)		104
Stock based compensation		163			422
Decrease in accounts receivables		11			-
Decrease in other receivables and prepaid expenses		64			127
Decrease in trade payable		(90	)		(89	)
(Decrease) increase in accounts payable		(16	)		91

Net cash used in operating activities		(2,625	)		(2,424	)

Cash flows from investing activities:

Proceeds from short-term deposits		-			1,200
(Investing in) proceeds from restricted deposits		(170	)		181
Investment in right-of-use asset		(25	)		-
Purchase of property and equipment		(5	)		(15	)

Net cash provided by (used in) investing activities		(200	)		1,366

Cash flows from financing activities:
Proceeds from issuance of shares and pre-funded warrants, net of issuance costs		6,011			-

Net cash provided by financing activities		6,011			-

Effect of exchange rate fluctuations on cash and cash equivalents		(10	)		240

Increase in cash, cash equivalents and restricted cash		3,176			(818	)
Cash, cash equivalents and restricted cash at the beginning of the period		1,466			5,230

Cash, cash equivalents and restricted cash at the end of the period		4,642			4,412

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 1 - General

My Size, Inc. is developing unique measurement technologies based on algorithms with applications in a variety of areas, from the apparel e-commerce market, to the courier services market and to the Do It Yourself smartphone and tablet apps market. The technology is driven by proprietary algorithms which are able to calculate and record measurements in a variety of novel ways.

The Company has three subsidiaries, My Size Israel 2014 Ltd. and Topspin Medical (Israel) Ltd., both of which are incorporated in Israel and My Size LLC which was incorporated in Russian Federation. References to the Company include the subsidiaries unless the context indicates otherwise.

During the six month period ended June 30, 2020, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $31,277. The Company has financed its operations mainly through fundraising from various investors.

The Company’s management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2020, management is of the opinion that its existing cash will be sufficient to fund operations until the end of the second quarter of 2021. As a result, there is substantial doubt about the Company’s ability to continue as a going concern.

Management’s plans include the continued commercialization of the Company’s products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

Note 2 - Significant Accounting Policies

Unaudited condensed consolidated financial statements:

The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2020.

These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2019.

Use of estimates:

The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 2 - Significant Accounting Policies (cont’d)

Functional currency:

The Company reassessed its functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency was accounted for prospectively from that date. In 2019, the Company went through a strategic shift which involved a significant change in its business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, the Company acted as a platform to fund its operational subsidiary, My Size Israel, which conducts its research and development activities in NIS. Accordingly, the Company has not been substantially focused on its operating activities for that period. By the end of 2018, the Company transitioned to a new business model (B2B2C) and concluded that the main market that the Company should focus on would be the apparel market in the US. Consequently, the Company established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, the Company itself hired sales personnel which are based in the US and signed agreements with customers for which it began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, the Company is no longer considered a ‘holding company’ for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, the management of the Company has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of the Company's operations is the U.S. dollar.

My Size Israel functional currency remains the NIS.

As a result of the change in the Company’s functional currency, the Company reclassified its warrants that were outstanding as a financial liability in an amount of $328 as at December 31, 2019 to equity.

Reclassification:

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 3 - Financial Instruments

Fair value of financial instruments:

Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company’s own credit risk.

In accordance with ASC 820 when measuring the fair value, an entity shall take into account the characteristics of the asset or liability if a market participant would take those characteristics into account when pricing the asset or liability at the measurement date. Such characteristics include, for example:

The condition and location of the asset.

Restrictions, if any, on the sale or the use of the asset.

As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

	Level 1 -	Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

	Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

	Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.

The carrying amounts of cash and cash equivalents, accounts receivable, other receivables, trade payables and accounts payable approximate their fair value due to the short-term maturities of such instruments.

The Company holds share certificates in iMine Corporation (“iMine”) formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB.

Due to sales restrictions on the sale of the iMine share, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 assets.

June 30, 2020

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 3 - Financial Instruments (Cont.)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Warrants and derivatives

328

(*)

For the six and three month periods ended June 30, 2020 and 2019, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $15 and $3, and $104 and $(425), respectively.

Note 4 - Stock Based Compensation

The stock-based expense- equity awards recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table:

	Six months ended June 30,				Three months ended June 30,
	2020		2019		2020		2019

Stock-based compensation expense - Research and development		51		92		31		84
Stock-based compensation expense - Sales and marketing		46		155		24		118
Stock-based compensation expense - General and administrative		66		175		38		120
		163		422		93		322

Options issued to consultants:

During the six month period ended June 30, 2020, the Company granted 13,500 options to consultants. No such options were exercised and 8,338 options expired.

The total stock option compensation expense during the six and three month period ended June 30, 2020 and 2019 which was recorded under sales and marketing was $5, $1, $59 and $6 respectively and under general and administrative was $12, $6, $55 and $27, respectively.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 4 - Stock Based Compensation (Cont.)

Warrants issued to consultants:

On January 15, 2020, the Company conducted a registered direct offering pursuant to which it issued 514,801 shares of its common stock and in a concurrent private placement issued warrants to purchase up to 514,801 shares of common stock at an exercise price of $3.76 per share for gross proceeds of $2,000. The term of the warrants are five and a half years. The Company received net proceeds of $1,694 after deducting placement agent fees and other offering expenses.

The warrants were measured at fair value of $52.

On May 8, 2020 the Company completed a public offering of (i) 1,925,001 units, each unit consisting of one share of common stock, and one warrant to purchase one share of common stock at a price of $1.10, and (ii) 2,620,453 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock and one warrant, at a price of $1.099 per pre-funded unit. The net proceeds to the Company from the offering were approximately $4.3 million, after deducting placement agent’s fees and other offering expenses payable by the Company.

The warrants to purchase an aggregate of 4,545,454 shares of common stock are immediately exercisable and may be exercised at a consideration of $1.10 per share. The term of the warrants are five and a half years. Pre-funded warrants were immediately exercisable and were exercisable at a nominal consideration of $0.001 per share. During May, 2020, the pre-funded warrants were exercised in full and therefore are no longer outstanding.

The warrants were measured at fair value of $160.

Pursuant to the anti-dilution adjustment provisions in outstanding warrants to purchase 144,277 shares of common stock, the per share exercise price was reduced to $0.9289, following the issuance of the securities in the public offering.

Further to Note 11a of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019:

In March 2020, warrants to purchase up to 66,667 shares of common stock of the Company that were not exercised expired.

Stock Option Plan for Employees:

In March 2017, the Company adopted a stock option plan (the “Plan”) pursuant to which the Company’s Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, is limited to 200,000 options. Stock options can be granted with an exercise price equal to or less than the stock’s fair market value at the grant date. . In August 2020, the Company’s shareholders approved an increase in the number of shares available for issuance under the Plan to 1,450,000 (see note 7 below).

On May 25, 2020, the Compensation Committee of the Board of Directors of the Company reduced the exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company’s common stock on May 22, 2020, and extended the term of foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during both the six and three months ended June 30, 2020 were $43.

During the six and three month period ended June 30, 2020, there were no grants of stock options under the Plan, no such options were exercised and options to purchase 22,000 and 21,667 shares of common stock expired, respectively. In August 2020, the Company granted options to purchase an aggregate of up to 917,000 shares of common stock to directors, officers and employees of the Company (see note 7 below).

The total stock option compensation expense during the six and three month period ended June 30, 2020 and 2019 which was recorded was $103 and $42, and $311 and $294, respectively.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 5 - Contingencies and Commitments

On August 7, 2018, the Company commenced an action against North Empire LLC (“North Empire”) in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the “Agreement”) in which it is seeking damages in an amount to be determined at trial, but in no event less than $616,000. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims.

The Company believes it is more likely than not that the counterclaims will be denied.

Further to Note 13b of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019:

On January 22, 2019, the Company was notified by the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

The Company did not regain compliance with the Rule by July 22, 2019 and, as a result, on July 23, 2019, the Company received notice from the Staff that, based upon the Company’s continued non-compliance with the Rule, the Staff had determined to delist the Company’s common stock from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The hearing occurred on September 19, 2019.

On October 1, 2019, the Panel granted the Company’s request for continued listing of the Company’s common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company’s stockholders, discretionary authority was granted to the Company’s board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty.

On November 19, 2019, the Company received formal notice from Nasdaq that the Company’s non-compliance with the minimum $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), as of September 30, 2019, could serve as an additional basis for delisting.

On February 7, 2020, the Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company’s request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders’ equity requirement.

On May 12, 2020, the Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the Stockholders’ Equity Rule. Accordingly, the Panel has determined to continue the listing of the Company’s securities on the Nasdaq Stock Market and is closing this matter.

MY SIZE, INC. AND ITS SUBSIDIARIES

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

U.S. dollars in thousands (except share data and per share data)

Note 6 - Significant Events During the Reporting Period

On January 15, 2020, the Company conducted a public offering of its securities pursuant to which it issued 514,801 shares of its common stock and warrants to purchase up to 514,801 shares of common stock at an exercise price of $3.76 per share for gross proceeds of $2,000. The term of the warrants are five and a half years. The Company received net proceeds of $1,694 after deducting placement agent fees and other offering expenses.

On May 8, 2020, the Company conducted a public offering of its securities pursuant to which it issued 1,925,001 shares of its common stock, pre funded warrants to purchase up to 2,620,453 shares of common stock at an exercise price of $0.001 per share and five-year warrants to purchase up to 4,545,454 shares of common stock at an exercise price of $1.10 per share for gross proceeds of $5,000. The net proceeds to the Company from the offering were approximately $4,300, after deducting placement agent’s fees and other offering expenses payable by the Company. In addition, the Company issued to the placement agent five-year placement agent warrants to purchase 272,727 shares of common stock at an exercise price of $1.375 per share.

In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to several other countries, including Israel, and infections have been reported globally. Many countries around the world, including in Israel, have significant governmental measures being implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. These measures have resulted in work stoppages and other disruptions. The Company has implemented remote working and work place protocols for its employees in accordance with government requirements. In addition, while the Company has seen an increased demand for MySizeID, certain marketing and sales activities have been adversely affected by the coronavirus outbreak. For example, the Company has three ongoing pilots with international retailers that have been halted, the Company is unable to participate physically in industry conferences and its ability to meet with potential customers is limited. The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could materially adversely impact the Company’s operations and workforce, including its marketing and sales activities and ability to raise additional capital, which in turn could have a material adverse impact on the Company’s business, financial condition and results of operation.

Note 7 – Events Subsequent To The Reporting Period

On August 10, 2020, the Company’s shareholders approved an increase in the shares available for issuance under the Plan from 200,000 to 1,450,000 shares.

As a result and pursuant to approval of the Company’s compensation committee that was contingent on the foregoing shareholder approval, the following occurred on August 10, 2020: (i) the number of shares available for issuance under the Company’s 2017 Consultant Incentive Plan reduced from 466,667 to 216,667 shares: (ii) the Company to the Company’s Chief Executive Officer (A) five-year options to purchase up to 160,000 ordinary shares at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022, and (B) 80,000 performance-based restricted stock units, each representing the right to receive one share of common stock, which vest (x) upon the Company generating revenue of at least $50,000 in the Russian Federation during the year ending 2020, or (y) upon the Company generating revenue of at least $500,000 in the Russian Federation during the year ending 2021; (iii) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company’s Chief Financial Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (iv) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company’s Chief Operating Officer and Chief Product Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (v) the Company granted five-year options to purchase up to 325,893 ordinary shares to other employees of the Company at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; and (vi) the Company granted five-year options to purchase up to 30,000 ordinary shares to each of the Company’s non-employee board members at an exercise price of $1.04 per share. These options vest on November 26, 2020.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our condensed consolidated interim financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 19, 2020, or the Annual Report, including the consolidated annual financial statements as of December 31, 2019 and their accompanying notes included therein.

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout this Quarterly Report on Form 10-Q. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to:

●

our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;

●

our ability to continue as a going concern;

●

risks related to the outbreak of coronavirus;

●

the new and unproven nature of the measurement technology markets;

●

our ability to achieve customer adoption of our products;

●

our dependence on assets we purchased from a related party and the risk that such assets may in the future be repurchased;

●

our ability to enhance our brand and increase market awareness;

●

our ability to introduce new products and continually enhance our product offerings;

●

the success of our strategic relationships with third parties;

●

information technology system failures or breaches of our network security;

●

competition from competitors;

●

our reliance on key members of our management team;

●

current or future litigation;

●

the impact of the political and security situation in Israel on our business; and

●

our ability to remain listed on the Nasdaq Capital Market.

The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to the Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors referred to on page 12 of our Annual Report, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

Unless the context otherwise requires, all references to “we,” “us,” “our” or “the Company” in this Quarterly Report on Form 10-Q are to My Size, Inc. a Delaware corporation, and its subsidiaries, including MySize Israel 2014 Ltd. taken as a whole.

Overview

We are a creator of mobile device measurement solutions that has developed innovative solutions designed to address shortcomings in multiple verticals, including the e-commerce fashion/apparel, shipping/parcel and do it yourself, or DIY, industries. Utilizing our sophisticated algorithms within our proprietary technology, we can calculate and record measurements in a variety of novel ways, and most importantly, increase revenue for businesses across the globe.

Our solutions can be utilized to accurately take measurements of a variety of items via a mobile device. By downloading the application to a smartphone, the user is then able to run the mobile device over the surface of an item the user wishes to measure. The information is then automatically sent to a cloud-based server where the dimensions are calculated through our proprietary algorithms, and the accurate measurements (+ or - 2 centimeters) are then sent back to the user’s mobile device. We believe that the commercial applications for this technology are significant in many areas.

Currently, we are mainly focusing on the e-commerce fashion/apparel industry. In addition, our solutions address the shipping/parcel and DIY uses markets.

We are in the commercialization phase of our products, although we have only generated minimal revenues to date. MySizeID has been incorporated into a number of major retailers including DeMoulin, U.S. Polo Assn., Slam and Refrigiwear, and MySizeID is also available on leading e-commerce websites including WooCommerce, Shopify and Lightspeed. In recent months, we announced an increase in online apparel sales and reduction in returns of online orders of Penti customers utilizing MySizeID; we reported that in June 2020 that we generated over 1.2 million size recommendations; we opened a subsidiary in Russia; two French retail brands, La Pièce and Habillez-moi, are integrating MySizeID into their e-commerce websites; we integrated MySizeID into Sweet Fit, a virtual fitting mirror; we received a notice of allowance from the USPTO for our patent application, titled: “A system for and a method of measuring a path length using a handheld electronic device”; we hired two new sales executives in France; we developed a contactless shopping feature for the MySizeID application; we released the new OneClick feature for the BoxSize application; and we received a notice of allowance from the Russian Patent & Trademark Office for our patent application, titled: “A system for and a method of measuring a path length using a handheld electronic device.”

While we rollout our products to major retailers and apparel companies, there is a lead time for new customers to ramp up before we can recognize revenue. This lead time varies between customers, especially when the customer is a tier 1 retailer, where the integration process may take longer. Generally, first we integrate our product into a customer’s online platform, which is followed by piloting and implementation, and, assuming we are successful, commercial roll-out, all of which takes time before we expect it to impact our financial results in a meaningful way. While we have begun generating initial sales revenue, we do not expect to generate meaningful revenue during the upcoming quarters. In addition, the coronavirus outbreak has resulted in work stoppages and disruptions and our marketing and sales activities have been adversely affected. For example, we have three ongoing pilots with international retailers that have been halted, we are unable to participate in industry conferences and our ability to meet with potential customers is limited. Because of the numerous risks and uncertainties associated with the coronavirus outbreak, the success of our market penetration and our dependence on the extent to which MySizeID is adopted and utilized, we are unable to predict the extent to which we will recognize revenue. We may be unable to successfully develop or market any of our current or proposed products or technologies, those products or technologies may not generate any revenues, and any revenues generated may not be sufficient for us to become profitable or thereafter maintain profitability.

We recently entered into a non-binding letter of intent with Logystico LLC, or Logystico, a third party logistics fulfillment company that specializes in automating the order fulfillment process, to form a joint venture. Under the terms of the letter of intent, the joint venture will exclusively operate and manage micro-fulfilment centers using our BoxSize platform for retail vendors in the United States and we will initially have a 68% stake and Logystico will initially have a 32% stake in the joint venture entity. Establishment of the joint venture is subject to the entry into a definitive binding agreement.

Important Information about COVID-19

In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to Israel and the United States, and infections have been reported globally. Many countries around the world, including in Israel, have significant governmental measures implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. These measures have resulted in work stoppages and other disruptions. We implemented remote working and work place protocols for our employees in accordance with Israeli government requirements. In addition, while we have seen an increased demand for MySizeID, certain marketing and sales activities have been adversely affected by the coronavirus outbreak. For example, we have three ongoing pilots with international retailers that have been halted, we are unable to participate physically in industry conferences and our ability to meet with potential customers is limited. The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could have a material adverse impact on our operations and workforce, including our marketing and sales activities and ability to raise additional capital, which in turn could have a material adverse impact on our business, financial condition and results of operation.

May 2020 Public Offering

On May 8, 2020, we completed a public offering of (i) 1,925,001 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a price of $1.10, and (ii) 2,620,453 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock and one warrant, at a price of $1.099 per pre-funded unit. In connection with the public offering, we issued warrants to purchase an aggregate of 4,545,454 shares of common stock. The warrants have an exercise price of $1.10 per share of common stock, are exercisable upon issuance and will expire five years from the date of issuance. The exercise price of the warrants is subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in the warrants.

The pre-funded warrants were immediately exercisable and was exercisable at a nominal consideration of $0.001 per share of common stock any time until all of the pre-funded warrants are exercised in full. During May 2020, all pre-funded warrants were exercised. A holder will not have the right to exercise any portion of the warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in such percentage shall not be effective until 61 days after such notice.

The net proceeds from the public offering were approximately $4.3 million, after deducting placement agent’s fees and other estimated offering expenses payable by us.

In connection with the public offering, we paid the placement agent a fees and expenses of $517,900 and issued to the placement agent’s designees placement agent warrants to purchase up to 272,727 shares of common stock. The placement agent warrants are substantially the same terms as the warrants, except they have an exercise price equal to 125% of the per share purchase price, or $1.375 per share, and expire on the five year anniversary of the effective date of the registration statement.

Nasdaq Continued Listing Deficiency

On January 22, 2019, we were notified by the Nasdaq Stock Market, LLC, or Nasdaq, that we were not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that we had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. We did not regain compliance with the Rule by July 22, 2019, and, as a result, on July 23, 2019, we received notice from the Staff that, based upon our continued non-compliance with the Rule, the Staff had determined to delist our common stock from Nasdaq unless we timely request a hearing before the Nasdaq Hearings Panel, or the Panel.

On October 1, 2019, the Panel granted our request to continue the listing of our common stock on the Nasdaq Capital Market, subject to our satisfaction of certain conditions including, among other things, compliance with the minimum $1.00 bid price requirement by no later than January 20, 2020. In order to satisfy the minimum $1.00 bid price requirement and to make our common stock more attractive to certain institutional investors and thereby strengthen our investor base, we implemented a 1-for-15 reverse stock split of our outstanding shares of common stock. The reverse stock split was effective for Nasdaq Capital Market purposes at the open of business on November 19, 2019. Additionally, on November 19, 2019, we received formal notice from Nasdaq of our non-compliance with the minimum $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1). In accordance with the Nasdaq Listing Rules, we subsequently presented our plan to regain compliance with the stockholders’ equity rule for the Panel’s consideration. On February 7, 2020, we received a notification from the Staff that the Panel granted our request for continued listing on the Nasdaq Stock Market until May 18, 2020. On May 12, 2020, we received written notice from Nasdaq informing us that we have regained compliance with the continued listing requirements under the stockholders’ equity rule, and this matter is now closed.

Reverse Stock Split

We implemented a 1-for-15 reverse stock split of our outstanding shares of common stock that was effective for Nasdaq Capital Market purposes at the open of business on November 19, 2019. All share and related option and warrant information presented in this prospectus supplement have been retroactively adjusted to reflect the reduced number of shares and the increase in the share price which resulted from this action.

Results of Operations

The table below provides our results of operations for the periods indicated.

	Three months ended June 30						Six months ended June 30
	2020			2019			2020			2019
	(dollars in thousands)						(dollars in thousands)
Revenues	$	21		$	5		$	51		$	25
Cost of revenues		-			-			(1	)		(1	)
Gross profit		21			5			50			24
Research and development expenses		(340	)		(379	)		(688	)		(671	)

Sales and marketing		(452	)		(479	)		(1,077	)		(861	)
General and administrative		(562	)		(710	)		(1,078	)		(1,318	)
Operating loss		(1,333	)		(1,563	)		(2,793	)		(2,826	)
Financial income (expenses), net		29			197			30			(67	)
Net loss	$	(1,304	)	$	(1,366	)	$	(2,763	)	$	(2,893	)

Six and Three Months Ended June 30, 2020 Compared to Six and Three Months Ended June 30, 2019

Revenues

From inception through December 31, 2018, we did not generate any revenue from operations and we continue to expect to incur additional losses to increase our sales and marketing efforts and to perform further research and development activities. We started to generate revenues only in 2019. Our revenues for the six months ended June 30, 2020 amounted to $51,000 compared to $25,000 for the six months ended June 30, 2019.

Our revenues for the three months ended June 30, 2020 amounted to $21,000 compared to $5,000 for the three months ended June 30, 2019. The increase from both the six and three month corresponding period primarily resulted from increase in traffic, as measured by the MySizeID engine per the license agreements.

Research and Development Expenses

Our research and development expenses for the six months ended June 30, 2020 amounted to $688,000 compared to $671,000 for the six months ended June 30, 2019. The increase from the corresponding period primarily resulted from the hiring of new employees offset by expenses associated with share-based payments to our employees.

Our research and development expenses for the three months ended June 30, 2020 amounted to $340,000 compared to $379,000 for the three months ended June 30, 2019. The decrease from the corresponding period primarily resulted from decrease in expenses associated with share-based payments to our employees.

Sales and Marketing Expenses

Our sales and marketing expenses for the six months ended June 30, 2020 amounted to $1,077,000 compared to $861,000 for the six months ended June 30, 2019. The increase in comparison with the corresponding period was mainly due to an increase in payments to marketing consultants and hiring new sales consultants.

Our sales and marketing expenses for the three months ended June 30, 2020 amounted to $452,000 compared to $479,000 for the three months ended June 30, 2019. The decrease in comparison with the corresponding period was mainly due to a decrease in shared based payments and in travel expenses offset by an increase in payments to consultants and hiring new sales consultants and increase in marketing.

General and Administrative Expenses

Our general and administrative expenses for the six months ended June 30, 2020 amounted to $1,078,000 compared to $1,318,000 for the six months ended June 30, 2019. The decrease in comparison with the corresponding period was mainly due to a decrease in payroll expenses and share-based payments offset by an increase in insurance expenses.

Our general and administrative expenses for the three months ended June 30, 2020 amounted to $562,000 compared to $710,000 for the three months ended June 30, 2019. The decrease in comparison with the corresponding period was mainly due to a decrease in payroll expenses and share-based payments offset by an increase in insurance expenses.

Operating Loss

As a result of the foregoing, for the six months ended June 30, 2020, our operating loss was $2,793,000, a decrease of $33,000, or 1%, compared to our operating loss for the six months ended June 30, 2019 of $2,826,000.

As a result of the foregoing, for the three months ended June 30, 2020, our operating loss was $1,333,000, a decrease of $230,000, or 15%, compared to our operating loss for the three months ended June 30, 2019 of $1,563,000.

Financial Income (Expenses), Net

Our financial income, net for the six months ended June 30, 2020 amounted to $30,000 as opposed to financial expenses of $67,000 for the six months ended June 30, 2019. During the six months ended June 30, 2020, we had financial income mainly from hedging activities and revaluation of investment in marketable securities whereas in the corresponding period we had financial expenses of $67,000 primarily due to exchange rate differences and revaluation of warrants.

Our financial income, net for the three months ended June 30, 2020 amounted to $29,000 compared to financial income of $197,000 for the three months ended June 30, 2019. During the three months ended June 30, 2020, we had financial income mainly from hedging activities whereas in the corresponding period we had financial income primarily due to the revaluation of warrants and revaluation of investment in marketable securities.

Net Loss

As a result of the foregoing research and development, sales and marketing, general and administrative expenses initial revenues, and financial expenses, our net loss for the six months ended June 30, 2020 was $2,763,000, compared to net loss of $2,893,000 for the six months ended June 30, 2019, the decrease in the net loss was mainly due to the reasons mentioned above.

As a result of the foregoing research and development, sales and marketing, general and administrative expenses initial revenues, and financial expenses, our net loss for the three months ended June 30, 2020 was $1,304,000, compared to net loss of $1,366,000 for the three months ended June 30, 2019, the decrease in the net loss was mainly due to the reasons mentioned above.

Liquidity and Capital Resources

Since our inception, we have funded our operations primarily through public and private offerings of debt and equity in the State of Israel and in the U.S.

As of June 30, 2020, we had cash, cash equivalents, restricted cash and restricted deposits of $4,824,000 compared to $1,466,000 of cash, cash equivalents and restricted cash as of December 31, 2019. This increase primarily resulted from the registered direct offering and concurrent private placement resulting in net proceeds of $1,694,000 that was conducted in January 2020 and a public offering that resulted in net proceeds of $4,300,000 that was conducted in May 2020 offset by our operating activities.

On September 13, 2019, we entered into an At the Market Offering Agreement with H.C Wainwright, LLC or Wainwright. According to the agreement, we may offer and sell, from time to time, our shares of common stock having an aggregate offering price of up to $5.5 million through Wainwright or the ATM Prospectus Supplement. From September 13, 2019 until January 15, 2020, we issued 87,756 shares of common stock at an average price of $4.77 per share through the ATM Prospectus Supplement, resulting in net proceeds of $418,524. We paid a commission equal to 3% of the gross proceeds from the sale of our shares of common stock under the ATM Prospectus Supplement. On January 15, 2020, we terminated the ATM Prospectus Supplement, but the offering agreement remains in full force and effect.

Cash used in operating activities amounted to $2,625,000 for the six months ended June 30, 2020, compared to $2,424,000 for the six months ended June 30, 2019. The increase in cash used in operating activities was mainly due to stock based compensation offset by revaluation of warrants and derivatives.

Net cash provided by investing activities was $200,000 for the six months ended June 30, 2020, compared to cash used in investing activities of $1,366,000 for the six months ended June 30, 2019. The change from the corresponding period was mainly due to increase in restricted deposits compared with proceeds from restricted deposits and from short term deposits in the corresponding period.

Net cash provided by financing activities was $6,011,000 for the six months ended June 30, 2020, compared to none for the six months ended June 30, 2019. The cash flow from financing activities for the six months ended June 30, 2020 resulted from the registered direct offering and concurrent private placement of our securities in January 2020 and the public offering of our securities in May 2020.

We do not have any material commitments for capital expenditures during the next twelve months.

We expect to continue to generate losses and negative cash flows from operations for the foreseeable future and expect to need to obtain additional funds in the future. Based on the projected cash flows and cash balances as of June 30, 2020, management is of the opinion that our existing cash will be sufficient to fund operations until the end of second quarter 2021. As a result, there is substantial doubt about the Company’s ability to continue as a going concern. However, we will need to raise additional capital, which may not be available on reasonable terms or at all. Additional capital would be used to accomplish the following:

●

finance our current operating expenses;

●

pursue growth opportunities;

●

hire and retain qualified management and key employees;

●

respond to competitive pressures;

●

comply with regulatory requirements; and

●

maintain compliance with applicable laws and exchange rules.

Current conditions in the capital markets are such that traditional sources of capital may not be available to us when needed or may be available only on unfavorable terms. Our ability to raise additional capital, if needed, will depend on conditions in the capital markets, the coronavirus outbreak, economic conditions and a number of other factors, many of which are outside our control, and on our financial performance. Accordingly, we cannot assure you that we will be able to successfully raise additional capital at all or on terms that are acceptable to us. If we cannot raise additional capital when needed, it may have a material adverse effect on our business, results of operations and financial condition.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of such securities could result in substantial dilution for our current stockholders. The terms of any securities issued by us in future capital transactions may be more favorable to new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then-outstanding. We may issue additional shares of our common stock or securities convertible into or exchangeable or exercisable for our common stock in connection with hiring or retaining personnel, option or warrant exercises, future acquisitions or future placements of our securities for capital-raising or other business purposes. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline and existing stockholders may not agree with our financing plans or the terms of such financings. In addition, we may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition. Furthermore, any additional debt or equity financing that we may need may not be available on terms favorable to us, or at all. If we are unable to obtain such additional financing on a timely basis, we may have to curtail our development activities and growth plans and/or be forced to sell assets, perhaps on unfavorable terms, or we may have to cease our operations, which would have a material adverse effect on our business, results of operations and financial condition.

Off-Balance Sheet Arrangements

We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.

Functional Currency

We reassessed our functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency was accounted for prospectively from that date. In 2019, we went through a strategic shift which involved a significant change in our business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, we acted as a platform to fund our operational subsidiary, My Size Israel, which conducts our research and development activities in NIS. Accordingly, we has not been substantially focused on our operating activities for that period. By the end of 2018, we transitioned to a new business model (B2B2C) and concluded that the main market that we should focus on would be the apparel market in the US. Consequently, we established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, we hired sales personnel which are based in the US and signed agreements with customers for which we began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, we are no longer considered a ‘holding company’ for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, our management has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of our operations is the U.S. dollar.

My Size Israel functional currency remains the NIS.

Our presentation currency of the financial statements was and will remain U.S. dollar.

Application of Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this report, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial condition or results of operations.

Revenue from Contracts with Customers

The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09), an updated standard on revenue recognition and issued subsequent amendments to the initial guidance in March 2016, April 2016, May 2016 and December 2016 within ASU 2016-08, 2016-10, 2016-12 and 2016-20, respectively (collectively, “ASC 606”). The core principle of the new standard is for companies to recognize revenue to depict the transfer of services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods and services. The Company has adopted the standard effective January 1, 2018.

To recognize revenue under ASC 606, the Company applies the following five steps:

Identify the contract with a customer. A contract with a customer exists when the Company enters into an enforceable contract with a customer and the Company determines that collection of substantially all consideration for the services is probable.

Identify the performance obligations in the contract.

Determine the transaction price. The transaction price is determined based on the consideration to which the Company will be entitled in exchange for providing the service to the customer.

Allocate the transaction price to performance obligations in the contract. If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation.

Recognize revenue when or as the Company satisfies a performance obligation. When the Company provides a service, revenue is recognized over the service term.

The Company’s revenue is derived from the sale of cloud-enabled software subscriptions, associated software maintenance and support.

Revenue is recognized when a contract exists between the Company and a customer (business) and upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company enters into contracts that can include various combinations of products and services, which may be capable of being distinct and accounted for as separate performance obligations. In case of offerings such as cloud-enabled subscription, other service elements in the contract are generally delivered concurrently with the subscription services and therefore revenue is recognized in a similar manner as the subscription services.

Product, Subscription and Services Offerings

Such performance obligations includes cloud-enabled subscriptions, software maintenance, training and technical support.

Fully hosted subscription services (SaaS) allow customers to access hosted software during the contractual term without taking possession of the software. Cloud-hosted subscription services are sold on a fee-per-subscription that is based on consumption or usage (per fit recommendation).

We recognize revenue ratably over the contractual service term for hosted services that are priced based on a committed number of transactions where the delivery and consumption of the benefit of the services occur evenly over time, beginning on the date the services associated with the committed transactions are first made available to the customer and continuing through the end of the contractual service term. Over-usage fees and fees based on the actual number of transactions are billed in accordance with contract terms as these fees are incurred and are included in the transaction price of an arrangement as variable consideration. Fees based on a number of transactions or impressions per month, are allocated to the period in which the transactions occur. Revenue for subscriptions sold as a fee per period is recognized ratably over the contractual term as the customer simultaneously receives and consumes the benefit of the underlying service.

Equity-based compensation

The Company accounts for its employees’ stock-based compensation as an expense in the financial statements based on ASC 718. All awards are equity classified and therefore such costs are measured at the grant date fair value of the award and graded vesting attribution approach to recognize compensation cost over the vesting period. The Company estimates stock option grant date fair value using the Binomial option pricing-model.

We recorded stock options issued to non-employees at fair value, remeasured to reflect the current fair value at each reporting period and recognized expenses over the service period. The Company elected to early implement ASU 2018-07, Stock Compensation: Improvements to Nonemployee stock-Based Payment Accounting, from October 1, 2018.

In accordance with ASU 2018-07, we measured stock options at the implementation date and reclassified the stock based payments from a liability stock-based payments awards to equity stock-based payments awards. The fair value as of the implementation date will be recognized over the remaining service period. We estimate share option grant date fair value using the Binomial option-pricing model.

The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.

The risk-free interest rate for grants with an exercise price denominated in USD for employees and several consultants is based on the yield from US treasury zero-coupon bonds with an equivalent term.

The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

Item 3. Quantitative and Qualitative Disclosure About Market Risk.

Not required for a smaller reporting company.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the rules and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rule 13a-15(b) under the Exchange Act, our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of June 30, 2020. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of June 30, 2020 were effective.

Our Chief Executive Officer and Chief Financial Officer do not expect that our disclosure controls and procedures or our internal controls will prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Changes in Internal Controls

During the most recent fiscal quarter, no change has occurred in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Part II – Other Information

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

On August 7, 2018, we commenced an action against North Empire LLC, or North Empire, in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement or Agreement in which we are seeking damages in an amount to be determined at trial, but in no event less than $616,000. On August 2, 2018, North Empire filed a Summons with Notice against us, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018, North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by us against them, alleging that we failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against our CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, we filed a reply to North Empire’s counterclaims. On November 15, 2018, our CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims. We intend to vigorously defend any claims made by North Empire.

Item 1A. Risk Factors.

Not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In June 2020, we entered into a consulting agreement with a consultant pursuant to which we agreed upon the three-month anniversary of the agreement to issue a warrant to purchase up to 7,500 shares of our common stock. The warrants are exercisable at $1.30 per share and have a term of 18 months from the date of issuance. The securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act since, among other things, the transactions did not involve a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit Number		Description of Exhibits
31.1*		Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*		Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Schema
101.CAL*		XBRL Taxonomy Calculation Linkbase
101.DEF*		XBRL Taxonomy Definition Linkbase
101.LAB*		XBRL Taxonomy Label Linkbase
101.PRE*		XBRL Taxonomy Presentation Linkbase

*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	My Size, Inc.

Date: August 13, 2020	By:	/s/ Ronen Luzon
		Ronen Luzon
		Chief Executive Officer (Principal Executive Officer)

Date: August 13, 2020

By:

/s/ Or Kles

Or Kles

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-31.1 2 f10q0620ex31-1_mysize.htm CERTIFICATION

Exhibit 31.1

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

I, Ronen Luzon certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of My Size, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations: and

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2020	By:	/s/ Ronen Luzon
		Ronen Luzon
		Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 f10q0620ex31-2_mysize.htm CERTIFICATION

Exhibit 31.2

Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the

Sarbanes-Oxley Act of 2002 and pursuant to Rule 13a-14(a) and Rule 15d-14 under the Securities Exchange Act of 1934

I, Or Kles, certify that:

1	I have reviewed this Quarterly Report on Form 10-Q of My Size, Inc.;

2	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2020	By:	/s/ Or Kles
		Or Kles
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 f10q0620ex32-1_mysize.htm CERTIFICATION

Exhibit 32.1

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of My Size, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronen Luzon, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Company’s Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 13, 2020	By:	/s/ Ronen Luzon
		Ronen Luzon
		Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 f10q0620ex32-2_mysize.htm CERTIFICATION

Exhibit 32.2

CERTIFICATIONS PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of My Size, Inc. (the “Company”) on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Or Kles, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Company’s Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 13, 2020	By:	/s/ Or Kles
		Or Kles
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-101.INS 6 mysz-20200630.xml XBRL INSTANCE FILE 0001211805 2018-12-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001211805 us-gaap:RetainedEarningsMember 2018-12-31 0001211805 us-gaap:CommonStockMember 2018-12-31 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001211805 2018-08-01 2018-08-02 0001211805 2020-01-01 2020-06-30 0001211805 2020-06-30 0001211805 us-gaap:FairValueInputsLevel1Member 2020-06-30 0001211805 us-gaap:FairValueInputsLevel2Member 2020-06-30 0001211805 us-gaap:FairValueInputsLevel3Member 2020-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001211805 2018-08-01 2018-08-07 0001211805 2019-01-01 2019-01-22 0001211805 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0001211805 us-gaap:CommonStockMember 2020-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001211805 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0001211805 us-gaap:RetainedEarningsMember 2020-06-30 0001211805 2019-06-30 0001211805 us-gaap:CommonStockMember 2019-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001211805 us-gaap:RetainedEarningsMember 2019-06-30 0001211805 2019-09-15 2019-10-01 0001211805 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-06-30 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001211805 mysz:ConsultantMember 2020-01-01 2020-06-30 0001211805 us-gaap:EmployeeStockOptionMember 2017-06-02 2017-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001211805 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001211805 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001211805 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001211805 2019-01-01 2019-06-30 0001211805 2019-11-01 2019-11-19 0001211805 2020-02-01 2020-02-07 0001211805 2019-12-31 0001211805 2019-03-31 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0001211805 mysz:ConsultantMember 2020-06-30 0001211805 mysz:ConsultantMember 2020-01-03 2020-01-15 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001211805 us-gaap:CommonStockMember 2019-12-31 0001211805 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001211805 us-gaap:CommonStockMember 2019-03-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001211805 us-gaap:RetainedEarningsMember 2019-12-31 0001211805 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001211805 us-gaap:RetainedEarningsMember 2019-03-31 0001211805 mysz:ConsultantMember 2020-01-15 0001211805 mysz:ConsultantMember 2020-03-01 2020-03-30 0001211805 2020-05-08 0001211805 2020-08-04 0001211805 2020-04-01 2020-06-30 0001211805 2019-04-01 2019-06-30 0001211805 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001211805 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001211805 us-gaap:CommonStockMember 2020-03-31 0001211805 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001211805 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001211805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001211805 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001211805 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001211805 us-gaap:RetainedEarningsMember 2020-03-31 0001211805 2020-03-31 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember 2020-04-01 2020-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001211805 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember 2019-04-01 2019-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001211805 us-gaap:SellingAndMarketingExpenseMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001211805 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001211805 mysz:PublicOfferingMember 2020-05-08 0001211805 mysz:PublicOfferingMember 2020-05-01 2020-05-08 0001211805 2020-05-01 2020-05-08 0001211805 us-gaap:EmployeeStockOptionMember 2020-05-20 2020-05-25 0001211805 2020-08-01 2020-08-20 0001211805 us-gaap:SubsequentEventMember 2020-08-01 2020-08-10 0001211805 us-gaap:SubsequentEventMember srt:MaximumMember 2020-08-10 0001211805 us-gaap:SubsequentEventMember srt:MinimumMember 2020-08-10 xbrli:shares iso4217:USD iso4217:USD xbrli:shares

11400000

616000000

7157836

2085900

514801

1925001

41000

26000

The Company was notified by the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company’s request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders’ equity requirement. <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 48px"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unaudited condensed consolidated financial statements:</td></tr> </table>   The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management’s opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles (“GAAP”) has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2020.   These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2019.

163000

12000

46000

51000

66000

5000

422000

92000

155000

175000

55000

93000

322000

31000

24000

38000

84000

120000

118000

59000

1000

6000

27000

13500

200000

917000

22000

8338

21667

0.001

100000000

7157836

2085900

My Size, Inc. 0001211805 false --12-31 10-Q 2020-06-30 2020 Q2 Non-accelerated Filer true false false Yes Yes DE 001-37370

5294000

2000

4793000

7000

36599000

-536000

-31277000

3057000

2000

29566000

-601000

-25910000

1051000

4031000

2000

30102000

29244000

-539000

-671000

-28514000

-24544000

3000

32193000

-540000

-29973000

1683000

1990159

7157836

1992243

2085900

1990159

2600701

163000 163000 374000 374000 93000 274000 93000 274000

-2760000

3000

-2763000

-2659000

234000

-2893000

-1300000

-1296000

4000

70000

-1304000

-1366000

328000 328000 4545454 514801 66667 4545454 272727

0.001

3.76

1.375

1.099

2000000 5000000 1694000 4300000

P5Y6M0D

328000

160000 52000

2439802

2620453

1.10

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><td style="font: 10pt Times New Roman, Times, Serif; width: 48px"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Functional currency:</td></tr> </table>   The Company reassessed its functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency was accounted for prospectively from that date. In 2019, the Company went through a strategic shift which involved a significant change in its business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, the Company acted as a platform to fund its operational subsidiary, My Size Israel, which conducts its research and development activities in NIS. Accordingly, the Company has not been substantially focused on its operating activities for that period. By the end of 2018, the Company transitioned to a new business model (B2B2C) and concluded that the main market that the Company should focus on would be the apparel market in the US. Consequently, the Company established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, the Company itself hired sales personnel which are based in the US and signed agreements with customers for which it began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, the Company is no longer considered a ‘holding company’ for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, the management of the Company has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of the Company's operations is the U.S. dollar.   My Size Israel functional currency remains the NIS.   As a result of the change in the Company’s functional currency, the Company reclassified its warrants that were outstanding as a financial liability in an amount of $328 as at December 31, 2019 to equity.

Note 5 - Contingencies and Commitments   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">a.</td> <td style="font: 10pt Times New Roman, Times, Serif">On August 7, 2018, the Company commenced an action against North Empire LLC (“North Empire”) in the Supreme Court of the State of New York, County of New York for breach of a Securities Purchase Agreement (the “Agreement”) in which it is seeking damages in an amount to be determined at trial, but in no event less than $616,000. On August 2, 2018, North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims.   The Company believes it is more likely than not that the counterclaims will be denied. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">b.</td> <td style="font: 10pt Times New Roman, Times, Serif">Further to Note 13b of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019:   On January 22, 2019, the Company was notified by the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.   The Company did not regain compliance with the Rule by July 22, 2019 and, as a result, on July 23, 2019, the Company received notice from the Staff that, based upon the Company’s continued non-compliance with the Rule, the Staff had determined to delist the Company’s common stock from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The hearing occurred on September 19, 2019.    On October 1, 2019, the Panel granted the Company’s request for continued listing of the Company’s common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company’s stockholders, discretionary authority was granted to the Company’s board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty.   On November 19, 2019, the Company received formal notice from Nasdaq that the Company’s non-compliance with the minimum $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), as of September 30, 2019, could serve as an additional basis for delisting.   On February 7, 2020, the Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company’s request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders’ equity requirement.    On May 12, 2020, the Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the Stockholders’ Equity Rule. Accordingly, the Panel has determined to continue the listing of the Company’s securities on the Nasdaq Stock Market and is closing this matter.</td></tr></table>

328

In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 272,727 shares of common stock, at an exercise price of $1.375 per share and a term expiring on May 6, 2025. In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 30,888 shares of common stock, at an exercise price of $4.8563 per share and a term expiring on January 15, 2025. 7232836

6215000

2958000

1090000

1133000

41000

26000

921000

966000

128000

141000

5125000

1825000

274000

321000

27000

38000

182000

93000

263000

4549000

1203000

1422000

1907000

598000

659000

598000

659000

824000

1248000

328000

361000

378000

348000

440000

115000

102000

6215000

2958000

-31277000

-28514000

-536000

-539000

7000

2000

36599000

30102000

51000

25000

21000

5000

50000

24000

21000

5000

1000

-2763000

-2893000

-1304000

-1366000

30000

-67000

29000

197000

-2793000

-2826000

-1333000

-1563000

2843000

2850000

1354000

1568000

1078000

1318000

562000

710000

1077000

861000

452000

479000

688000

671000

340000

379000

3835651

1991161

5166772

1992151

-0.72

-1.5

-0.25

-0.75

3000

234000

4000

70000

5995000

3000

5992000

2632134 2632134 16000 2000 14000 16000 2000 14000

2084

48000

1925001

4301000

2000

4299000

1160000 848000

-2625000

-2424000

-16000

91000

-64000

-127000

-11000

163000

422000

-15000 104000 16000 54000 -19000 -269000 21000

19000

13000

-200000

1366000

5000

15000

170000

-181000

1200000

5230000

4642000

4412000

1466000

3176000

-818000

-10000

240000

6011000

15000

104000

3000

-425000

103000

42000

311000

294000

North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims.

The Panel granted the Company’s request for continued listing of the Company’s common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company’s stockholders, discretionary authority was granted to the Company’s board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty. The Company received formal notice from Nasdaq that the Company’s non-compliance with the minimum $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), as of September 30, 2019, could serve as an additional basis for delisting. The exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company's common stock on May 22, 2020, and extended the term of foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during both the six and three months ended June 30, 2020 were $43. -90000 -89000

Note 3 - Financial Instruments   Fair value of financial instruments:   Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company's own credit risk.   In accordance with ASC 820 when measuring the fair value, an entity shall take into account the characteristics of the asset or liability if a market participant would take those characteristics into account when pricing the asset or liability at the measurement date. Such characteristics include, for example:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The condition and location of the asset.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Restrictions, if any, on the sale or the use of the asset.</td></tr> </table>   As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 48px; text-align: justify">Level 1 - </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 2 - </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify">Level 3 - </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</td></tr> </table>   The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.   The carrying amounts of cash and cash equivalents, accounts receivable, other receivables, trade payables and accounts payable approximate their fair value due to the short-term maturities of such instruments.   The Company holds share certificates in iMine Corporation ("iMine") formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB.   Due to sales restrictions on the sale of the iMine share, the fair value of the shares was measured on the basis of the quoted market price for an otherwise identical unrestricted equity instrument of the same issuer that trades in a public market, adjusted to reflect the effect of the sales restrictions and is therefore, ranked as Level 2 assets.   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in marketable securities (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in marketable securities (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial liabilities</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Warrants and derivatives</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">328</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the six and three month periods ended June 30, 2020 and 2019, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $15 and $3, and $104 and $(425), respectively.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in marketable securities (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">41</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial assets</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Investment in marketable securities (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value hierarchy</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Financial liabilities</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Warrants and derivatives</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">328</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">(*)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">For the six and three month periods ended June 30, 2020 and 2019, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $15 and $3, and $104 and $(425), respectively.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense - Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">51</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation expense - Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense - General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">163</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">422</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr></table>

1450000 53000 53000 43000 43000 1450000 200000

Note 4 - Stock Based Compensation   The stock-based expense- equity awards recognized in the financial statements for services received is related to Research and Development, Sales and Marketing and General and Administrative expenses as shown in the following table:   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense - Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">51</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">92</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">31</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">84</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Stock-based compensation expense - Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">155</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Stock-based compensation expense - General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">66</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">175</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">120</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">163</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">422</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">322</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>    Options issued to consultants:   During the six month period ended June 30, 2020, the Company granted 13,500 options to consultants. No such options were exercised and 8,338 options expired.   The total stock option compensation expense during the six and three month period ended June 30, 2020 and 2019 which was recorded under sales and marketing was $5, $1, $59 and $6 respectively and under general and administrative was $12, $6, $55 and $27, respectively.   Warrants issued to consultants:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 15, 2020, the Company conducted a registered direct offering pursuant to which it issued 514,801 shares of its common stock and in a concurrent private placement issued warrants to purchase up to 514,801 shares of common stock at an exercise price of $3.76 per share for gross proceeds of $2,000. The term of the warrants are five and a half years. The Company received net proceeds of $1,694 after deducting placement agent fees and other offering expenses.</td></tr> </table>   In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 30,888 shares of common stock, at an exercise price of $4.8563 per share and a term expiring on January 15, 2025.   The warrants were measured at fair value of $52.   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"> </td> <td style="width: 0.25in; font-size: 10pt">b</td> <td> On May 8, 2020 the Company completed a public offering of (i) 1,925,001 units, each unit consisting of one share of common stock, and one warrant to purchase one share of common stock at a price of $1.10, and (ii) 2,620,453 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock and one warrant, at a price of $1.099 per pre-funded unit. The net proceeds to the Company from the offering were approximately $4.3 million, after deducting placement agent's fees and other offering expenses payable by the Company.   The warrants to purchase an aggregate of 4,545,454 shares of common stock are immediately exercisable and may be exercised at a consideration of $1.10 per share. The term of the warrants are five and a half years. Pre-funded warrants were immediately exercisable and were exercisable at a nominal consideration of $0.001 per share. During May, 2020, the pre-funded warrants were exercised in full and therefore are no longer outstanding.</td></tr> </table>   In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 272,727 shares of common stock, at an exercise price of $1.375 per share and a term expiring on May 6, 2025.   The warrants were measured at fair value of $160.   Pursuant to the anti-dilution adjustment provisions in outstanding warrants to purchase 144,277 shares of common stock, the per share exercise price was reduced to $0.9289, following the issuance of the securities in the public offering.    <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">c.</td> <td style="font: 10pt Times New Roman, Times, Serif">Further to Note 11a of the Company's Annual Report on Form 10-K for the year ended December 31, 2019:</td></tr> </table>   In March 2020, warrants to purchase up to 66,667 shares of common stock of the Company that were not exercised expired.   Stock Option Plan for Employees:   In March 2017, the Company adopted a stock option plan (the "Plan") pursuant to which the Company's Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, is limited to 200,000 options. Stock options can be granted with an exercise price equal to or less than the stock's fair market value at the grant date. . In August 2020, the Company's shareholders approved an increase in the number of shares available for issuance under the Plan to 1,450,000 (see note 7 below).   On May 25, 2020, the Compensation Committee of the Board of Directors of the Company reduced the exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company's common stock on May 22, 2020, and extended the term of foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during both the six and three months ended June 30, 2020 were $43.   During the six and three month period ended June 30, 2020, there were no grants of stock options under the Plan, no such options were exercised and options to purchase 22,000 and 21,667 shares of common stock expired, respectively. In August 2020, the Company granted options to purchase an aggregate of up to 917,000 shares of common stock to directors, officers and employees of the Company (see note 7 below).   The total stock option compensation expense during the six and three month period ended June 30, 2020 and 2019 which was recorded was $103 and $42, and $311 and $294, respectively.

0.9289

144277 -25000

Note 7 – Events Subsequent To The Reporting Period   On August 10, 2020, the Company's shareholders approved an increase in the shares available for issuance under the Plan from 200,000 to 1,450,000 shares.   As a result and pursuant to approval of the Company's compensation committee that was contingent on the foregoing shareholder approval, the following occurred on August 10, 2020: (i) the number of shares available for issuance under the Company's 2017 Consultant Incentive Plan reduced from 466,667 to 216,667 shares: (ii) the Company to the Company's Chief Executive Officer (A) five-year options to purchase up to 160,000 ordinary shares at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022, and (B) 80,000 performance-based restricted stock units, each representing the right to receive one share of common stock, which vest (x) upon the Company generating revenue of at least $50,000 in the Russian Federation during the year ending 2020, or (y) upon the Company generating revenue of at least $500,000 in the Russian Federation during the year ending 2021; (iii) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Financial Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (iv) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Operating Officer and Chief Product Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (v) the Company granted five-year options to purchase up to 325,893 ordinary shares to other employees of the Company at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; and (vi) the Company granted five-year options to purchase up to 30,000 ordinary shares to each of the Company's non-employee board members at an exercise price of $1.04 per share. These options vest on November 26, 2020.

Note 6 - Significant Events During the Reporting Period   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On January 15, 2020, the Company conducted a public offering of its securities pursuant to which it issued 514,801 shares of its common stock and warrants to purchase up to 514,801 shares of common stock at an exercise price of $3.76 per share for gross proceeds of $2,000. The term of the warrants are five and a half years. The Company received net proceeds of $1,694 after deducting placement agent fees and other offering expenses.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">b.</td> <td style="font: 10pt Times New Roman, Times, Serif">On May 8, 2020, the Company conducted a public offering of its securities pursuant to which it issued 1,925,001 shares of its common stock, pre funded warrants to purchase up to 2,620,453 shares of common stock at an exercise price of $0.001 per share and five-year warrants to purchase up to 4,545,454 shares of common stock at an exercise price of $1.10 per share for gross proceeds of $5,000. The net proceeds to the Company from the offering were approximately $4,300, after deducting placement agent's fees and other offering expenses payable by the Company. In addition, the Company issued to the placement agent five-year placement agent warrants to purchase 272,727 shares of common stock at an exercise price of $1.375 per share.  </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">   </td> <td style="font: 10pt Times New Roman, Times, Serif">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to several other countries, including Israel, and infections have been reported globally. Many countries around the world, including in Israel, have significant governmental measures being implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business.  These measures have resulted in work stoppages and other disruptions. The Company has implemented remote working and work place protocols for its employees in accordance with government requirements. In addition, while the Company has seen an increased demand for MySizeID, certain marketing and sales activities have been adversely affected by the coronavirus outbreak. For example, the Company has three ongoing pilots with international retailers that have been halted, the Company is unable to participate physically in industry conferences and its ability to meet with potential customers is limited. The extent to which the coronavirus impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could materially adversely impact the Company's operations and workforce, including its marketing and sales activities and ability to raise additional capital, which in turn could have a material adverse impact on the Company's business, financial condition and results of operation.</td></tr></table>

Note 1 - General   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">a.</td> <td style="font: 10pt Times New Roman, Times, Serif">My Size, Inc. is developing unique measurement technologies based on algorithms with applications in a variety of areas, from the apparel e-commerce market, to the courier services market and to the Do It Yourself smartphone and tablet apps market. The technology is driven by proprietary algorithms which are able to calculate and record measurements in a variety of novel ways.   The Company has three subsidiaries, My Size Israel 2014 Ltd. and Topspin Medical (Israel) Ltd., both of which are incorporated in Israel and My Size LLC which was incorporated in Russian Federation. References to the Company include the subsidiaries unless the context indicates otherwise.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">b.</td> <td style="font: 10pt Times New Roman, Times, Serif">During the six month period ended June 30, 2020, the Company has incurred significant losses and negative cash flows from operations and has an accumulated deficit of $31,277. The Company has financed its operations mainly through fundraising from various investors.   The Company's management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2020, management is of the opinion that its existing cash will be sufficient to fund operations until the end of the second quarter of 2021. As a result, there is substantial doubt about the Company's ability to continue as a going concern.   Management's plans include the continued commercialization of the Company's products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.   The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.</td></tr></table>

(i) the number of shares available for issuance under the Company's 2017 Consultant Incentive Plan reduced from 466,667 to 216,667 shares: (ii) the Company to the Company's Chief Executive Officer (A) five-year options to purchase up to 160,000 ordinary shares at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022, and (B) 80,000 performance-based restricted stock units, each representing the right to receive one share of common stock, which vest (x) upon the Company generating revenue of at least $50,000 in the Russian Federation during the year ending 2020, or (y) upon the Company generating revenue of at least $500,000 in the Russian Federation during the year ending 2021; (iii) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Financial Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (iv) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Operating Officer and Chief Product Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (v) the Company granted five-year options to purchase up to 325,893 ordinary shares to other employees of the Company at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; and (vi) the Company granted five-year options to purchase up to 30,000 ordinary shares to each of the Company's non-employee board members at an exercise price of $1.04 per share. These options vest on November 26, 2020.

See note 2 c. Represents an amount less than $1 For the six and three month periods ended June 30, 2020 and 2019, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $15 and $3, and $104 and $(425), respectively.

EX-101.SCH 7 mysz-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Interim Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Contingencies and Commitments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Significant Events During the Reporting Period link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Events Subsequent to the Reporting Period link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - General (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Financial Instruments (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Stock Based Compensation (Details Textual) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Contingencies and Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Significant Events During the Reporting Period (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Events Subsequent to the Reporting Period (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mysz-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 mysz-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 mysz-20200630_lab.xml XBRL LABEL FILE Equity Components [Axis] Additional Paid-in Capital [Member] Retained Earnings [Member] Common Stock [Member] AOCI Attributable to Parent [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Income Statement Location [Axis] General and administrative expense [Member] Antidilutive Securities [Axis] Employee Stock Option [Member] Common Stock Additional Paid-In Capital Other Comprehensive Income / Loss Retained Earnings / Accumulated Deficit Selling and Marketing Expense [Member] Research and Development Expenses [Member] Title of Individual [Axis] Consultant [Member] Sales and marketing [Member] General and administrative [Member] Sale of Stock [Axis] Public Offering [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Type Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Filer Category Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Entity Interactive Data Current Entity Incorporation State Country Code Entity File Number Entity Common Stock, Shares Outstanding Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Restricted cash Restricted deposits Accounts receivable Other receivables and prepaid expenses Total current assets Property and equipment, net Right-of-use assets Investment in marketable securities Total non-current assets Total assets Liabilities and stockholders’ equity Current liabilities: Operating lease liability Trade payables Accounts payable Warrants and derivatives Total current liabilities Operating lease liabilities Total non-current liabilities Total liabilities COMMITMENTS AND CONTINGENCIES Stockholders’ equity: Stock Capital - Common stock of $ 0.001 par value - Authorized: 100,000,000 shares; Issued and outstanding: 7,157,836 and 2,085,900 as of June 30, 2020 and December 31, 2019, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Research and development Sales and marketing General and administrative Total operating expenses Operating loss Financial income (expenses), net Net loss Other comprehensive income (loss): Foreign currency translation differences Total comprehensive income (loss) Basic and diluted loss per share Basic and diluted weighted average number of shares outstanding Statement [Table] Statement [Line Items] Common stock Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Balance Balance, shares Stock-based compensation related to options granted to employees and consultants Issuance of shares, net of issuance cost of $1,160 Issuance of shares, net of issuance cost of $1,160, shares Issuance of shares, net of issuance cost of $848 Issuance of shares, net of issuance cost of $848, shares Exercise of warrants and pre funded warrants Exercise of warrants and pre funded warrants, shares Liability reclassified to equity Issuance of shares to consultants Issuance of shares to consultants, shares Total comprehensive loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Issuance of cost net Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of operating lease right-of-use asset Revaluation of warrants and derivatives Interest and revaluation of short-term deposit Interest received from short-term deposit Revaluation of investment in marketable securities Stock based compensation Decrease in accounts receivables Decrease in other receivables and prepaid expenses Decrease in trade payable (Decrease) increase in accounts payable Net cash used in operating activities Cash flows from investing activities: Proceeds from short-term deposits (Investing in) proceeds from restricted deposits Investment in right-of-use asset Purchase of property and equipment Net cash provided by (used in) investing activities Cash flows from financing activities: Proceeds from issuance of shares and pre-funded warrants, net of issuance costs Net cash provided by financing activities Effect of exchange rate fluctuations on cash and cash equivalents Increase in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Organization, Consolidation and Presentation of Financial Statements [Abstract] General Accounting Policies [Abstract] Significant Accounting Policies Fair Value Disclosures [Abstract] Financial Instruments Share-based Payment Arrangement [Abstract] Stock Based Compensation Commitments and Contingencies Disclosure [Abstract] Contingencies and Commitments Other Receivables and Prepaid Expenses [Abstract] Significant Events During the Reporting Period Subsequent Events [Abstract] Events Subsequent To The Reporting Period Unaudited condensed consolidated financial statements Use of estimates Functional currency Reclassification Impact of recently adopted accounting standard Schedule of significant assets and liabilities that are measured at fair value on recurring basis Schedule of stock options granted to non-employees General (Textual) Accumulated deficit Additional cash proceeds Significant Accounting Policies (Textual) Warrants outstanding as financial liability Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value Hierarchy and NAV [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Financial assets Investment in marketable securities Financial liabilities Warrants and derivatives Financial Instruments (Textual) Recognized gain (loss) of marketable securities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Research and development [Member] Stock-based compensation expense Subsidiary, Sale of Stock [Line Items] General and Administrative Expenses [Member] Stock Based Compensation (Textual) Number of options, Granted Number of options to purchase common stock expired Stock issued options value Common stock shares issued Exercise price EX-101.PRE 11 mysz-20200630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 04, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	My Size, Inc.
Entity Central Index Key	0001211805
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity File Number	001-37370
Entity Common Stock, Shares Outstanding		7,232,836

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 4,549	$ 1,203
Restricted cash	93	263
Restricted deposits	182
Accounts receivable	27	38
Other receivables and prepaid expenses	274	321
Total current assets	5,125	1,825
Property and equipment, net	128	141
Right-of-use assets	921	966
Investment in marketable securities	41	26
Total non-current assets	1,090	1,133
Total assets	6,215	2,958
Current liabilities:
Operating lease liability	115	102
Trade payables	348	440
Accounts payable	361	378
Warrants and derivatives		328
Total current liabilities	824	1,248
Operating lease liabilities	598	659
Total non-current liabilities	598	659
Total liabilities	1,422	1,907
COMMITMENTS AND CONTINGENCIES
Stockholders’ equity:
Stock Capital - Common stock of $ 0.001 par value - Authorized: 100,000,000 shares; Issued and outstanding: 7,157,836 and 2,085,900 as of June 30, 2020 and December 31, 2019, respectively	7	2
Additional paid-in capital	36,599	30,102
Accumulated other comprehensive loss	(536)	(539)
Accumulated deficit	(31,277)	(28,514)
Total stockholders’ equity	4,793	1,051
Total liabilities and stockholders’ equity	$ 6,215	$ 2,958

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	7,157,836	2,085,900
Common stock, shares outstanding	7,157,836	2,085,900

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	$ 21	$ 5	$ 51	$ 25
Cost of revenues			(1)	(1)
Gross profit	21	5	50	24
Operating expenses
Research and development	(340)	(379)	(688)	(671)
Sales and marketing	(452)	(479)	(1,077)	(861)
General and administrative	(562)	(710)	(1,078)	(1,318)
Total operating expenses	(1,354)	(1,568)	(2,843)	(2,850)
Operating loss	(1,333)	(1,563)	(2,793)	(2,826)
Financial income (expenses), net	29	197	30	(67)
Net loss	(1,304)	(1,366)	(2,763)	(2,893)
Other comprehensive income (loss):
Foreign currency translation differences	4	70	3	234
Total comprehensive income (loss)	$ (1,300)	$ (1,296)	$ (2,760)	$ (2,659)
Basic and diluted loss per share	$ (0.25)	$ (0.75)	$ (0.72)	$ (1.5)
Basic and diluted weighted average number of shares outstanding	5,166,772	1,992,151	3,835,651	1,991,161

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands

Common stock

Additional paid-in capital

Accumulated other comprehensive loss

Accumulated deficit

Total

Balance at Dec. 31, 2018

$ 2

$ 5,294

Balance, shares at Dec. 31, 2018

1,990,159

Stock-based compensation related to options granted to employees and consultants

374

Issuance of shares to consultants

^[1]

Issuance of shares to consultants, shares

2,084

Total comprehensive loss

234

(2,893)

(2,659)

Balance at Jun. 30, 2019

$ 2

29,566

(601)

(25,910)

3,057

Balance, shares at Jun. 30, 2019

1,992,243

Balance at Mar. 31, 2019

$ 2

29,244

(671)

(24,544)

4,031

Balance, shares at Mar. 31, 2019

1,990,159

Stock-based compensation related to options granted to employees and consultants

274

Issuance of shares to consultants

^[1]

Issuance of shares to consultants, shares

2,084

Total comprehensive loss

(1,366)

(1,296)

Balance at Jun. 30, 2019

$ 2

29,566

(601)

(25,910)

3,057

Balance, shares at Jun. 30, 2019

1,992,243

Balance at Dec. 31, 2019

$ 2

30,102

(539)

(28,514)

1,051

Balance, shares at Dec. 31, 2019

2,085,900

Stock-based compensation related to options granted to employees and consultants

163

Issuance of shares, net of issuance cost of $1,160

$ 3

5,992

5,995

Issuance of shares, net of issuance cost of $1,160, shares

2,439,802

Exercise of warrants and pre funded warrants

$ 2

Exercise of warrants and pre funded warrants, shares

2,632,134

Liability reclassified to equity

^[2]

328

Total comprehensive loss

(2,763)

(2,760)

Balance at Jun. 30, 2020

$ 7

36,599

(536)

(31,277)

4,793

Balance, shares at Jun. 30, 2020

7,157,836

Balance at Mar. 31, 2020

$ 3

32,193

(540)

(29,973)

1,683

Balance, shares at Mar. 31, 2020

2,600,701

Stock-based compensation related to options granted to employees and consultants

Issuance of shares, net of issuance cost of $848

$ 2

4,299

4,301

Issuance of shares, net of issuance cost of $848, shares

1,925,001

Exercise of warrants and pre funded warrants

$ 2

Exercise of warrants and pre funded warrants, shares

2,632,134

Total comprehensive loss

(1,304)

(1,300)

Balance at Jun. 30, 2020

$ 7

$ 36,599

$ (536)

$ (31,277)

$ 4,793

Balance, shares at Jun. 30, 2020

7,157,836

[1]	Represents an amount less than $1
[2]	See note 2 c.

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Statement of Stockholders' Equity [Abstract]
Issuance of cost net	$ 848	$ 1,160

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (2,763)	$ (2,893)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	19	13
Amortization of operating lease right-of-use asset	21
Revaluation of warrants and derivatives	(19)	(269)
Interest and revaluation of short-term deposit		54
Interest received from short-term deposit		16
Revaluation of investment in marketable securities	(15)	104
Stock based compensation	163	422
Decrease in accounts receivables	11
Decrease in other receivables and prepaid expenses	64	127
Decrease in trade payable	(90)	(89)
(Decrease) increase in accounts payable	(16)	91
Net cash used in operating activities	(2,625)	(2,424)
Cash flows from investing activities:
Proceeds from short-term deposits		1,200
(Investing in) proceeds from restricted deposits	(170)	181
Investment in right-of-use asset	(25)
Purchase of property and equipment	(5)	(15)
Net cash provided by (used in) investing activities	(200)	1,366
Cash flows from financing activities:
Proceeds from issuance of shares and pre-funded warrants, net of issuance costs	6,011
Net cash provided by financing activities	6,011
Effect of exchange rate fluctuations on cash and cash equivalents	(10)	240
Increase in cash, cash equivalents and restricted cash	3,176	(818)
Cash, cash equivalents and restricted cash at the beginning of the period	1,466	5,230
Cash, cash equivalents and restricted cash at the end of the period	$ 4,642	$ 4,412

XML 19 R8.htm IDEA: XBRL DOCUMENT

General

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

Note 1 - General

The Company's management expects that the Company will continue to generate losses and negative cash flows from operations for the foreseeable future. Based on the projected cash flows and cash balances as of June 30, 2020, management is of the opinion that its existing cash will be sufficient to fund operations until the end of the second quarter of 2021. As a result, there is substantial doubt about the Company's ability to continue as a going concern.

Management's plans include the continued commercialization of the Company's products and securing sufficient financing through the sale of additional equity securities, debt or capital inflows from strategic partnerships. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. If the Company is unsuccessful in commercializing its products and securing sufficient financing, it may need to cease operations.

The financial statements include no adjustments for measurement or presentation of assets and liabilities, which may be required should the Company fail to operate as a going concern.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Significant Accounting Policies

Note 2 - Significant Accounting Policies

Unaudited condensed consolidated financial statements:

The accompanying unaudited condensed consolidated interim financial statements included herein have been prepared by the Company in accordance with the rules and regulations of the United States Securities and Exchange Commission ("SEC"). The unaudited condensed consolidated financial statements are comprised of the financial statements of the Company. In management's opinion, the interim financial data presented includes all adjustments necessary for a fair presentation. All intercompany accounts and transactions have been eliminated. Certain information required by U.S. generally accepted accounting principles ("GAAP") has been condensed or omitted in accordance with rules and regulations of the SEC. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for any future period or for the year ending December 31, 2020.

These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and the notes thereto for the year ended December 31, 2019.

Use of estimates:

Functional currency:

The Company reassessed its functional currency and determined to change its functional currency to the U.S. dollar from the NIS as of January 1, 2020. The change in functional currency was accounted for prospectively from that date. In 2019, the Company went through a strategic shift which involved a significant change in its business model, that clearly indicates that the functional currency has changed, beginning January 2020. In previous years, the Company acted as a platform to fund its operational subsidiary, My Size Israel, which conducts its research and development activities in NIS. Accordingly, the Company has not been substantially focused on its operating activities for that period. By the end of 2018, the Company transitioned to a new business model (B2B2C) and concluded that the main market that the Company should focus on would be the apparel market in the US. Consequently, the Company established marketing and distribution channels in the US along with having a new pricing model denominated in USD. Throughout 2019, the Company itself hired sales personnel which are based in the US and signed agreements with customers for which it began generating revenue in USD for the first time since it began its operations. Accordingly, by the end of 2019, the Company is no longer considered a 'holding company' for the matter of determining its functional currency under ASC 830 based on the currency of its operating entities. As a result of being an operational company that enters into operational agreements and generates revenues on an ongoing basis, the management of the Company has concluded that as of January 1 2020, the currency that most faithfully portrays the economic results of the Company's operations is the U.S. dollar.

My Size Israel functional currency remains the NIS.

As a result of the change in the Company's functional currency, the Company reclassified its warrants that were outstanding as a financial liability in an amount of $328 as at December 31, 2019 to equity.

Reclassification:

XML 21 R10.htm IDEA: XBRL DOCUMENT

Financial Instruments

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Financial Instruments

Note 3 - Financial Instruments

Fair value of financial instruments:

Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, relating to fair value measurements, defines fair value and established a framework for measuring fair value. ASC 820 fair value hierarchy distinguishes between market participant assumptions developed based on market data obtained from sources independent of the reporting entity and the reporting entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price. In addition, the fair value of assets and liabilities should include consideration of non-performance risk, which for the liabilities described below includes the Company's own credit risk.

The condition and location of the asset.

Restrictions, if any, on the sale or the use of the asset.

As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

	Level 1 -	Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment.

	Level 2 -	Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

	Level 3 -	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The expected volatility of the share prices reflects the assumption that the historical volatility of the share prices is reasonably indicative of expected future trends.

The Company holds share certificates in iMine Corporation ("iMine") formerly known as Diamante Minerals, Inc., a publicly-traded company on the OTCQB.

June 30, 2020

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Warrants and derivatives

328

(*)

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Stock Based Compensation

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Stock Based Compensation

Note 4 - Stock Based Compensation

	Six months ended June 30,				Three months ended June 30,
	2020		2019		2020		2019

Stock-based compensation expense - Research and development		51		92		31		84
Stock-based compensation expense - Sales and marketing		46		155		24		118
Stock-based compensation expense - General and administrative		66		175		38		120
		163		422		93		322

Options issued to consultants:

During the six month period ended June 30, 2020, the Company granted 13,500 options to consultants. No such options were exercised and 8,338 options expired.

Warrants issued to consultants:

The warrants were measured at fair value of $52.

On May 8, 2020 the Company completed a public offering of (i) 1,925,001 units, each unit consisting of one share of common stock, and one warrant to purchase one share of common stock at a price of $1.10, and (ii) 2,620,453 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock and one warrant, at a price of $1.099 per pre-funded unit. The net proceeds to the Company from the offering were approximately $4.3 million, after deducting placement agent's fees and other offering expenses payable by the Company.

The warrants were measured at fair value of $160.

Further to Note 11a of the Company's Annual Report on Form 10-K for the year ended December 31, 2019:

In March 2020, warrants to purchase up to 66,667 shares of common stock of the Company that were not exercised expired.

Stock Option Plan for Employees:

In March 2017, the Company adopted a stock option plan (the "Plan") pursuant to which the Company's Board of Directors may grant stock options to officers and key employees. The total number of options which may be granted to directors, officers, employees under this plan, is limited to 200,000 options. Stock options can be granted with an exercise price equal to or less than the stock's fair market value at the grant date. . In August 2020, the Company's shareholders approved an increase in the number of shares available for issuance under the Plan to 1,450,000 (see note 7 below).

On May 25, 2020, the Compensation Committee of the Board of Directors of the Company reduced the exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company's common stock on May 22, 2020, and extended the term of foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during both the six and three months ended June 30, 2020 were $43.

The total stock option compensation expense during the six and three month period ended June 30, 2020 and 2019 which was recorded was $103 and $42, and $311 and $294, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Contingencies and Commitments

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Contingencies and Commitments

Note 5 - Contingencies and Commitments

The Company believes it is more likely than not that the counterclaims will be denied.

Further to Note 13b of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019:

XML 24 R13.htm IDEA: XBRL DOCUMENT

Significant Events During the Reporting Period

6 Months Ended

Jun. 30, 2020

Other Receivables and Prepaid Expenses [Abstract]

Significant Events During the Reporting Period

Note 6 - Significant Events During the Reporting Period

On May 8, 2020, the Company conducted a public offering of its securities pursuant to which it issued 1,925,001 shares of its common stock, pre funded warrants to purchase up to 2,620,453 shares of common stock at an exercise price of $0.001 per share and five-year warrants to purchase up to 4,545,454 shares of common stock at an exercise price of $1.10 per share for gross proceeds of $5,000. The net proceeds to the Company from the offering were approximately $4,300, after deducting placement agent's fees and other offering expenses payable by the Company. In addition, the Company issued to the placement agent five-year placement agent warrants to purchase 272,727 shares of common stock at an exercise price of $1.375 per share.

In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to several other countries, including Israel, and infections have been reported globally. Many countries around the world, including in Israel, have significant governmental measures being implemented to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement of people, and other material limitations on the conduct of business. These measures have resulted in work stoppages and other disruptions. The Company has implemented remote working and work place protocols for its employees in accordance with government requirements. In addition, while the Company has seen an increased demand for MySizeID, certain marketing and sales activities have been adversely affected by the coronavirus outbreak. For example, the Company has three ongoing pilots with international retailers that have been halted, the Company is unable to participate physically in industry conferences and its ability to meet with potential customers is limited. The extent to which the coronavirus impacts the Company's operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could materially adversely impact the Company's operations and workforce, including its marketing and sales activities and ability to raise additional capital, which in turn could have a material adverse impact on the Company's business, financial condition and results of operation.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Events Subsequent to the Reporting Period

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Events Subsequent To The Reporting Period

Note 7 – Events Subsequent To The Reporting Period

On August 10, 2020, the Company's shareholders approved an increase in the shares available for issuance under the Plan from 200,000 to 1,450,000 shares.

As a result and pursuant to approval of the Company's compensation committee that was contingent on the foregoing shareholder approval, the following occurred on August 10, 2020: (i) the number of shares available for issuance under the Company's 2017 Consultant Incentive Plan reduced from 466,667 to 216,667 shares: (ii) the Company to the Company's Chief Executive Officer (A) five-year options to purchase up to 160,000 ordinary shares at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022, and (B) 80,000 performance-based restricted stock units, each representing the right to receive one share of common stock, which vest (x) upon the Company generating revenue of at least $50,000 in the Russian Federation during the year ending 2020, or (y) upon the Company generating revenue of at least $500,000 in the Russian Federation during the year ending 2021; (iii) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Financial Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (iv) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Operating Officer and Chief Product Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (v) the Company granted five-year options to purchase up to 325,893 ordinary shares to other employees of the Company at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; and (vi) the Company granted five-year options to purchase up to 30,000 ordinary shares to each of the Company's non-employee board members at an exercise price of $1.04 per share. These options vest on November 26, 2020.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Unaudited condensed consolidated financial statements

Unaudited condensed consolidated financial statements:

Use of estimates

Use of estimates:

Functional currency

Functional currency:

My Size Israel functional currency remains the NIS.

Reclassification

Reclassification:

XML 27 R16.htm IDEA: XBRL DOCUMENT

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of significant assets and liabilities that are measured at fair value on recurring basis

June 30, 2020

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial assets

Investment in marketable securities (*)

December 31, 2019

Fair value hierarchy

Level 1

Level 2

Level 3

Financial liabilities

Warrants and derivatives

328

(*)

XML 28 R17.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of stock options granted to non-employees

	Six months ended June 30,				Three months ended June 30,
	2020		2019		2020		2019

Stock-based compensation expense - Research and development		51		92		31		84
Stock-based compensation expense - Sales and marketing		46		155		24		118
Stock-based compensation expense - General and administrative		66		175		38		120
		163		422		93		322

XML 29 R18.htm IDEA: XBRL DOCUMENT

General (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
General (Textual)
Accumulated deficit	$ 31,277	$ 28,514

XML 30 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details)	Dec. 31, 2019 shares
Significant Accounting Policies (Textual)
Warrants outstanding as financial liability	328

XML 31 R20.htm IDEA: XBRL DOCUMENT

Financial Instruments (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Level 1 [Member]

Financial assets

Investment in marketable securities

^[1]

Financial liabilities

Warrants and derivatives

Level 2 [Member]

Financial assets

Investment in marketable securities

^[1]

Financial liabilities

Warrants and derivatives

328

Level 3 [Member]

Financial assets

Investment in marketable securities

^[1]

Financial liabilities

Warrants and derivatives

[1]	For the six and three month periods ended June 30, 2020 and 2019, the recognized gain (loss) (based on quoted market prices with a discount due to security restrictions on iMine shares) of the marketable securities was $15 and $3, and $104 and $(425), respectively.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Financial Instruments (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Financial Instruments (Textual)
Recognized gain (loss) of marketable securities	$ 3	$ (425)	$ 15	$ 104

XML 33 R22.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Stock Based Compensation (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 93	$ 322	$ 163	$ 422
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	31	84	51	92
Sales and marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	24	118	46	155
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 38	$ 120	$ 66	$ 175

XML 34 R23.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended			3 Months Ended		6 Months Ended
	May 25, 2020	May 08, 2020	Jan. 15, 2020	Aug. 20, 2020	Mar. 30, 2020	Jun. 30, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Stock Based Compensation (Textual)
Stock-based compensation expense							$ 93	$ 322	$ 163	$ 422
Number of options, Granted				917,000
Number of options to purchase common stock expired							21,667		22,000
Common stock shares issued							7,157,836		7,157,836		2,085,900
Exercise price		$ 1.375					$ 0.001		$ 0.001
Share price							$ 1.10		$ 1.10
Warrants to purchase		272,727							4,545,454
Warrants measured at fair value							$ 160		$ 160
Consulting agreement, description									In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 272,727 shares of common stock, at an exercise price of $1.375 per share and a term expiring on May 6, 2025.
Stock option compensation expense							311	294	$ 103	42
Increase in number of shares available for issuance				1,450,000
Incremental compensation cost							53		53
Incremental compensation expenses							$ 43		$ 43
Reduction of exercise price									$ 0.9289
Number of warrants to purchase according to anti-dilution adjustment provisions							144,277		144,277
Public Offering [Member]
Stock Based Compensation (Textual)
Common stock shares issued		1,925,001
Exercise price		$ 1.099
Pre funded warrants		2,620,453
Share price		$ 1.10
Warrants to purchase		4,545,454
Gross proceeds		$ 5,000
Net proceeds		$ 4,300
Selling and Marketing Expense [Member]
Stock Based Compensation (Textual)
Stock-based compensation expense							$ 24	118	$ 46	155
General and Administrative Expenses [Member]
Stock Based Compensation (Textual)
Stock-based compensation expense							38	120	66	175
Employee Stock Option [Member]
Stock Based Compensation (Textual)
Number of options, Granted						200,000
Exercise price of outstanding options, description	The exercise price of outstanding options of employees and directors of the Company for the purchase of an aggregate of 140,237 shares of common stock of the Company (with exercise prices ranging between $18.15 and $9.15) to $1.04 per share, which was the closing price for the Company's common stock on May 22, 2020, and extended the term of foregoing options for an additional one year from the original date of expiration. The incremental compensation cost resulting from the repricing was $53, and the expenses during both the six and three months ended June 30, 2020 were $43.
Employee Stock Option [Member] \| Selling and Marketing Expense [Member]
Stock Based Compensation (Textual)
Stock-based compensation expense							1	6	5	59
Employee Stock Option [Member] \| General and Administrative Expenses [Member]
Stock Based Compensation (Textual)
Stock-based compensation expense							6	$ 27	$ 12	$ 55
Consultant [Member]
Stock Based Compensation (Textual)
Number of options, Granted									13,500
Number of options to purchase common stock expired									8,338
Common stock shares issued			514,801
Exercise price			$ 3.76
Warrants to purchase			514,801		66,667
Gross proceeds			$ 2,000
Net proceeds			$ 1,694
Warrants term			5 years 6 months
Warrants measured at fair value							$ 52		$ 52
Consulting agreement, description									In addition to the fees above, the Company issued to the placement agent warrants on substantially the same terms as the investors in the offering in an amount equal to 6% of the aggregate number of shares of common stock sold in the offering, or 30,888 shares of common stock, at an exercise price of $4.8563 per share and a term expiring on January 15, 2025.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Contingencies and Commitments (Details) - USD ($) $ in Thousands				1 Months Ended
	Feb. 07, 2020	Aug. 07, 2018	Aug. 02, 2018	Nov. 19, 2019	Oct. 01, 2019	Jan. 22, 2019
Contingencies and Commitments (Textual)
Plaintiff damage, description			North Empire filed a Summons with Notice against the Company, also in the same Court, in which they allege damages in an amount of $11.4 million arising from an alleged breach of the Agreement. On September 6, 2018 North Empire filed a Notice of Discontinuance of the action it had filed on August 2, 2018. On September 27, 2018, North Empire filed an answer and asserted counterclaims in the action commenced by the Company against them, alleging that the Company failed to deliver stock certificates to North Empire causing damage to North Empire in the amount of $10,958,589. North Empire also filed a third-party complaint against the Company’s CEO and now former Chairman of the Board asserting similar claims against them in their individual capacities. On October 17, 2018, the Company filed a reply to North Empire’s counterclaims. On November 15, 2018, the Company’s CEO and now former Chairman of the Board filed a motion to dismiss North Empire’s third-party complaint. On January 6, 2020, the Court granted the motion and dismissed the third-party complaint. The parties are now engaging in discovery in connection with the claims and counterclaims.
Seeking damages amount		$ 616,000	$ 11,400
Nasdaq capital market, description	The Company received the formal decision of the Panel, in which the Panel determined that the Company has evidenced full compliance with the minimum $1.00 per share bid price requirement, and granted the Company’s request for continued listing on Nasdaq pursuant to an extension, through May 18, 2020, to demonstrate compliance with the minimum $2.5 million stockholders’ equity requirement.					The Company was notified by the Nasdaq Stock Market, LLC (“Nasdaq”) that the Company was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The notification provided that the Company had 180 calendar days, or until July 22, 2019, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
Lease agreement, description					The Panel granted the Company’s request for continued listing of the Company’s common stock on the Nasdaq Capital Market pursuant to an extension through January 20, 2020, subject to the condition that the Company regain compliance with the Bid Price Rule by such date and that the Company demonstrate compliance with all requirements for continued listing on the Nasdaq. Previously, on August 5, 2019, at the annual meeting of the Company’s stockholders, discretionary authority was granted to the Company’s board of directors to effect a reverse stock split at any time until August 5, 2020 at a ratio within the range from one for two up to one for thirty.
Nasdaq non-compliance, description				The Company received formal notice from Nasdaq that the Company’s non-compliance with the minimum $2.5 million stockholders’ equity requirement, as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), as of September 30, 2019, could serve as an additional basis for delisting.

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Events During the Reporting Period (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	6 Months Ended
	May 08, 2020	Jan. 15, 2020	Mar. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Significant Events During the Reporting Period (Textual)
Issuance of common stock				7,157,836	2,085,900
Warrants to purchase	272,727			4,545,454
Exercise price per share	$ 1.375			$ 0.001
Share price				$ 1.10
Public Offering [Member]
Significant Events During the Reporting Period (Textual)
Issuance of common stock	1,925,001
Warrants to purchase	4,545,454
Exercise price per share	$ 1.099
Gross proceeds	$ 5,000
Net proceeds receivable	$ 4,300
Pre funded warrant	2,620,453
Share price	$ 1.10
Consultant [Member]
Significant Events During the Reporting Period (Textual)
Issuance of common stock		514,801
Warrants to purchase		514,801	66,667
Exercise price per share		$ 3.76
Gross proceeds		$ 2,000
Net proceeds receivable		$ 1,694
Warrents term		5 years 6 months

XML 37 R26.htm IDEA: XBRL DOCUMENT

Events Subsequent to the Reporting Period (Details) - Subsequent Event [Member]	Aug. 10, 2020 shares
Events Subsequent to the Reporting Period (Textual)
Subsequent event, description	(i) the number of shares available for issuance under the Company's 2017 Consultant Incentive Plan reduced from 466,667 to 216,667 shares: (ii) the Company to the Company's Chief Executive Officer (A) five-year options to purchase up to 160,000 ordinary shares at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022, and (B) 80,000 performance-based restricted stock units, each representing the right to receive one share of common stock, which vest (x) upon the Company generating revenue of at least $50,000 in the Russian Federation during the year ending 2020, or (y) upon the Company generating revenue of at least $500,000 in the Russian Federation during the year ending 2021; (iii) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Financial Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (iv) the Company granted five-year options to purchase up to 130,000 ordinary shares to the Company's Chief Operating Officer and Chief Product Officer at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; (v) the Company granted five-year options to purchase up to 325,893 ordinary shares to other employees of the Company at an exercise price of $1.04 per share. One quarter of such options vest on November 26, 2020, one quarter vest on May 26, 2021, one quarter vest on November 26, 2021 and one quarter vest on May 26, 2022; and (vi) the Company granted five-year options to purchase up to 30,000 ordinary shares to each of the Company's non-employee board members at an exercise price of $1.04 per share. These options vest on November 26, 2020.
Minimum [Member]
Events Subsequent to the Reporting Period (Textual)
Increase in shares available for issuance	200,000
Maximum [Member]
Events Subsequent to the Reporting Period (Textual)
Increase in shares available for issuance	1,450,000

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 98 219 1 true 16 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://mysizeid.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Interim Balance Sheets Sheet http://mysizeid.com/role/InterimBalanceSheets Condensed Consolidated Interim Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) Sheet http://mysizeid.com/role/InterimBalanceSheetsParenthetical Condensed Consolidated Interim Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) Sheet http://mysizeid.com/role/InterimStatementsOfComprehensiveLoss Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://mysizeid.com/role/InterimStatementsOfChangesInStockholdersEquity Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://mysizeid.com/role/InterimStatementsOfChangesInStockholdersEquityParenthetical Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Sheet http://mysizeid.com/role/InterimStatementsOfCashFlows Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - General Sheet http://mysizeid.com/role/General General Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://mysizeid.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Financial Instruments Sheet http://mysizeid.com/role/FinancialInstruments Financial Instruments Notes 10 false false R11.htm 00000011 - Disclosure - Stock Based Compensation Sheet http://mysizeid.com/role/StockBasedCompensation Stock Based Compensation Notes 11 false false R12.htm 00000012 - Disclosure - Contingencies and Commitments Sheet http://mysizeid.com/role/ContingenciesAndCommitments Contingencies and Commitments Notes 12 false false R13.htm 00000013 - Disclosure - Significant Events During the Reporting Period Sheet http://mysizeid.com/role/SignificantEventsDuringReportingPeriod Significant Events During the Reporting Period Notes 13 false false R14.htm 00000014 - Disclosure - Events Subsequent to the Reporting Period Sheet http://mysizeid.com/role/EventsSubsequentToReportingPeriod Events Subsequent to the Reporting Period Notes 14 false false R15.htm 00000015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://mysizeid.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://mysizeid.com/role/SignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Financial Instruments (Tables) Sheet http://mysizeid.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://mysizeid.com/role/FinancialInstruments 16 false false R17.htm 00000017 - Disclosure - Stock Based Compensation (Tables) Sheet http://mysizeid.com/role/StockBasedCompensationTables Stock Based Compensation (Tables) Tables http://mysizeid.com/role/StockBasedCompensation 17 false false R18.htm 00000018 - Disclosure - General (Details) Sheet http://mysizeid.com/role/GeneralDetails General (Details) Details http://mysizeid.com/role/General 18 false false R19.htm 00000019 - Disclosure - Significant Accounting Policies (Details) Sheet http://mysizeid.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://mysizeid.com/role/SignificantAccountingPoliciesPolicies 19 false false R20.htm 00000020 - Disclosure - Financial Instruments (Details) Sheet http://mysizeid.com/role/FinancialInstrumentsDetails Financial Instruments (Details) Details http://mysizeid.com/role/FinancialInstrumentsTables 20 false false R21.htm 00000021 - Disclosure - Financial Instruments (Details Textual) Sheet http://mysizeid.com/role/FinancialInstrumentsDetailsTextual Financial Instruments (Details Textual) Details http://mysizeid.com/role/FinancialInstrumentsTables 21 false false R22.htm 00000022 - Disclosure - Stock Based Compensation (Details) Sheet http://mysizeid.com/role/StockBasedCompensationDetails Stock Based Compensation (Details) Details http://mysizeid.com/role/StockBasedCompensationTables 22 false false R23.htm 00000023 - Disclosure - Stock Based Compensation (Details Textual) Sheet http://mysizeid.com/role/StockBasedCompensationDetailsTextual Stock Based Compensation (Details Textual) Details http://mysizeid.com/role/StockBasedCompensationTables 23 false false R24.htm 00000024 - Disclosure - Contingencies and Commitments (Details) Sheet http://mysizeid.com/role/ContingenciesAndCommitmentsDetails Contingencies and Commitments (Details) Details http://mysizeid.com/role/ContingenciesAndCommitments 24 false false R25.htm 00000025 - Disclosure - Significant Events During the Reporting Period (Details) Sheet http://mysizeid.com/role/SignificantEventsDuringReportingPeriodDetails Significant Events During the Reporting Period (Details) Details http://mysizeid.com/role/SignificantEventsDuringReportingPeriod 25 false false R26.htm 00000026 - Disclosure - Events Subsequent to the Reporting Period (Details) Sheet http://mysizeid.com/role/EventsSubsequentToReportingPeriodDetails Events Subsequent to the Reporting Period (Details) Details http://mysizeid.com/role/EventsSubsequentToReportingPeriod 26 false false All Reports Book All Reports mysz-20200630.xml mysz-20200630.xsd mysz-20200630_cal.xml mysz-20200630_def.xml mysz-20200630_lab.xml mysz-20200630_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 43 0001213900-20-021755-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-20-021755-xbrl.zip M4$L#!!0 ( !)(#5&1#J;G@UD -O= P 1 ;7ES>BTR,#(P,#8S,"YX M;6SMO6MWV\BQ*/K]KG7^ Z[B)/)9)$6 #Y'VS)PE2W:VLFW+V_(D)_>+%D@T M2<0@P$$#DIA??ZNJ&T\")$&"+PF3V;,I$NBNKJYW5U7_\G^>IY;RR%QN.O:O M9VJC>:8P>^@8ICW^]>SW^_K5_?7M[9GR?W[[7_^/ O_\\O_6Z\HGDUG&.^7& M&=9O[9'S7OFJ3]D[Y6_,9J[N.>Y[Y1^ZY>,WSO_]\/TS_"G&?Z=T&FU=J=?7 M&.P?S#8<]_?OM^%@$\^;O;NX>'IZ:MC.H_[DN#]Y8^BL-]R]X[M#%HXUG?/_ M_%F[T9I:L]EM-1O/(P#Z1O?@)_P.?FKVX#]JZX>JO6M>OFNW_K\UY_%TS^?A M/,WGIOQ'O/[+\\"US'?X7P40;_-WS]S\]2RVM*=6PW''%P"7>O%_OWR^'T[8 M5*^;-O=T>\C.@K30R KCD^05( MX%?#"U^(/]RY$#\F'C4S'^V*1\W@48.EGN-LV!@[CQ?PPP7N4+VIUEMJ\+C+ M1KD@=R_@U^!!DSMM3;UD[]FO,B>AY/LE_"7+/3IYI!GOT$_P2OJ9?(5;@ZS M7X ?,F;@KK>(,O@RXU$4+N&S\(?Y'V8:(*FF%X&\.0LD"7+?.TX\_IV-%&+< M=Q,B9QRE'@DH;IS)GW&3?CWCYG1F 1=>!$,)R3)T;(\]>XII_'IV+3X_7/&' MN]%#2WWXHKL/@(C>CV;S0?S[XR[S^P"^<%AF>Z8W#[\-OS<-_&5D,E>A5; $ M,088O;[][[/?0 :JFJKVFIU?+M(O1]-=9,XG9YL!(3M&!A0DD[S?< UU58.M M"*>0OZ3'3XP4?"EQMPN$/J!> /38WL<_?%C9M3.=.3;\R:^>3?YP91BF!PI2 MM[[IIG%K7^LST].M+VPZ8.[!-B,%+8 M$E)"OENZ]+/?@L>6XN"7B\SIXJ!>9,/Z2BGJ._-TTV;&1]VUP93CKXJ4LA=? MT5!!&H(_IXY][SG#GZ^*?!;675%.47TV'/I3WX)'C#MOPES\V643W(]'=@ON MY92]*HI:&Q\OE=(^N(W91O(E+9K>2+Q2QH8(ST5L"'[N MUENG9OO'\1PLIQ">@W7O!L]7_&YTLKB-I$,:2>5*AR22'J34?/BDFR[%T6[M MF>_QS^R16>K+T!OATC[,PX__!?/H(/KFM-"D EF"BL.IC*,A"JTBBA0J*J*P M6A51I%#Q4HDBWY8)"40<35E7MG%E3$W;Y)ZK>V![?WR> <*E\1T^_7$ZLYPY M8^0"WLTP*O4RB$FX&J'3\MD9ZKBX) 6MA:O5M%0$KBM8KV%:/DX3.0(?GX>6 M;S #]Q<])M\C:.]&05SG&W/O)[H+K)$]0')=N;NZ;[XX[/#'SM2P7 M['*G>.Y'8DM\UK13QG-_ WH.UKUO5S<4^%6D\T"1SB,7A3GF9D4N!P^,']RB MK(YLC^S(]C1%245&1T9&QR1BJE.TTSA%.U'14Y'7:9#7$8FD*JWHX&E%IREL M*L(Y..'L]XP&8SHG?>0=+& ?2*HB"\<363C(OE=NX-&Z@8>AA\HV/S7;_"!T M4IE51V16[98"HN/"?EWMR.-"%1V $S.QTL>%N)RBQX6T[H,=%]XSRP*"N[*- M+[K[DWGP.9$<<>K\MU::R"HD5'YQ\> *9YC6!2B]P;0M9T8R\-51UAIXJ(AK M)QEPKX*\2LIOJPA,$)BLW[EV;.Y;:.^<-BEQUWOWP_0L=C>ZM0WST31\7:;8 M8D7^N_0Z*T+)LE(O<8ZF1E;J94H2O=CLVM>;Q1KL=S$S_O+ *G&5!;N:8B\[ M_4ZGU3Y KTCH8H MJ@*]XRG0VRU19%>ZG&!V0"F5+CMWOF O8WB&SVK_M/&L;H)G6O>N?0LMYEMH MIUTA%RRGL-FI[:Q"+JE,3@RW>]>XS=:)(XD6L&\-5)V^G-;IRS&KW7SBJDZ, MC_S$^#3)JCK4.YE#O2,DL%2J?G60=R#G>X]5/:W 60'GJ%/M^.'$0; ?A;TM M-98M=YSZYN4?]%9ME([MS.QHM>M")+RJ\#F&"I^#!+LK&C@T#9R*R*!(6$4N MAR:7?44GJ.S[!NN,#JZ** M9DZ#9DY4157D=1KD=6#55;5".*Y6"(=52A4U')P:3E/=5(1S<,+9KR*I3L,/ MO#Y#ZU-LLU;>TB'ZM2;O9--I X6L&N9V:LWVR>- M)%S KD5.^V5=KMH^KK+DR ]HUU]475EA/.\C$SF+GJLSZD.?49\LBU:D[:E@5,Q4<5$E3E71A"MXJ2JRW.EDTJ+ZE3L5+%3I9U2 M-?A!@X9O_@!PSB?:-$\ZNC-DTX9Q8VL\)X5EK1GC6.B_?;GF]]D&P MWQL0HK;3.XID]Y:0X7L Y(DS?&\3AN_%-F<_>%9CH3907^P/'T_]']FIM\Z* MZ^38HG[,9RP5.@]?]&=SZD\K$MK6I\4.<-]U M>RQGQ#\3N#VL Q&GN-UU)5N/XDR[HKA=45P/W^YO<"4SNM#7U\AT\L\WX#[#T!S)2%V:B[I$9 M*@1?_^I/F:M[3@:I% Q#6;6J+%);YCM3$U[U;2K49^>-VO@X/<$%K)P&C#8 M9X?S:R 9,/R9/9S?Z%-]S/B]XX\GWC]TRV>*)*CO;!3&C'N1<24_:T&X(W(3 MOOGN<*)S=C5V&<5-I<^\Q(P)>\Z3@&D^3D&%BW7S^=_7:I=BY[K6X$ M5RH[1Z:H#L%<64\<"68:E_K-#> M\]9^9-Q#[N.?=-,E,KPQ^=!R4+ LH;30$@E?N[5GOL<_8\JTFLW*Y'XYCE=O MPB!GRC,WW]FF]>N9Y_KL3+G8#VS::MC4-#.WU00C+P=L/\MHK5Z&M@,4+]Q- ML>'VMPX%VQK;WTYOO];=Y_:OM8PUMK^3CV(*PG_5N:'_$70PHF29&\:')H7H M>)823"7*JG5-._OMQX0I&";4[;GRI'/%=L@5,)3!7/'@-S&-0I)($=/4E,^? MKY7SO_RIIVG-]^(!^D-]_Q;>T3UZ,36H8MH TQ1,;=T>,N7)]";TV%38Y,K M-)29:\)/+C@$IDLF!5HTQUT\;Z947/6(8S4MZH MC693F:%3AC*\INBVD3UC3VV>#]^>M]Z>7[V%]QVT[KC I:Z,=--"6L,9&?-6 MHTUAX/( \LP1/6NP$?@W:+.$Z.&$+%T1+@;"VFKBC[@^C 8K Y^;-N-<,?0Y M;RA()8(RQ-EX *.QN-\3W5# NU2&NL5L0W=IA)H"T_DPMZ7\W;?FBJ;5%*3" M&B[*96,]@SJ6;PW E/%FC4!);$(,-B12]?(],@=J5X4344]!<0/4L&A=0;;& MR1(CP (ML-2]]'Y*' 9; 4^JRY#XR\4:?+L=BZ/JT6)A40WMW 2+NVS( #2# MT +P@Y0D:8D^N,*0)V 9#&?F6 MM93?T[C,)&3!,6,7##X)) (B-3KPAV69 4E-',M@+I= *HQ:(,37M0$M M_&[KOF$"&L &-C#C!#]PQS(-[.WS"?Q$>VCJ5IC%\@U^&LY_P$(_6$CEV<2B MUM-=X/]B>>\]?0"\-F26Q6?Z$!#YZQG8>_CW3#>,X&_NS2WVZ]D(!GX'E#_S ME!_F%"3+5_:D?'>F.N"6OJ@I]R!E1N\!;?S[[R]A[3U.YQ<=Y9*X' M,. #4CB!GR@C )&@&DD)_!WN6NE MCVZX;/$W$G_BJUEQ)$QU=VP" O#1IOAOX[)CVCM"SU_TZ>S]G]1N,X/\9M%: M3F=!H+((6GTX% (?I;D?$$'>YH,U!B-,,XD ?A3GXLJ$N0QT&VG\ 6-HR[ 9 MJ*#0Y TTFFF',+A&4O:[8(QP4DY@@F![-5+(4G_^;A.0)(JY$D7,Z/F/S\,) M1J5QEJG)2>^>B_TC<_K^XW7X%]C3PO3R$^1?@/05W17*RS7Q>0E@YI-)4ZFA MW-JPZ;8^II\#D$CG.C/0?* Z"1A\9Q'O )&.>.7,%AM#N =PP"K0#203,:D- MY@CGNCN7MA28NF[P'B&UH5S!*S2!I 0%]\.GM=D"'Z"B;:X/Q1Y$V\HLD\*G MS&@HUZ RT%(T;;)YR(25^IBV_??&?4,9BQ1/BZ9@,P1KJV_Q#2.(T!8B&**M@N4Y4],3V%#2-+64GH D&LK=#(/0" A@Q[<\8<'C MS]Q\5L!2\29@?\%L B=_]VT&-KTP9X@*T <+T&U:2-T&&?./H94<#$RFW13, MH0$#0VG&AD1=N#^ _9'OH2\2. YN",:<@:T/ "(!,$-S$5G,BU50)&AIH 8;B ]J*M$D2H]O.(4!KD6UK9Z>#1[YS=C3["-DU) M%50V>&6#1U .3LT&ET(" 0.-P0*RKLSK4Y3X!*VP?(4Y!%NZ6M0+V8XV%$8T M2+2C 13%27T9&/W)(@(AN:US[D]EX$K$-4CY\'1@V@Q)4QDF'L\I")QKHL$G5 Y(9!R'QT#/ M5Q?9(CZM ,!XQ6HB9HB,6YT4RA0KA@CILGAH7<6P_&B]VTH<[<+6:3JV=&T=]6C7ME[/J^59),>[<]OW([CL]#N= M5EM;L<&'Q$!6;Z 5O*8=5(HL;6:T-;/UCW=MVTE(M7-T9%:F&%$O3WQYVZKV MPVYOYG7)RQGMH*98YK7#2^%M'5;J;=WL>_GB#FYB;-YK>NG"M/;1+JP$H=?J M'1L/E4>2O8/N7 F=7E<[8D>ZO"WM#/7@1+G+5I?+=7#_:*7-KI=^4 6RZZYR MRQW8H]WSO=B=!UW^7EHW+3^Z7/\ZNI)=PT! M)_\;9O_Q6_L;G3C_S77XN@=IFU>-J*U.?.$[6,)AL*1>(F::&I'498JDUB&2 MW$J@I,9_,0C+[.>P$AU]]?+4T/')<4?,Q-0.#C(%6-D4QT+AK,7/*/)H12L5 M-RL!/U9,;2Z=>JU6[Q4B<$D()H_4U&[W\H"8BA7Q?=/=.Y?21@RJ!0J:\*Q7 M#)HLB4XOL]G(*QW,F[4<0#,J1?<(J"B+O/*]B>.:_]FRK%9M-M/EODNFV@ZJ M]0ML2X;JSO>PT0 F#^VX!CDVTY90E5F-G &5P-GZYR!MO<;YK$"Y@P-_:!GO^;S9?>\)X^X[+378$8 M,U"4?;+T\=K3C "Q3,R0&" ^\K7ONOBUR8>Z]2^FNQ]%LYZU)ZF+O173Y(T6 MG_'&&?I3V4AD[5G49OU_Q!3QU[.&%5*\Z"KBC7QS1\N:+EKJ)_AF_?1 _)R< M*C52_F0"IF+3_8^6-5ELI$7B_F1:S+V&98\==WW2_NK8=@S2P/@0U=^O.BK6U\4D2HV1,,F&6%50(;,!-BZ,LSO%QRC =; R6 M_I,WV7JRS.$R)))@P.^4@ 6/HSHN0";_PKXFJT9;G/464_LQ>?^1 9_H\K5- M9\T>+6O6H>,"9&2_D=UQC>EG[OS:,=;G_)N/R;F7C)G-(U]]RI!?7_:K]=9E MZ[*99@HQSH*A'JM%%-BAI3Y\T=T'[(_RH]E\$/_^N,O\ M?D6@6.LGCS<6X=@;I ]+[Z%^N#(,$W<+Q)EN&K=V4(F9&1M;U?#@4(O(N4#\ M1*"/66EKA21/A;*&H"RQD(<9=UBH@#^[; ).)X@FT7!^)_NTS(5+]U-%TM]/O[P?(3YD MS]=,?FEV=CK[IFQ0LJC+ 6H+-M#ZG>Y.R&H1R)+8H-M4]P+O1FR@=?IJS)[LQ'0L3MHX0J"2FME&0P&?[P=Q6XDMKE^RH MY&&R-"V^$ZMC$:EEB=O+_?#T9N*VUU%WM?U)=&X&7KNS&^I$FVT;X;,SEZ$L MOFYIZN[\FIWP2:>]$[V_ .]FA-CO7^X4G:O*&GN%9U]ZKG202$9NV]=^4^WT M4T?4RX[/BISDK<7AZY[QE0)9(9:UFZ5#]GZ=N*Z)Y"EX6QM>;UW.ML6 M,NS->AE/"LB%C/IST-B#= K'=T8R^(<3SY?"OX.4-LS7B/)LUC[36*O>ND2X M#K?4]8V!I3UI#P/S%K;"R]S$TH//!US+=J<;NP6\>'EQZ[)]FO2VM/3D2(7& M4IBW<3!>Y":>F-!842E_O$)CXVKBDR2W8G7(VJERUM)2I2,6C[GU14<*\U(\ M;R'27Q*+E1(;?Y&,>((J+G]S3VLM*UH\'*^Z7M$(H(S4JXRM^\J\N]$/_;F4 M2$5=N^PN5!'DS5@^<-OKE!W 4FKF7YEPE7.DT#J"[=[LM.&RNR?8BSOO=:V; M:H*P5^ .Q4?EN='[A*LA83S _.WAL)=9";Q[ / M&\+>+2Q6(]].W'][X^.MNJ+VD K%/YOZP+2HWG9HZ9S3W97@WRTFG:SO/46W M<*IXSVTZNZB7BHQL ME>U[>^%(^O7%W'X]X'U(7D:GP%VDO:NXU%7QPC2Z[M MW>]JUA,@<=#;*T#_I^Y2EYP?3G Q?6D=:]H=^I^DF\6)-H:C%[ M.9YX'Y^9.S0Y^X9WJ88_B M-EJ7G2-?S)HLO&JAS7Z_I(42%U*SM6^N,V1L26.OHH(\IZ8G,D[BTQ:%9T/9 MF'-WPQHP@=$NO^;?Z7II<779#I&E=ONQ\\G,^3>&L#STM5MQ]"V%,B#8@!BO M;$-08RP1]@=SIYL(O-^^=?[5_=*\B=ABU2QIJ,)[[P(;T&3\DVZZ9!?>B#N: M_*6]S$+#+WSMUI[!I)^Q?;:Z68ADQU!I1PE5:]]0+23&'\4.K@55S@YF^X0% M8=KS4@IN>\* _,)TG-JX\L*1-VX9H79C$FW)!"4 LIEFZ&B%X$L4%2TZOJ(8 MX2M[HI]*3:;/NH#35=T4-C%YZU1!MW38C,L6V.S"%@ MZBJ\QIHNK 5T_F#RRMJUFT^5=K-EI]NXG'F9-UO*+TV\>Q?&KXM'R[D0=H ? MOCJ>N/E24^I*#$%*A"$E0!'=]CC(OD]V![=^[OV:TGW=,!S.5^8UPR7=Y%O2 M?<-+$'^,-P_KIW;S<' K=PC>N+$A;XK[Z8W;;S.=YIW+PTWK25B?[(E %CMB+N0(9?!O/X-?7P1@B#:\" ++K)WO4M>:NQR\9X M)H.YI7B!,O[XNTU 4JTX5R(#AI[_^#R<8+=QG&5J<@XO*N=G]Q^OS]XV%%AV MM$J:O "9*Z)']W3FFOB\!";S2?F;7&A#N;5A@VU=]$#_*_P^,VT K!;>S;R( M68!#1\QQ9@O4$W8!",M2= ,)04QELR'C7'?GRLAQ%5T9@0$>O$=H:RA7\ I- M(/>:KG'VY;W. @0P]C@V]40L1QO'+',* ,'\#>4:](0.VVK2W=0T!ZI/8!<;"V&>[L^1E>:GWVEF:?Z%S,%VT&+,69FIY8 MN9*FD*74 5O=4.YFV.$6)PWNI4;LX,_9DI&_B$;D@? M( 7IAKSO_=^^3=P724 I.T!8Q"8)AQ;7J2^[JIUN9\=/+O.6\Y-%!$+:0>?*:5**;TJI30\,:7T29JPNA7%D.ARB.'\T'KI-/6.NG.E M$P1BP!'A'%Q=E.[H*H<[&>Z@T $,I/04DTI1L\@P2]X+\ 3%:C L8#B6!7Y' M(-:5K[?WH(4(!-!U?]=M'^,7@>-+49I@=#MS\">=!X$%Z6S/7(>C[PT..GCK M&P1 QLE$# M)Q%H M-W0R0)#-U24.W1=$#)HTO'DRO3*0:!.%)FENZAD8#[ 5.*#79$=(1P MROT!-PT3QA;1*'G=EG++71W7(5" #JX_1+.## -Q.;LDBO!Z=H6NA1&A., * M['*#3GUUH @O\4N/MD&,TP$FH%+TM;ZG= %!["@^D&:$QAB@ ! M,PBDHLDG ,8TN(&[O]_?(!L26SB^X))%!H*-8=9(F5 (D.L8DX.=X Z"(.D&0VG4 M,R .$4"-?(0D.G:9-!T)0G%X"V/0WDKN0QH9ZR)6+ *,,K#WR&R?27##",?( M=#EL"(@\F 0CAL'[2+Y$:$BDO>BIB<@4*))*#S!66R&H1[D31C@(RB,HNEH&,N9R$VWYE$\W0;/ MSW)X;D@[EGJZ5H)I(A4\"L-=2[5)S\\W2T?=E[0O6] ?A7P_":E>A9FK,',5 M9J["S%68N0HS5V'FXPXS"_70T]3N^U3 .?SE\GT5>JY"SR<22SKRU52AYQ>R MD45"SS%)>MI!:%FBO3(>D-'$<&J*XA+1NAVE/+P'(CZJLC],<>NNB-U*UZYV ME+J26#E9$S',$)KW5[EZ'%Q>A?Y%:.@ NU%^Y&A'B]A9X6L(VI'RTIT=+G"M M?Z[\,4RM7-8R'$@PDD'*#"GU6A%E>6 3HY'A*5_!YIPH'Z4SY^OE?- M8VG-]_1C,3C$2.$8ZONW@4*\]\'YGR)4OAOJ3"JZQ#\0%_]RW)\U_-WVYO'O MT 4I!L7 93HX83"&'B_H#/O_704>@7*.4,26'/Z27D+HUIF\&"R=-5NK=EL-HH! M*@2!)@>L!'=0B MU,(/(*31A5;;25J6E91,.NR0,K:&T0*,B&@]),1HQ4$+)P^QN( MKGNL.24[J2LPEHTP@:-B8,!\:/Z04>!3*:J$0/(G$!H> (DIG/3.I:#3 K8O M!D/68A#A'.S,H+2#N:)6T*>"7TLWIV&81D(:21<1C2@&0QC\BPAL6A.;@TRS M$*<"=]D283"#62:H9Y"N9#>BHAZ)<&4Q"&"H!"*&.D;6 GY=^#E8?(PFF[5^ MIU?K]/J-Q*/%P$!F"BG*FYBN49_I+C7JGY-C(X+\)6<2#TF,("S5K45QJ:+LBLI[+&[E$M$Q 9@,ZB)D M\H<<,/"8!+\D+X@JXY^*@<#LL4ZR 4@.R\A@A]RYK%^S6:KL.2!5.R7#ED95 M@IE.Z1"O3)AW?'X7T9)@Y@$(P M!(0!99O,:*Q&U?)#W*/R$$_5*3Q-N/<"8D5R)T1R.ZOB+RWT4$;VBXLM/38P MF,%K5UN#U*%4P@RYLFTT K]3FAJZ,)_P0%]MUO][:?N00J $X>N,5)U*G>\W M0A6F>@@7-9VU(O(FQ,&&/+7^JG-#_T.A?JG*%TH/J"V&H.BA1#!FP2=\TI,N M'QH,9 ^"T6DF&X'AJ?74GRH#TZ!< A8T.)#-=)B'Q.E-*!-$P/?9Y.3]?/:Y_O9<>TM$+/UW6),EGDK (7,VY3CR%ARYTL:JX8FX2^'%! M\@]U K.P^13.SIBW&IT).-@SS 0FGI 7!AMASBD>=P8HY++A6-#;:J2TFI2N M .NF/EEAPHNAST7:K*0HD3 ;P&LLT$<"#@RJJ#T86;= \(#XP=%JV$H+LV$M MY>^^E:!A!WN"Z1G4M'S[ +Z,-Y/Q&00Q0MP223JDKL0RT#'%,!!E)NL*GIY1 MLD)\%!U#A3H\E-IWB5^Y96DB49*25);%=NO(@%:BP130X3(F\]_31B!BN)G-\_)F3?_X=B4O; ML>MYL-=B0R.[1M'Q)/N($."2>%B";PAFR;2^+8/IL20[V !*JO\#1!$F"BD3 M,$Z(N=@(/=)(DB>@^"_Q%%>^Z9@_ECY.H&_CVDL(KF!L9TAY !3AC<*YN!4K M&Z<=+=^]% Y,V3=A0#+.+&+3X^&P+#J41)5M,:PK^->V+)29[W)?%X=+N@V: MU\,[Y^@5D3$<9>4&<4#N#_Z-528R_1GS9DT1;URF2Y?(H \@ID1O]4 :<7\X MH;QFV=4I9<,9#,^<*)%Y84#L41HWTQ) Y" UCJ &@!*4S=1BARF=8"LE++KP M6-"Z6;$QM".8,\EB2\5>Y'2*&@P$6KE889+B4LD M(1U;& K>DP.R'"*> *QR"N+Q,ZU%7J <>\$/>#D'CQ5JD@Y/YB%(O1ZO'%KN4W*%H>])I^"8R[TT]I#V MRS*=9^&EK[ L4MIXJ941\EB>>5 +[8,O^ES!DTZ)3V>9V5VY##DM&DU9S6XZ*B*N%C#HO 0HR=*IL4#+4 KFO8<7' M(G=)NST>^21V!_T2A'3 VN*RY"97RV2?+%GQ8M3$W>T%\K#7NIXJ=@GADFO2 M5M\PU=)Z*VZ7BLV4J$Z75XW!UV'BU@T# ]RHC_&_8;J^DZH.C-+>D*HX6A?XC6D_@LAVW#"GRI$W M3"4SWT \ BO!G-T_AVEBXS&Z7R"0;;IY"[\7Z!7]?F.1#PY,D!Z?(I[:I5:[ MU"YSWJL)SP(4A+A]-8HPOJ';:6,:C'+%:&5X98'I2H6#DD*DFG0:LGQ@^8:5 MO[?Y=VR^TCT'8[?7ZQ7?\G:CU^FV5N]Y6/G6V63C#6:^^X@%@//837SBYKSE MP@;WNU=OME<+FTL-Q$VK^\O%>G.E!>$W[!HB;O1+-X2Y"J]1V40&[;,BHNR\ M@^UK($XBS:!J?U2U/SJM2L6J_5'+ M\=:>)<.@SKJ6OM_IK3W+5\<.-FKC"X:;_6;&?-'(&\R\WDI5M=4J-+/PM% 2 M135!)6"@K2:@6#[+UC"M207=+6 *;SO[S'3.A ,V^ITSPN_&:.IK23PMG65; MD-;#4K_;W1RD;RXV8/#FWRQLIV8;&%B@AC)?MT"2FKKNVR MG<+_RKG* 6\]1+6T-'D4!D]V(N3?*7J(,@I(:7NT);=OR1Q;PK,FGGH;PW,# MA@XW/5X./0%E)R#)''U3$/)P\5Y>7"O9N4=SN MM/L):/<*XYK276NVMH?QLVRT@G']C;FQK279,39HL?G67'F_>;G!?"48R9U^ M+V_B?$-T71#66WRWTR\.0M(D#%Z9[P C*V5%.UZNK9EI,R>$W!F)-?%QFFVV%@/CAZL;VZ&@OA20^QW;@K(>8=KNY*3@Y MLF1KNS856UL^S=9 K2D^FMH60"TYL2]1D!2;95,+/R8W899X;H;,QR@MJ+IJ MIA(@VS 06Q2R[PQC]\SXJ+O8:I4#D_E3W\)NMS=4/[4YMP#PVN5ERJM8-5LI M\*V'N[K6ZZCM+>&+/4%1"#S.=]D$L]T>V:T]=*;LL\,Y>-YWHQ_Z\^;([+2Z M:6E89.+RX5X3R9U6OTRX8\?HV_F02<),#[O!M&LR;*%IK\+,X&^Z:=S:L@@C M]MH6MD^GG]J9E9.5 MZ:5E$SK=>*@_<]Z+J\9GK$B@AQ2E*(L0O,"0L/Y\3/ M:P08.]O.B6MK%UJG5LHZVX76N=XR_^:"7/CF.J.4S-]X1Y/F96SX8C-OL*_M M>G>W6O,V>[QDXFN'@^C_F^,89,$P]]$<,GX/1LS=(W,G3#=*V7TU)8A7 M35H*F,5)Y2!@KD-7JTW^#?&SBJQ630R60V1&E$(J=>TR%1U/S%$4@.)$ )9J MOT0 BHN-NMIJMLO%0#'I 0"DCM&7 O WL.+Q^SO[EA)A1:Y1&;302BF-K(DV MA68#PNA>[@Z<#;1+?[?(*48S:G\#Y(31D_)E2(J%,V;:#)B-Y(F6DY2R+3 ; MR9;6#C%35,YTNIL#(S,2RJ$8K=?.@2289A,X-C!6>RE#N10XBM.)VNJT=X./ M@F*ET\TY4\N#XV]T#Y %9M"5@96+5.1H/C+Y?$GF;.H88<6DV\.X@2W;4O<, M8W$JZW2U_:.Q& %>JLUM0/P2W)%6,ODEE6UZE@V@*$Y@O6Y6ENQ60!2GH'9' MVP4FBM%(^[)?"(CO\MY"(**;Z-;",BFDVTOR_M(9MP6O..ET+]-QKQV"5YRH M6JFST)UCKQBYM5+D5@B\?S(\]F?&U2.(L3'[2F6'=R.JDHOE GS0N3G$ 4W+ M%]<%%"3*O,+@7JO3[:BQA(2-X-G9JE;0 M:D>[JA65JK+[0$T5TZ?7VT3^8D[?;B ]'$(V" RTVB\;)1O8_B\;(1OXJLU#8(2R M 6ZIH<:-CTTC1#TNI5A\94_T2TE9 ?U^\F!SK:EW">^#'/0AEA@AVY$4$&_' MLXREJ:VV;"I3&N1[Q4=:;YTH/HAN=T >*Z*9 MXG"L5, .N=I-=8+V0M&PA4Z1"<,O$"=E:Z2#KF9W&JLLT L>?IZX1-I(';T\ MB92+AE9]W/@"/SK(MEPSS+.5;=CLM5,XCE=O:O7F=C[PUL!N(:E/9D,. M$IW8&NJ=2MA"(!;,U3@RLMA(@B[PJ7H85+]$/LU?XS'S:2[4>["$"!M[B(RI M?2S14]>T$0BJ(J@NLHP5)(WUE.L2]4[AW,[S.Q[PMY$O6JKR]@A6-*483>.(+P&:#.)]_D MC;8?YK]S!G0<9K-?#3WS<;$3V.8%,-U4.?/Z )0*^B;E,FUMH?IM0]"!EUSL MRW+#Q/^_M5-M;T;,$D?J62*6A7@&#^B,38ET*68*Q&6XICL9)-=(4!6KR8V #D!@[3 2+8J MNW9LNOH'*!VG+TDJ]%>L=#L@#X"$3:S7[EZQ8/A#(<2"QL97="?,W>B[:XXG M/SPG\T:%C:NDU?C:UIZ[1)C+L": JUQ85HDV1#+ $!^_X-R;E/FN/7>.'R44 MX"Y\T&9S'3\N8_Y2(=\$IXOM3S:$''PIZGSQP[D:THVXN;=ME-9E*W9UP]J3 MEPKV!@@O&^Y/C@OO#!DS.,(4*M2R&]2HJ93[ O.7"_HF[FM/+0WVK.=OV*!L M.WB3^3:@QK3@RIUNH0T7"(G4E0,+5SLDOX@]F8#]6GQ^N.(/=Z.'EOH KLD# M+*#WH]E\$/_^N,O\?H6 T%(]E;8">7?K+W1!1;>MG U'A\$-E%@O MU>3FL!@4W]Z-XD_>V=EWT93DE>1$ 2@9^P\:L)0&?8Z%_$I>4EN[;=)NI M@/KZ\Y<*>1GN<-RZ^#>,WV(#NB^^2[8"YQ=C5U& M5Y#+)*7?OH(^F"@?IS/39OCF<.F:*/ 0;NT7WD M&(C7[7E-@<4ZPLQZNHZ'PB[?@[RM_#.A4-#%T:D+M M4GQ=RYP25\J?X#'=AK\X9ZYH<./C:>$0=G4:7DPO)Q\Z4UC6$!<\C^,ZCO]I M36 %T>1-],2>*".=IO8<($?+?(2YN;CV L]'Z-YWV +X-0'N4/<)Z6*+%GX. M0(QM6;/6[_1JG5Z_D7R4*") N#BN(M$9QY,$W'3A@P$& MHN'K%JQUI@^)*6@K[X:>@QNIAAN9P*9"8.D0EN+LFGYJ<9P.4B7@"[.\ZT+P[%XRB-0.P@&N5,9Z\(>G -W(> MA$U.)'_(&?D'_(1?H@6N QG@@I@]UHE&81<,9#@@QCG^ :QG,T'N)&%PW&#W M[!1[-&(722T5C8GS,[IH+)01-XP/77.VY#BI7U<[4K*KJ)K/?L,%?=-M9B70 MDMX_E_WA@Z.,>Z=(@0)/6B8=> 0[F'YI2&G&DBT=P5I?=6[H?R@R95<1.1;* MS'<1U_/ EW$S=2;"?W!__&P &\06AU;)$4O"@H7(:< M(C;1)#$8;L8'TU"^N2@KO_L60TG$?9"]!L@.VJ&%L0R&^@*[O+*% 4%4$9Z M/D5@/@=9<40T8'KV:#H^MT#+1#)8,%,?Y)^87[=M9.DI8\L0SF-WCM6(%%U& MB=* .=WWP"7""\^>=![MM9,YT(!X$68Q8#$@-UR2I$R$:E!( (6#]2!VE@,6 M/ 04$>29H!R!K$TKL12M20\HF*/I$+JDJ'71MQO.&/&O.I?D$9PC\XA6FX3:M9 \U9AG"9[4OV",B),QL ZRA!(/=L(6:)> E M7:<))L2H[=CU+ K$KL%3?ZJ\T1J=T#2([Z,<06'BMKH8@0%QP)8S8DH8#1 J M@?@L*8UHNM/I-,\';\_5M\HY3HCC:R@22QGSEC,7 UL1=QT)J=69JZTI9S8#:R.F!Z_ M9G(<+I5(P#!)'I5TS%#4D8&*OR/*QF.43Q[]K;:;-:UUJ8B2%_PF*4*3(YX3 M$27AY,10".& >4^,V6#!]!IJAV![TX=/;Y&QWJB-9EN9H@H MAZPDL?0 &P9-G;BZ,.ADW2#+#]G M8.405^';(+1@0?"3(;'$GL$$H)P&H8Y-#-$B0Z#-DTS !/$#B/0M+S2T2>8P M7!A^A0M^TVG5I+#'79?MZ@VJF !!*/F4F\_R(9 [8#78WH0K8HE_]P'FEE1, M"AC!3'G3;@747H2$4QE^Z<@S7;M::JYZ/UXVL72^[4#;));?+PI:8#Z%\0QT M?H"2?2"!'P#/!RM]*]X2O/WV%\M[/P,2GUOLU[,1O/1.49LS3_D!"@Z,4?:D M?'? >JV)+VH@(5US]%Z9ZBY0ZSL%'VW2?SO=QN7,>Z_@K'7=,L?P*[;1,T=S M^278[ S'KXM'S_XR]M[C]#AK40C"EP?X 1Q!$.5JZWU+J2LRB Q<NL!IPC]F] E?%_\I"R/-1L>T,Q%2PM+UZ>S]G]1N\X6L!XF9H'VD MNR]1BH;;:$;;^.YEK/:E[9ZLB0!A3S#?H^0'RQK\8<<0,0K44^=G5_?79V^5 M'FI/W'!%7'3Z!62='S@3J'QB JT&6LRB@B?4YR-\25#(-/92C68U&) , !I[ MB%0TQ]QVDT_(WQZYX&4^.>Y/TLEB$%*:X4L-!:!$&.,#34SF8K?Y.7H;"(V/ M _+0^IB2?T=@D-<\-&?HYNF<^U-I QBB2ST&@C#W%>T)\18J?%UQ!J+H4*AO M#@[\D$)K!ILQDIN!601:W1&!$O@2[=A IX<_$!CB1S!BG"<[ 8<^ ,OF+H ML#C% 'UCTR:_0,03'G73(F4H_9RAZ0[]*:I^ +]!D 3HS-H?88<)^XM\BB0NY#$C>A4" CP?8!_//TG"<@-#E&QNWQKV?@A>#?,Q15\N_":WXR#6^"CS;_?!9-BO.YQ0>CZHZA;@6X M\IQ9-"BZ.32PL3&4[=[L>;>(]XPRX=7:9<"K9TCRDN#<"6'_F+ 0L"BR38K2 M&8:*,!01^:NCCVZ"*B^(#1)?;JZDJQ,[%PG\&CK:1\,MYF?60F,V\M(YY1FX MC-7!JUGPOP,'",Q'/.4S_R/]&].>^>#! 0$9PE(5Q!56HH(E"9:IX5C.V!0I M*UF^?V4OOF:%=23=8R#@3 W1(GC+>LYA0,9&AKL"_%>XP MX[RAA),K>GCO4 0'&L,#.M&AE!N?XE24D.,I^FQFF2)$1EL!6Q"+E3>4>Q.# M!J$,%"_F+(P@QM]=IALFQ;F,$ B7C7U+=_';>,!/3R&C%I.W0HW3>:V#M>]< M,1S&"6P\PC0!50J'7:3P,'KW##,=\+5_^\:8,@&+*/^CDBDO2HR<(,Q\!R7(I+,QQ? M<0:8,H6JHJ8P$WO"A4"(Y"'0)HY(Y!5_5?+^Y;+4J7)0)>]? 7$FY7WK9[;D8 F)R,NQF6Z-";XHX3/3KNH@G,G%A8*3ELP^1,; 2B/#J;6D#\J MHZZ4)ANFV+*1Q88>#^*Q,FH7.;<3DWN.2W[OBJ%,'$WGC@U4((^20>_C$<]C MD.LJ0!KY'I"7XKG,-GB5EW"4ZPGH:"@[VE9E(>A4)8>&K\EN,?+C.LSG59=ZG* J+R2G#9X$4 MXU@B7Z?D;'@^Z*X*L%(T.AXP>1G;\U+)+0RE.9;!I7A)%$&"XV)^,6T,NKDS M1R92G9_1=V=O93T>>!T_;9$3I]R8^A3K@Q1\ C0=3'MK#QM JLK,'UCFT)K7 MB1I%)&PH 9 '5W<_KO_G0T4S1[F>&U_*!8?.%U'F1$>1R9-'H:T$X<@JD<4T MOE"A<:JED%90E!=)IUWR.>E-QU-"P_H23$Q$B?>$E2Q1U-BWW; ]3U !%0FF M$ LR#;QH@M7ZF"D31&3E@0;!F)%*)EBPP2"U.6B^$/4MX6C+N '1:Y):A]> M4,YJ?>A8EC[CX/4$G]8Z M2TL[D /'\YSI,A\RCLHAPQ+=+&1$-GW2SZD_,7,\\7 BRWBO2$S4Q;0 :J,3 ME'ADCI<""98*N+-_/5,CS$E\!"-^L/3A3S&NPAW+A$DSX,A95*)X*7==F8O( MF&8YGO+# =4>+=NC3QGY]M56;;=5VDYV2IXV[GAS3AY!6H6@Y0AJG0![DV0* M:]%D/4<:[&W0&L<0]H)?MDDK)JM@V3DIG,1B*UC*(0*PR4'&C5W'MPVTRQT7 MH!@/SK5FNZ:U>C6MTWF[S"209GNW_>>D(+38R),E/D%[\>C8E9P+'MT#=/Z_ MW^:*R< O^//Z@CW]9@YD:R@=.40_-42T3?75<&\]^Y$NO9UO'+WXM>]@VU<= M)U61AJ.,-!S>>MV1JWK#AK)-D"K:!)V((?LB-^-$XP:'WX\J.% %!XX7055P MX$7[8L<$2Q4RM*U[NM=^ZD'!WJ=1K.3T^>P"@^ M_F94X8$C=.ZJ\$ 5'GAMX8%8L\8C=H,J6*H8007+J<0(_JF[KA[T3<8N2X]4 M4[4H8%ZM=W@J2V]IO=>[^"HJ4/7S6B8'"T/Y.AM$!M'@DZE8_^1$74%RKI_! MZWM,Q\B^A0:?%;G^G>!V(GD-SQNUV18?SMM:YVW4'Q.&PV)H MT.)K]D1)"+?H>KVE]\/D7B9S16>8\DH&X\[^ZM@N+@0[)7[ ,K>PR< /-IS8 M)MZ7=\!;9ZI\E[=*+AVZ/>JBJR6T5VCQ=!IQ?9K1*_3A26*JA; MP7)\0=TJ\>N%ACFKJK#3#?%6D88J[:M*^SJ=S3C1N,'A]Z,*#E3!@>-%4!4< M>-&^V#'!4@4'*EBJX,#)>XFGLO2J*NQT@P-'FO]5A0>.R2.MP@-'M!E5>. ( MG;LJ/%"%!UY;>*"J"CME6*H8007+\<4(JJJPE^(85U5A552@J@JKJL*V@;>J M"JNJPA:KPK8J]$J7C]T/)\SP+78W^CB=61H($!QVH&K7."/H31]"<&FW>#O1Z2)#HG!JE!MH]W;0[7G26-GYR=3)XV= MBG8.2CM'&G'=?RRSFO$HH[(=+2,H);\Q;;SR^9U21_,WXF5\0IC$PCCSP/&I M"_=T&/.:%/:,GYE25[XSSO#(6@9XP2ET9I@2=J*!OLXKKHOJYY_IOOBUMU[Q MOO?:Y:^]#)'WSXGIL74=!2';-I=C]W3Y/ HQ$2*#43;7&SGPK;MC.26;^5F9 M12%K$3+YYS36HBJYA_N[9_QB]@Z^3(@9=R7:_;\C=G,Q9(:$!BZ M,35MDWLN'6T7IDO$"L4KH7" M5K[\JC"X'A$6CR8=H4F8AK1=4/1O0 #MLK8?!E(,QQ]8K.3=SQLXMOG=]=-5 MVV5RSTM 7EM;/QFZ0EXZZ% 1WL:X:^V6\%;D;^PLTR)(Z9C.^7_>W=I#E\%8 MM_97'TN6[D8T/+]ZU$T+@?KDN+><^[H]9#DI&KU8BD:OKC7/%-\VQ4,B.^9, M,=C0G.H6__7L]NNGL]_4=J<)__QR41B$1=@Q&*I;<4S@:M?-)HE _?W^)@YG MO77V6Z>5 C)[KBUA:A\*IH_"V^*EX*J]&JY@OA)@*X:SK6 CPER3)Z[XW2C@ M [7Y(#GYX=X?@]?]&=SZD_%-YOS31%^V>UZP%$O ML!ZMN>%R AD9-3R_&\6W\SNS=(\)N1>)RV_Z''?^D%W,.]W&94Z><-J.%H^6 MD]@UP ]?'8^1YFUC/!9C, JA18ECCK31(-1+NTYFVWMR=$D=XBYWUR+NQT3L M$H]%R61@K*X VV$NJOZDNP:/)[R:-N6?CL)J,^X!!Q"Y*R,'7$%A.] [S'S$ M-_ SL0FFN2;.&6^BDE^?9/8- MODSI3WQG")O?)?R MG62'PWA?0P(DH[6AZ&B(F7FZ/5?&V.07'E%;M4ZSJ3B"-E,$V5"^.@KWAY/P M]R?F8B(6WP<4N/'!-L]>I0YAZF1 D4$ M0V:@PDCN:7;7RJ5-*Y6GB0F;AHH4$QVU7>LU5=EP&/L-FQZ6QTRG3@2%4%THS$T;IH)IL<\OWB XHZL! MF#(#!XB).P7%N$_!#0(P)\P_G.B@W/P9_KDXI9@NF,:#F4+S(H2!VBKCPV]: MCQKM63.\^M>H, ^?I?N5O 'J@^RX("RJ0Z!-GK@/+(DKT9J&;]- MDT=(EL@&_H"CTC9U"PPOL@3UJ:!B*GO ;TRZQ--QILL HD&+^F ,N!W=GK]>1K!$7J MU5J*DV, (3I8(OB9W)5P7R5#SO!#1AI=23NN,"?I:A)F)?A:PE@LNS+F"Y2 M&VI3#'MN HQ:K0M6=KL#VLEE]9%OB_!)!&[JZPS(8T](*!/P9$*\"&5RG;5% ML)O]/FG0%$#"?$U8J=+FD+N6 &;D.M.D[4"B6Y_!R\_F%$P$,$% 7[>4J6E9 M8.;45EFZ?^4K;5UEIL_)@(U#,IC'@4S'A_9#ZKG1H?U,_R/NG\3)!(VYT&1S M1@F0VK5.NP,$V\[UIV _S>F4&:;836F/D0P7V9-S99"(YWK"Q^.FP5P1G0P8 M)3+9(L\JS6SK>EG?%MA$V@W+@(V'GL67"*SM3$T;C-P$T&FXWC0;*'IB*Y#Q M=ZD7T7(MY@#X]\RY+16?@-?%!&:[4=Q7+L,5*][Z$5C^HP3LPOT+%[ M:6=UK]RQTRZUVJ5VN9EGIS9:EYW5CAT:%-T#^'2[/.%]]4X=K+W:S&-=T*Z7 M(?ZW8@G?8H%H$E<@"^N&:?DD9W4#GZ52-(0(+-!'D]-Y,HBIF#K-MI'4=KNF M75[FB#NIVD.YE!)=XK 4+%HAR,%4Z&N]OCBVC#460?D<-#22$C=V'9\4IBGG MI[$WE7@T[% =MKW6FT*'NSIIVQZT3[Z+IGH(![ Y=JY25%4/>%E:=.#!7MDV MVE;?VJC!;.X)(CS&ZWUNWFZ9H4.<%GL)7(>+(=+^9%)K*D3C]R_ (CX90O M0[5E!+?(W52^6>#[H!@(&JB^P.R:8/&I77V12SR^A=VBARP$D7J9C#;HAC/S M9#J"GL@IQ-"#K9SCPV=(HF=O,Q(_DFKN@Z.[!HJK&\H8<5Q.T4!*"TV,C3)0 M1@)&8"^[(KS[D\T5%O" # A2JF,4? A31FEV&6H,TDX!*B.8N*8$0]>B,67& MH3ZRA-!38O2M_#-NYF+'S5RYTQL2Q M#,(BQMD?*8<6W ?1J#3P(](1'+'E0?=2$D"A,Q+@B0GA! M1:^V.0,PY9Z1Y MF'()F !7YNWKR,M="H4\U-+"M*JT+%FL9'L**]D\&1F)-SC%'0::]%CH&68P M5\HP"#W.R8)#BJP3\W@#:H:O0^80]& ;$0^EQP],U>BX:90^2@"WN5G36NN: M,N?$/TE8!2# 6.$=,"\)\9LY8W::P17T_?ATUORJ]5&LQUYX;58JC+.@CUW MZ42)4!! '[%.$C*Y@YH0"F(7<3K8<6&6>['4+PS0CYTX*G%X1(:,\@+[XW$; M6?71H9AKCNE@P9#8(I.-]EN(.S-J^[R8TCW$YMR 5-^B<[)P5)?A J/$ZU8M M.$B(3LAD&OC \29YN> \*PM<1.S0UGS3;AV197D43'^S-+=>!)UR\^MKXJ0G M,.2%S">&22K*I"BNX:.KBB=2.C9D5XUR&$5BO[K,X9">1"V1LK]4$84*,5;S M$V0A=<&>KTM$BIU-.. O>+92?9O3%V4G(BCPZP M'J39$FJ@K0E!]Z:EJK(RI-].T6R.Q(JNK]BR-7NZT[NLG/@H^?$;:IX;)@VQ M32XP> !T/1 "VWI15 Y6LJRN1,-]H/[*X(RCQ_.-\FJ5T/$-NS>#^?*]LP@ ME'X51M*_14'T[ [\J17DWA#0UBXO94?]4L!)W2" AY[XP*W]'8MEG9$/HW'. MRKEQHZYUXA<"Y$ZV!5!J/P(*/VQDG$\L4-$[2O[,"FFL M)HYH$1@*@S^#BD8P;K%W,*:6$0%)7UJB8B]$YJ MLNN)R48*:.:A3U/<"5-6.;]Z2^EL=?(3\VQG82L#O8C %&I$K&((UIR?.Q-W MCAO*'9A:?_BZZTF4Q;T(5$VX65^!^PBG6C=@67!C"8K@U>!1\I;%4RH]I:2? M2 ^FAEFH2\:21MWYA[=*3RP8E@"[.<6=%"W91( 7H6EHL\A3-)X4BVZQ(PS M(D/A(Z/"12S*^JME*<'"^"30SI_?@J 5;Q&YC-F&V]%<;S1 B!L#^,9XH0H4C/MT!X2^O4>OU6 M%L)%$GIN_"&CW'07(GE]7"9H[L!*OC:SX0*X/E?#M[L&Z,H&7]. Q$1H,70WA:;QP_ZN+ M390C1 0>6"Q*>F#7Z]AR%JJ\MM>:U_8J.DAD5.UA+XA8AFNA1A(A!%%#B5AM M6UG](9;VA0A!V'U_B)R^$"$$I]X?HA*VE;#=D[ =[#R)^$A-M+MDS>+*?V)E MV:5*]6)01"H@JN_.ZB84A&MF*%A3]979_L?:($1%VT5U1JHFE"1PZ!X5 V*) M1EM=HYOO'JG-8F"L;(S4B13?DBKQQD20_5.@HK,8$)&KG5L8&B>79.WENJVQUOHGMT9S:990\/812\W5=L5R8^F( M%']I"FI?UEJ9Y+%G2CAT/=+.2J66LUDINP22$[-M*/>G1OT7'AEF&KFZ2;TB MKN_^<7M3I]\L[B@_;;RGG0X:7;L8IYQ_<&+M-_TL&E!9"A9L&&A"!375T.0^_7T#(!J0K0/2D^:N&+3'EH^G:[<(0#3' - MP1Y;S@#!:X ]1K:7' T\2$P?%EZEXUI&?'@ 4LY (-"P/!:+&P-&75MDE@8U MUQPFIG>QZ0[^%'9Y]5S'$F?N8IG2EQ6(CLWJL2D C=$ F4.%3PY\;MJ,@Z84 ML!"",$M5G->)O&-; >SB)@>9JE.,QM*)\0A4B0,0U6(:&S6^BV=$E*BO1X-, M6&".U\B&GZ)(<+A^0I,X A<;#7C]B;IQ-@.E&C<9#).[?E 1$/?7D2#B M"'39%',/<2#$$(4F<%!2UV@<@>)U+"XK@5VR9Z.S!.S'0#E/=&Q-R='1SL'8 M?_BFR _F*7/CB4C;2P'&D;!BJ11X/^>43%*8^ 8@"$^_TM7695NTR -3"0P!*.(@@FNBXC6G32_%MLM;0+-)1 MRYHS:C ZF7/4N "_B0@R0*ZY<\F_P)\N@QT0%(!;I ],R_3H9'_*P,HEN&:P MT]1]0QG"V\X488J*202=4/9XJF FCB"@'4 OSSC&#L>\EKLKE4>G%JCG3XQQQ-8EF\'>XJ+ "F U8(#ZD=CB'-S6@2NUC1PM0G. MECF?AB\/C8D:D),1"U(>!)L;Y9OKDK]I9V1UCJ3:4+;HIKU()B[( P;O(*X% M2I# Q>D9[9H/LKD6\#O0)QK42>D4'R^0H344GY81R@^DUI!NQ3RI,Z<(ZV$] M!/(O,$P200CH"EZA0%]$-Z#,L/525!\PU&<@RZQ@ZQ MOFM+B(FL=5DA)(6? M!#T /)D< + 'XJ\&;D)PJ([2T0QW4,@Z+BJIY$)7=Q-*1 !EUF/!$Z]T:N*= M.]9M\S\$ ";AX+U4],>5;7P3J1OTY]THS ^XAV^$[(MR=E_XB9H:W3/X*K,4 MJYCM:XW9[NR [-ACME_FQ<(P:,/5,'FQ@::'- E0)?FV^8_%P"!C1(QWXRBWGO(O&!4T M_DCA,)PWFV"Z"SV$XL5#L(*)@O,[B2>R'PW7! 57# 2PA,'4GR$FT#N*HS@T MTP*K%&0'6C<>DQH:S?_XMO$$7HO! 9L@?.DG?9YUY/?" G,GLI"@H"H =<$3 MHLY^IF'J(HKP94YL+CU\C)*TE<\>.!A(,#^<&0>&5[Z@50\&W[EXZBT]41,5 MGT &$=V!#>NXZ+9[L5L(\)\PAD#C!I-^_GP=*\>*OXPO+*:7-A2PP0+W*74& M(,QGX:?&EPC""JOD$] $ICYL +IG*)$P@HW>^!,8TKG$?'K!V>-5ZB< X@%D M345=QT)=K_9D7SC;Q6R!H!YW517N8G3.%-?S&(F(,CC@G!4T$%&OV%@"CGE0 M0YU/E)'E/'%A(<;B7?@<3JQ3.-2?DGF$P4N8V_1$A$KU1-2.PJ-!Y)9"@VAWR%H9)@EU;=H+VH1@R1IG3!234<"UH7P(?"8Z MQW>=?XNX=S1:&#.DKP:ZI8LH,D7<4EP66YD95A&@[T8]HBY64 -"(% M@@=H/&'EABDCRTB?Z<"E#Y@09S@4- Z;BSKP5ZSB $L &DJL%#!H2P$@Q=I+ MTS7$'G:K]M,!TUB$,T"_P *.*6+Y=)SFVKOLP?^R6&"["$)(5W]-BF?L>,43 M-G@42I<..6RU#,HN5F/,1-$0ETEF0D'F2>JUG>O4^="NSGA6M+>X87SHFD%?FJS3H%[L-*A75YL/ M7KZWNM#5I>7*,925*XL.RY MU%+R8R7>/960*X[-W%Q=/34^-YX%H-QQU? M:,UFZP)_OL 'S^3PP01@'27&A;]USWRE#)U- MQZ4,G4W'I0R=3<T/WT&C45Z3(#K$RT0UK,J@\ACP09FHQ:$H\GRAV,3\ M8@:..0PNK4P[#0O6ZF_4<%2I _G;:WS-M5C.'N34M^B[0>_ M_'*!Z#??X7_AS_\?4$L#!!0 ( !)(#5$71@!65@T %B' 1 ;7ES M>BTR,#(P,#8S,"YX&Y_U^R_KEY[_]U8+_3O_>;EM7!+O. MB77![':?3MA/UBV:X1/K Z:8(X_QGZQ?D>O+$O;E_> :?@;Z3ZPW>Z^1U6Z7 M4/8KI@[CGP;]6-G4\^8GG<[3T],>90OTQ/BCV+-9.75#YG,;Q[IF*_'[/PXN M#O8/]O??'N[O+2< ^@)Y0))E0-I_!_]T#T?=@Y/]HY/7AU]+UN,ASQ=Q/?O+ M_?"_Y'',W4GW8D>0Q$CC6#%1B MX"=4>(C:*7['BP62S&\Z 3'%2K2L;P-6$K$Z.,,GL+WWP!8=('1D&VCO=]N' MW8C=%^T'A.:QR 2)L5(=$O0BG+E8:&4412,DN)?GAT(]:]M;S745Q"2-&&64 M^C.]_QV/=Z1(-\%EWWSD4LF!#LMRT/\ 7NR/XDYLO$&;5&G1)0RZ+LP M2H4ELFP^)] YH> OI[(5G\BHC0"Y)1]@;-+KEL0.]&Q?HNQ1YY)ZQ%O);LYG MJH:619RSEI%#U@D(5*T.GA!*%+1P,.E:;2L23SXBZEB!+BNA[+2359-0[@OL MW-&?U?.<8P%JE- U%(2"(4N!D(UKR:RA:$7"@LC;6_F_3SUHC+/WR)5C MR7"*L2<"OVLI9G\?@)/ER(Y#AY\SZF *>.638"YQ@.98H68K5&T%NG^X/W3R M/>)@WA1[!$ 7QR+-9@[,X7,"8[U*5?6O70Y4[$1Q-SEG,[!P"GXD"WS-1+K? MF#G-X7I=+5SKJBPVL5*56;(VZ]4GBGR'@,R/X$4AF2+Z@$6?#CUF/TZ9ZT#N M??G-AW="<1@-,N: OGE60(-J+4*M9,7_M(*J?T2W4J2*1]>M%)CC_O8/BON/ M(;J@'2 QO7+9DV%HCCG,D3QZ5B2A$DO5LO.=-5C\"#M>],/L^GBW%Z/'N?M;CL0XKH60G_:S>>N\1Z)0Y+8RV MB56! IK9U]UP9S<"&_B-:45*[<"[3L9I, M0W\L\#T^8EAE2G64$GSFP.1F MV>95J5WO,Z76G(JRKA(BYF 9)]V;5ZMV/'@;%Z12<2O-;0Y9;GI>>A7K_S%: M\A]YO'> )Y8Z%GPBSW:>M029S5UYB%>533F>G+7DZ,23XO>):BQ9#S2@SDN8 M[*)Q59-!!+O?T=9KJ?]%C8365]7(3(/]3J:>KVMY48.AZU0U.-W;OI.]%W$E M27/#P\V=]>GF\'?V!/0I& [#ET5S1ZE-A_:#ZP;7S%:J#"+R5SN2:\NB=O>@ M?=C=6PIGC;0*B+4;JH&(Y+8 H;^-4++Z2$#6^Z92C467%705BR(A^=!>2Y<% M8+SZ4&"YJE\KV,&N)Z*29Z+)7RK8'H[2M06>$O*GALKQ5LA4(0N[HC(B'Y\)RA)'O?JM0H$@D%(XB\ M@?4\!-N.9GD<&X:R\#J5FB')O.:W6R0<].T? H2K8!#>'*RV_?P3'*! MT3"K@GS&EYP?.//G$2,!%I,9\8'4^$AK\D1KO)H;GVA5&QPKN43UWF7V8V3G M\]54=D1P1>_$BW2\@#/4VMPXN]XWP*XT8L3N@JA]X(BJWY>0\K(5#M>?J/!= MR-*\./8OIJV":P+:.+C!<]:R.8:HI)O.C%&87O/52_FK+X2/G6#U)9C JYNY MUP2-B4N\U0#;+A)"W3L$*\-+%@D7;:F@L5[YC+B,J1BQ>Y_;4Y5J!^9J*=N. M %,$\^\7@ O,0MQS9F-Y+S0 FBG;WM4.'G]'3]]B+P0IH)%@LI HXZ&W@-A4 M8Z+&<8.17#%S>MX5(EQUA6S[T;-L-"R81GI_L%U7/K6E$'+/PP2PX!U2AK$) M;XEP<(;1JO? L2+*=SH/7NJ1-1NYZG[S%XR]PV!<4>672\QM(O#=)&IY\&ZZ MYQ@BY6 G*MLPF&^EL.Y!T?1B>D'?;*.OL>\]:8>L2-YX%1X,OY'Q.D)CK1C@ M!01%5=VG"RS4]E^?!KF[A#S$,)$EGCI4&MA73:2I[Q]U>0W 0[-+&'0W&4YA M&@:DV06>,T'642W/WU234[BC+G;-$+T ; LH7ZAL7%DT6END"WQ5^3^52Q+F MZ"[<5#+^ > ?ND,XS>>K;JYCK2\>U@2#@'6UKB335\&M(3K$I,S(QU)T4!>LUMXS:T 1=(OVEL6 C5]UF1,G$ M/2?RM7OG>S+SEY\K"U<=-$95E*G;Q#Z%1 :T@4._M^G(XX%]N;(PQE^]5F=OV%H@HQ%>,1WE5UMB2,G7GV JN+(()7V+ ESEBRJ)" MED;'+H_Z?)>V&'68_ J=/-S/Y2@X8CWJ M$8>X2GO/^:\?)/KWG"V(2"WZOY"RFGV2G,L,(/WPV,3/9"QFEJ8VWW(G$W/K M4]7%FK!:E>QO0^3B 1:8+_ -EFTT,FT3T[:&.&R&"'V)A$:M^O>>$'=$&KJ6 M4CO>>/-"![F(6#OJ];93&K"FO$%8AV19!#=):A)B#.-'(>84L7;4HRE,U!+[ MD6G8A=3:<:]!79'L<%= :P#F&;SFU#K('\&F%[F@:L*:\=:U]PA%V2!IHMK!UEF.SFVJVFO':L%VAU-XDF'VFX>E+M MB-<["/%4(EI 2^,OPUB_->L%\7&^Q112Z\>M1E^U G8/,Q5(EN-#.QD32C V MR9KU*:1;1C?;M(&]=LNB_JNRD^RXJ2,U!K$>;/-PYCJMCM 8M*,G5M *$H3& MH+UB/M?#35&:@S>77VLIC<&;FR_J"+6C38RL:;0Z0NUHUXF^9LPM(C8(=;[/ M%= :A#DWJNE)#4*LF=3J2 U"?$N*(:=HM6.^]\VHP%^_;9Q-L)#;(L@=8KX@=LX:$T?M^ =8GN&8 *C(M^$7*WQ*@FLJ:6LJ M\-=NVXBC!78SJX+ILMHQJIU'][12G_. &5GAFF9I[OKM0B[B)#=1RY;6 MCC-Q:DL[XR^F(ZB1(]N+L#?*%GD"+5Y=$84F%;#5;DFX,M>S/;(@WDJ[;)04[Z&,FK2#DE@$=TT;/QEJ@W"/GK!;O(>2H=:..[N9;=[J;@[N](S# MP\4M)4=O$'9O2HS8<_3:L0?G]"'?PCQY6R>S,;2!J78K$@F*/'+NCVU&U:N3 M\?RK:3-G[?9LRL+D'X0L6*C>1K)V>^-%J/PK0D]J#&+-OJ^>5#OBV_XPLY:6 M**@=792WJPLUZI*X?N9>@J]V6^0!,L3M*6"\@%;KLKFD1SA'+#7J9">_VXC6 M;G$?QA>NV<+)%=>.-%CYB5YENE6A'*UVS*8_ ]P+YXCQ%GXIWN?/+,/CMB]V M]81YLGGGOY4AL@:6X6R<>>%'Z\./VV9-*J(VSHS$5P6N.)M%/85-LC=^RS#^ M"0Y(YS^87Q#!:C*-BZOVSY#H+2W%VC@#"_[01T$PRS$WSLC$!YN#RZ+K#SH7 M6%I%HG'F!O<08?B?J#\RO>&^HI&O;E/*7ZXPCSU5A!L7SXV?7BZPO[I7-Z+3(P M,C P-C,P7V-A;"YX;6S57=U3XS@2?[^J^Q]TV;JKV8>0!.:3&6Z+(3"5*G9" M)UKU,"5LANG&DC&P'V+_^6K;SX<26VR&V!0] ''6KNW^M5JLM6Y]^>YQY M9,&4SZ4X:_6.NBW"A"-=+N[/6M_&[?/QQ6#0(GY A4L]*=A92\C6;__^^]\( M_'SZ1[M-KCCSW%/2ETY[(";R(_E*9^R4?&&"*1I(]9'\0;U07Y%_?AY=P\>X MNU/RYN@U)>TV@MD?3+A2?1L-5LRF03 _[70>'AZ.A%S0!ZE^^$>.Q+$;RU Y M;,5K]N3_]<_C_G'WN-M]>](]>IR T'T:P%?Z&GS5?0^_>B>WO>/3[KO3UR?_ M1?83T"#T5_UT'[O)3TS^R>/BQZG^=4=]1@ *X9\^^ORLM:'=P\F15/<=$*W7 M^?/WZ[$S93/:YD)#XK#6DDISR:+K??CPH1-]NVRZT_+Q3GG+/DXZ2W%6G.%; M;FB_(8G/3_U(O&OIT"#RJ,)N2&X+_:F];-;6E]J]X_9)[^C1=UM+XT<65-)C M(S8A^B_XR*I7P)7_Q;@+?C'KZ"\[ % X8R(X%^ZE"'CPI-%2LTA84"#B-E5L M>X3O_H*A#9[F,$)\/IM[8)#.GE(.1, 4GWVFGC;L>,I8X!=)9Z*I M3JH;JL B4Q9PAWK[B)C)X*#RZC'(-&[^<'(A9W/%IDSX?,&NI8^U*HI'=5)/ MJ;AG_D", ^G\F$K/A0!Z^3,$%]Q'_F)N36BRCR<]AW5U.E)_>N7)A[U\:YOV M,%+&4W&A5;>:':;O,;\7? *6A\#I.#*$R"GN;Z3''B>9 UM/._!GF/U>''8@YJ)G*3'48R2YD! 8DBP %3(G0TXP' M*+,A2 _N>Y<+S;X?*NAXQ.9219X$XT^Z)9P0P>4PDL<=C<,[G_T,X=];65)H M-(,:1OE!1GM]H_Z6WGG%PA935AD!<#)B: \ZP_190+E7*%=VZQH\$2E?&1[5 M^2%26 1IY3+>LL<@+$XP\!RJ'#M8)\ 0UR GTK9E>%2> 2!-C.=09SY0/DC@ MF=64'2!5*,O')#TLK9S0BYSN&CZG*,#[F'#9*N?02CRS2 .7-8^DG-8C;;*D MVOR7"I?$+$B*1V6B&ZLP*9&/0<[5T@_^A['@PJAEKO[/A[G&A>]2 ML$SD7VK@22TG![9?D\O=SWP8$UFMJ'5O@CRX'+*BG MG?X\N*!*/8&G1[79?$60Y-L*;OC4N7*(5"Y39ZW>LA^JG)0G[58_DQ8=/YS% M7MOFX"M+^HF2,Y.]$]O*?539Q 6D:)$'QN^G021]@SB.&.0,W(%!\4Q$2S/" M87O<*+9[6L#1.WV$"FNL$%X*9*1*8J.S(K':AV(D"Q:I; MYV;#N=ZB 4G!-:,^&VF1AI-O$,2TSOF %9#9D2\5(H92WCK(?J?J!ZS*(4$8 M,]"/!YRAXD01G1U)4B%H./6M0RW6KBB*VQ+L\G+4_:?.9D* 48\7X#77G-YQ M+_+QPM0LJZT%Z[@;^J0'ZZVB+D,OXS*)FAX:^6#D+.4,JEOG:5LRET6J)$C5 MC?M]0;(=G_]0I:@NXP@W2E3\81A$>W(A?5;CD MH&$('%8N(4II] )\*G^[]ZYK9;5M\A:NG,UDO+&[Z&[M3LNF!X9AE[TL$-U2 M1SIW7:[UIMX-Y>Y 7- Y#ZBW(;]AW8"@;7K@HQ'#&\(^#!TGG&FCLOAN5>JA MEH%PY"QZM.4K"X:36_IH7 B68]3TJ@./[GXFL@[JD=[#)9A[296 7,C?T*O/ M)MSAAH000]OT@@0-*-X0UF&XD6G (KC,3%Y,V?0$B=4M/_EZ,7ED&?V*GL[+ M4_-39UO+:_AN0@--I"+!M5VY RU8:OI (9 M17R[TWFZ553XU(E,+MSH4P* ^[\P]LC/; (T1I0KZ[#I45S>0RJVO86%MK(O M\DK5I-X\JR85]T:X()O]_8O.I?^1Q-VFJE3U5N7*OOTK99BW=1JFX?+ESAO& M4I9X]RQ+ &\2,;>D7*D?H029;I1<<+#:YZ=OH,E K!*T' ?D6TN!+&NF6D?HN@HW$%D/]18/RF(../C>60K?'L:R+O,=3V&M MF_LFXHR-YSGM<4B^MQ#) L4LQ0T654H_---G\=^!V'U!43Z*.&HS;\;$K?51.78MN*"-@:)&UA>Y+PC?/0H=$-S?GV18F>K \>7XY-],Q$R$Q MLK$ A%'OQ077?#0+0TY93"VN'*'M8QVR.:K'Z=OS"LZ9/)I]U9?#F.M? ?P; M2\$[\WN^\D@L+40;@-M]_9?9'-;Y*HREZ,[-E529PJ,VA)1B8FE)NP3(Y4U6 M2V:P7AQ&[\>0D]!E)>KR MXQ!O,/N67SE&2([(>%:JD,G#DE1AQ.8)>$D=LES:8""W-(4P &I((0K-9%T0 MT[IOO7-\YYWDZ0L;+>/3)G;S?L<+W6C_MA-MLAG1@%U.)LPQ>$O=F\U0K?VWT?*_/2>*^XTD_5 P^K%I7MAT5=YIK2LH/VU)N M\"!K)F3-I3+IC8>];@K=ZVX+O2(E*=KJ#&T^_S4E;&_'PIJ81-0D^R;LP>7% M' B;$OIX6^@4A^C8KQ2/.EP:K$I>)625VK?,L;4ILQIE38F8W-*I"$6?VCU@C$SO2(TJA8U2Q^TF])P9P9'YU7;RB7K3_U+;^*' M*_\'4$L#!!0 ( !)(#5'=*O+-QQ "3\ 5 ;7ES>BTR,#(P,#8S M,%]D968N>&UL[5U9<]LX$G[?JOT/7$_M5O9!EF4G3N*)=TOQD565$[MLSU'[ MXH))R,*&(C0@Z6-^_0(@*9$4<9#B 3J:AXPLH9O=_35Q=*.!3_]^GKO6(R0^ MPM[QSFAW;\>"GHT=Y#T<[_QR,QC?G$PF.Y8? ,\!+O;@\8Z'=_[]K[_^Q:+_ M??K;8&"=(^@Z1]8IM@<3;XI_MKZ!.3RROD /$A!@\K/U*W!#]@W^_?/U!?TS M>MR1]6[W+; & PUFOT+/P>27Z\F2V2P(%D?#X=/3TZZ''\$3)M_]71OKL;O! M(;'ADM?\Q?_S[_NG^WO[>WN'!WN[SU,J]"D(Z$_L._K3W@?ZS^C@=K1_M/?^ MZ.W!?S6?$X @])?/V7O>B_^+R#^YR/M^Q/ZY!SZT*!2>?_3LH^.=E'9/![N8 M/ RI:*/A[U\O;NP9G(,!\A@D-MQ)J!B7(KK1QX\?A_S7I.E:R^=[XB;/.!@F MXBPYTU^=8$F0;OQN&/V8;HHDK%-"^^C(YYI<8!L$W/F4$EG"%NRO0=)LP+X: MC/8'!Z/=9]_927#BQB;8A==P:K'_4W=:/I6Z /H3(H>ZT'S(?AQ2+,,Y](*Q MYYQY 0I>&+!DSH6E"G!N,P*GQSO,?08KY_&=GW1H@Y<%?9E\-%^XU"##BE). MO 2-/\,7&;8FQF$@:^23D;3G%17@%"+S&" ;.!6$;&00:WRLM<5,MS\R^D) MGB\(G$'/1X_P ONZ5M7BT9S4,^ ]0'_BW038_C[#KD/[VK,_0NJ"5>17<^M" MDRJ>M GKYG0$_NS)ZY#Q''NV5$' G=#PCO*-7BB>CJ!EMDT2&OWO;-'QOXT)/3!UW"!"?50NKIFRR!]"3 M48>VUA'F% 8 N4JYBENWX(F:\I7AT9P?:@JK0=JXC+?P.0C5$PQ]#DV^.[I. MH$/<@IR:MBW#H_$9@*:)]3FT.1\HWTGH,VMI=J"I0ED^,ND!L1,%BAJG!1%$ M?)+ $POUO./RS2@+8H?W<."@.5MPLTEL_*"TA99I6Y"8/VDPA_-[2$J*FR5M7E;@NN4DY 3-R^7A8%Q6M(2F59^$ M4Q"Z066G3,BS,M.OD8?8F'-!_\S(301@##>,T=*O&8\X\#ZR!E9" ME?X(/,>*6%@9'DU)+HW!9B3>IV(N S_T,QT)'6I?Z+!//IUI.O0WQXH96C%' M*V'9I@+%T;.,-@>;:&.]R3SAGXUKIQ?,S2CXMIR"JR=8>&IEGF&QAUAO?O% MZ"!*T[*Z&K'?C.+O-E(\>IJ%/"O]O'^ !?9_MJ+'9DP1&R(QA8OMC/XNRRIA M4M@!\HYK"OQ[WGN%_N !@,60S7:&T W\Y!L^_QGLC>(TTD_QUW=+P:G1X81^ M7#J""^ZARY]]%S&.2"!_W_II#;#3D'-ET5D]= M]E&J0-3 79L3"A_G6\,]I;R>)BZJS'.W2U M6:!R%RA%;L_Z!.RQ%V7\C'1\K9BL5@P+)\LJS+)0"/"2Z5P 7Z= Y60]C:?@ M(H $S6L%9GU!H$)%:G"LHX (G/V]WJ-S-RK0H2Z DLGQIGWAI@AR)44@'G0+ M(@OSX&@*\C5>-8H 7&MZ5SMVV>6K !?Y6X+5,IO9V8T=A]L-N%< .1/O!"Q0 M %P5*E*R!EZOVB%2*R#$JV/ ;+JT#5TVZ;ZD*R:265M,/#KWATKP=%G<%?7U MI@%92AGAH-8MJ-.5=UB(UXH%TW6 M\VWO#KO!I,22JE!D,T>KFQD@T+\, [YQF?J/!(I\4_.1*)18V&-5!&(]!\2^ MB;S\/I\\O(:\8[W%EPOVI_^% (__?39?N/@%QCD[SZ^&_PB?\BC6-HD)L+<6DM1""^-1'$J.NI MCF*.OJ\P%JDAPO&=B3AR/^33X&HO(B?M*WHY#43 '9H(7#SV5T(N1=M7Z/(J MB+![W\"D1^!(T==GSY#8R(>7T]\ 86,W&Z^O"#P/61HN^4XV[:F!O;FHUJZE M"/@/K0 ?N6%SR)?GWTOH*ZHIPOYC>R_]!0+WR*5KX&MHN\#WT13QR;IHV:_R M?RF_7F*KJ98L,6O>Z)OJJ\XQN8'D$=E5US)K;,R%N;(VAH;&-;JC3> 5\.DK MOC)UA !7C3K5EC;,Q_:_P>!R>@N>I0E$$9'QT*ED%^*4"A5]&N;4H@_];L2& M,XU]A8=M[C[K=A_B6N%OQA#O-S($Y6UQYNWL.\R7$6#7%&R(]Y(5,\K!43:\6E*>&E%<9IF4=[>9F7I%:&MC$SRVN.,[*. MUNS+B"U.;67)FQ)7IP8Y(_-^7N8,![[5/,.C!7?6J4;.Z' @\^N(FQ6QLV@W M:"UY6@G3II32KU;.Z/,VKT^LPXJ1%>"652E7Q)Q1YUW);H>.6/&G!GMSC3KG MC!*'6OV0]2;BT:#@6L7/&='?ZW9++4@O*)'.R"L:2ZTW,5F3UBU3(IV1NNS@ MVH8V.C74:27V]4;;E.C=+9O. 2)\-9^NZOE"<+B@5EZ*O9PRGH H5[VV.%E? M6VW.NM3&E%C4Y0.Y!6H9&_:C3".ET?+C?Q#M5(D]>[F MC]"5UVOHTG=6N%$*,B':&K8Q;?/84N2O$+ ^FW?0ZWJH*@I*LNFF#J0D4@*8 MRQC*N$*1+N VN;"D/9J;9;2X@ZJD:I]HH*,"W6RO!. M/"7T?A7\]KNM56D*P'WS*UB*Q#ZH N%!MU4J34%X8'Z]2M%J>?G=V/=AX!?- M+?WQ/6T.[$""\X:<[]YW[ PUKZ_J,(?(B;H=B2?>(_2#[$NS"JB(/41.UQG^ M-0*%R^IKZ% M,TFRA0C!1GH*7?8_4G=1RB;"@<<,ETKI4JKST&1@9"]2!3^! M>VAH+UR_=;.SI,3!H9DP_5JB61ZFMV)FK6>EI+F&M]/0'B:"0P:=T(674Z4BOD@3U2%/]3W" MF.1%?1Z5WQI9-Q[]R'%$.PE7NQ#CNWKDB0TI47?'4-6.8'[VK325:?-N@"K)L\AH[YM0 S/%G1!&8F)R-JQM7DC,,U]"$+!(X]YY2%]_""G^[US+HH MY5$]&L0=92#TWK/\X2]:VIC9K=Y E_)\H+)_!>0[9#N4-$%447:5@Z@"H98N MAB8>XLUQ5/:Q,Z?&9$,VE;0]/4%,<2ZMC+'KH;;;RB8\7/36,9KAA:W^(S?X"%<#!=IJ6+2'=3*A#<%;*ZF1"X>*(M$]4/&(=UAUQ).=>[]^&EZTQ452 M;KD\#%Y%>[??%22E=D:4U$>$3\=AUG9VOK6.:#5P*NUNDZ)KP#6'53;^I6^9 M\R=>=-+I%X+])DKJQ _KI]\T9@@STW2;JGN.R12B("3\]&3Z5B$2)=L3"S3G M95GUU%VJJ6GF0IR=G(ZC.R+2%Y.( M0180]!-*J3(BP+J]@?*$7?RTO-7KDERCAUF0N-H507;JRJ_X5W\D@;,*NYZ" M75U5D2MT>Z=EH4+?0F9!NAA;)L=/@.M"Y_/+&;!GV;8EW:(,ZU?D(N75%KE+ MU6LT:YQXVWSC/N)>2U*BQREZB68]3C* M%<$VA([/=K+%6WP5$GL&"H-]K.5ZPYZ9 M7J:$T-HUQ\YY,"<&7V#G=),>6GA=?'$JOE[;?H-!\EI=0QNB1T%I)VMP9?*:V$8%8-MBA&@_@D M:F<<+(]U5 P+!10] T1+&R$058,H\H(YMG7M@4 >M#V%ODT0#\4)L) 3]1 . M'87$>>_NP]!1X/3*!>I$:G'[GF&FH8L0KJJQ!,$+E(N#I7K5.)JM?IW*L.@9 M4-74$V)7-?H@P&[BV81VP'#B+5>]/)@]?@3(93.<)]@7[0F24/05&9DVPB1^S0M[@2!Q9UP4;9&(GU"] M'D"R&@E!Z7;_3BXTQ'OJ4QB]^LJ%4B%5SP#4UD@(8-U!AKB[70\DL?MF"5^U MX55-)S6H\[\PNG6#+M0?$=NQ*WKW:N'=,X!KUEOH!AW=-B"Y&UYZ4/_:=>3R M.^);OJ993J2^/-N)1@6;&D<79>0=M.EZ2Q.*I#[W+MS#FY3FC[ MM05HD:;;(^>:J 0K-O7VW+CMN7';<^.ZJ^W:GANW/3=N6\6\T=A5O12YXWJ, M;2GRMA1Y6XKCJF1HQ,3[[4@*/19^)GA58>A%_4O.V]!=KOC12?EG<4:&W6N6;'T8EW MNJ5^-G3,R0K92OA7W[!"YTZD3AJTOQ-MW6BX6+1V1H3:;6ID+Z]O]Q9[<"W3 M?Z5VFX=SF?$S35J_RDO@ME@BGK 7;K^W^ J>E>9--VE]FX+:O&OB"3N.FLN! ME$$+O>T'9=G+I;2\ MO+]XDIPN>.\ID'J*:4Q51:'?^'OVSSUU%OK-_P%02P,$% @ $D@-41Q[ MK&85, NI@" !4 !M>7-Z+3(P,C P-C,P7VQA8BYX;6S=??MSY+B1YN\7 MSS3MG>C6H]>W:E5.DGCW;N)C0F*1$F\89$U?%1WS5]_ M>/!-O,AB 2D[PK:Z*A/U)? A\4HD_OJOW]81VN(T"Y/X;V].WYV\03CVDR", MG__VYJ>'X\7#^?7U&Y3E7AQX41+CO[V)DS?_^B__];\@\I^__K?C8W05XBCX MB"X2__@Z7B5_0;?>&G]$GW&,4R]/TK^@OWM103])_N/3_0WY)_^YC^A/[_[H MH>-C@\+^CN,@27^ZOZX+>\GSSUR3]-7OG)V;%/21%ZN.Z MK/4N^_V_?[CX/9Y^^'CRYX]_ M//N_AK^3>WF1U;]S\NVD_ ]7_VL4QK]^I/_SY&48D::(LX_?LO!O;UK6?3U[ MEZ3/[PFTT_?_\>7FP7_!:^\XC&F3^/A-I45+$>F=_OCCC^_9MY7H0/+;4QI5 MOW'VOH)3ETR^#17R+219^#%C\&X2W\L9H[0_@Z02]%_'E=@Q_>CX],/QV>F[ M;UGPIJI\5H-I$N%[O$+,S(_Y;D-8FH7K341!L<]>4KP2@XG2]#W5?Q_C9]+B M ?VA'^D/G7Y/?^@/Y<O'3EFETGO;8.]P&B;!93P-=5_; M$7S2=])\#P/:^M9->$QR+YH$OJUI'?8MGE;CC9[]FB:#"9Y6TRW-@\#.AY!' M5Z^X7B/ZX0WYJP,1?\O),(F#"B0M0N&!V2^P@:$LNRX]\3OE1M2;)ZG0=E;D MRLN>6+E%=OSL>9OW=-1\CZ,\JSXYII\_T $2KW&<7_Y6A/GN M/%EOR!PCSK/%MS"K?I!9^[2EOJ9>2HGW?D)&M4U^'/$6 MX.JK-%D;0RDK,3%4^"5ZJG^'USR!(C&H(Y;BC$UH1C5\VZHQ-5RB7$=$BTX2 M<7S\T\.;?^&BJ)%%/U/I__SK^^87W/%L$00AG9!XT9T7!M?QN;<)B9_]@M=/ M.)74@D;')L^,X+=YIE0 PS,3E'V>-3J(*I&),"K5T,]<$0CE[G'NA3$.+KTT M)JNI3,DUF;!-DJD!M]DEE@1#*R6\/I\J851) Z,1<:CK)'[($_]7)8,$M;'?K&FM49!DV5P1!Q+.+!\+@\OT:+/$_#IR+WGB*,\H0,E"F9D0'C MZY47IFQ?[-.N_O/?0IR2BG_9W> M891\#6"J;).IXPQJT]1,$PQ'1\'M$Y1J M\/W0(U0K@5HKU#9=QYLBSYA!ITK7J=1P0D$Y="'OAN+PR";%J&(85SI"3 V= M0G6!+=L^C&;:!RA,^S".:1]> =,^3&3:AU? M+/13#N#PK2S<4P[>P5,.YO( MM#-@3.-SU'H'L3H)5,SEE!HVF68 O)@$:S#.,SRE(#,8M'U>EKK(BP/D M=;01YNK '.$BSL,@C H*\0'[11KF(#@BK0_7=N313KM7,M5M?UX MA].'%[)>_[03%Z!PI ?]1:M[/H>ONLXNT>%^#DS7.[R-@YVHE@)J-$ -(Y?K M393L,&;[NPVNZ7"8+BI0S@X:B[ERVUXKF'D_>$=@'RP MV@I;G#XE=="+X4G(!X.S$$>5/O.Y.+C&,(.K.R*_KH_(7363G3,<>,TW&GJ_ M*9D:ZNBAR0R-EI>"8^VNE# >8NK M4 V7CI68ZV7[0685X":WQH@'$PPO(@Z;>O)U/;UPW&('/BL!UW;C8(\X-H$U M/7PHGK(P"+UT1SFW7+%M)=4M(+F\U56)#G;'<BZ)*%J _P;\5=-&R M)?_S2'Y/XTV$TK9]B0)RWY,(1)USR S?P(O4THB)(RH/ZJ"P9X]ZVTPLZY!) MBJFL2! JB]1;87T.N=]EN"?X1$ZG]YVMW80!G&H'H?["><.+T P:FL8H9'GH MDUGM%^QE1M47(&#/J18F)DG.^C$7:YU&ERC9$N#)J:9-1 MI-2?Q:MDE5O)L/_N.=F^#W#(O0KYH^]0R$>_<$3W^)EMT\0Y32/6JP&YF UZ MZ4!2-LEDG)-' VP09\;IT7%.B)MZT74]MT4$(JZ)!YTL0S2]" M-(BMJV00%7+2V.=%2J_S7X4960+]'^REEW% DU4*+)*+VJ* #FS%!ID<"&)H MP U.-[DXXO*(*I"I1L RBCIA3#7IH=MJ O.Z7]MBA@A4Q8;V=R 8( DG5E2 M&:?-7"?PE'@%B9SMAA?"[#.@(P2*"B)D4DYP81A>H'%C5^23_N:D4M(V1210 M^R3IB8&BB1B;E"CM,8,I * *)Z\963JR;N@B@"LF3$L0(&6&Z'2D*9V,.]KP M-=%5&.'TG'BYYR25KU%[4G97J$*(W?5I1P0$/>2X)&M3)HHJ68>,>%A[4?2I MR,(89R(7(I2RRP@AQ"XC.B* &"'")6$$$T65K$M&O. HHM>:O%CN(KI"EOD@ M -BC0TL"$AN&L&1DH)*H%'7(A[Q)4AJCS-]=D>_P2L0M;Y,K0?=VRX6R@&BD!"C; M.R_WR6JE\KT\2IF.262GZ2$UNQ4F273.D^*.$]WYTD@/]'5:-FFE8$)?78I5$"13(]3 MRK66*D^3ADIE1+4=+[QO"T$HDEC$_I*["VZXWN;? ^+) )1BI8VXH,M94).Z MA25MRI9%SA[N(T.K?.!6*EF>$1D8T)L7*30 \<@ IFR.U$JRS%?NA%=TD6*L+FQJDZ>=3)P!CAVTX*/>>+G>$Z'V'0YMS+:"(4^G_TF;NM%V'Z&%Y^[J7IC@S" M+#&WQ'A#7:MO-8TQIY.^T$01#.W&H!W0D"BQ$'&?_H$;=1B$O,>D$X5^CH-] MJ#FZ%,LYEJ:8V,NW-*8(,,2=AEN0AZDLA9$8!G$O\(9.$[/.D""I!HFL31(J MX;:I)A0$0R@5.@5M@E(-!G46OD^WV;)[[&/2$YXB?(MS-8/4*I9?L=."[R4] ME-7%31IHVN3;"E#;E#-3 M,,\09UI&N>-.GN1>=&.Z))6E)*2%(+]< MD'J MC'NTF2#TWQW1_"R2[!D;LAR;!+_*^TQ*A6[[DD/ONN7Y/* ')(6Y"!] M4JG"'!"NY(]0C(%DC5X2>!X-R[C!7H;OP^>7?+GZB;A;VA,D]:#1LV M=:8(I#=3L4DD$_!M.JGDP9#* &2?6I4*F\63V7NX9<^> /%/P\FB\:S2]33= M;'H.:Q="BD]]Z->:F<.@C63ZI]W)-- #,#U7[W5JE;,*&.F0FZ0UVQAH-5\ R1,D+<%R@=QQ#=FQ(YW?G24Q= M((Y].3>4&E:O4NBA=RY0R,7!#%YZC(-]S.67+]>/7RYO'Q_0XO8"G2]O'Z]O M/U_>GE]?/L"@V.B#'"A'-^,.:U[!\7:"1^\J_Q,Z>7=RG/QXA4OX&LZ0U M$92-^"!@5[B]Z,X+@^NXK,I6]_'88Q\K@N$@KY?K(O(RS&/Z:>YY5+\@N.,]!.:>V>-;Y(LN\7YT< 8XJ 0]M)N 6'!E4I*&'W.?QV.2A*YLEM.L<]W=P+8QQ< M>FE,AHVLA?P"KT(_E$T_313MWL8U-:1[ 5>G!8:9QE!59 RX) SN#2?:QC-R MUTLT(=6*PS1*O="'P5H8ZM MV>V=ERY3EH@J8"O".YRRW&CZ!:1*9(4N4P,SHIIC'>PGMM;M1\UJ M'1P)>3:^9@=!7Q%##4>DDT&7D*TO#I%D$HQJA3"NADG9* MKBYD);&X*%Q2=? 9$2ID&D#)I(]FR'%UNM1-PV4HQ:?""="I5&U%$R>FL[V%,(2_C)B6AC"T26:M#F0IN9P 3"8+A MC I=GS7-NV$AWX?^KO(V;P&EP+W%N=;;]&1L\D8(K\V7C@"LO2$1M#Y)B P@ MIZ**6/Z$5TF*'[UO=_0EZR1>Y'D:/A4L^^ECI,/?/:9>G-&7O4F%Q '[ M5\1>7EX$_Z_@(TQ=<1,J?:]?@]+-9J@RTUZWQT^]BDZXOWV#>0XOL:53 >$DSG'WJ,2E^-,+EV/0=;OV.:0@X'BRU.O6=\6]"+VZT)!46U_([NU $<#NS<"V!!BN M"6$-4U;4T9=,#$CH90WK)HSQ-?E3MODE$G3"C@%0(4-J*7@LZ4-3,(6*(B:K MI,MA)]M5 /L7EM9$,L7N"OUR9G=JC=,,:Z;6$H"JZ'M'52[)^"&O?J4"M*8P M SM/,I-#-I(^OX6BP4R5P37>:.!S9_0X: A<-S&$O/W$DM :2X-RS_06!QWJ M)Z:)^&"U SA:IXE/+R49Z@A/\">N8_03_"U8^PG1N_^1D@_I5:Q>^;7Q0IZ>YWS$VP MM!FW^"O[1KX8-]*UGMO)U)S!.*Y3=,[R*6@']W#)E]1S-[N$+ "*_C.LOO++ M&W/_='IT^OT):*;R\6HB50?* +@J,<^F&&EZO6VVMW*;XJX@ 'U6?26?\L9=M=R\U8'=W5W P% M.^\ A["FWT\;T"M%UC?$E M@^X;D\W9IW,X'#SJQ^[NL1]Y61:N0K:U(TH:O&]AKCN!N<%&XX&R)- D-X;? M)W6M@]*6$MNF Y1W6#_L725IE?]HPH)&4 : 2;O:/--EY: YT3>![5^5D^Y M^UHVE=MCTV0&2PL!0&&-@<9KT%='8C7LT2PVF4\<-MILKJL==F,!5"UG@M+D M9H?#T)C)$1EV0V+X0?MEK,RUHD Y(1X#7F2#BR 8795+01XXMF'F&.GE:L+K MHD:Z3B*I3K%,&XW3%HY2'89*!L:_\SXOHSIE"6++VKH7JYHDE4R8 A M6J4)A*PME:4 ZR7P0,(Y-Y2P5),EMF$/)EE)B]KG7O9R%25?= MEN(OB!?DL_)+LJ[0T'*NPBWGXIFQ0GI)?&8H&4RGF-6$.,")F+EU1O5\1F[Q"!:[.Z_3T8-@I ]5G4%CG0!P5+GT1O M=*;ICI)\G11T0GR?AL\OCWE"^L BR\0+V5'JUI:X$XRJ%[\C=)U3:2+@@;-: MTX1VO_.[&611T[BA"'L91K24_#A9'1,_A3Q:T,'(2)\193B:"(P+G(9;EAT[ M$]]6Z;ZP2Z:D6TS,>8J(0_?ZONIP/V.1W >KI%8GF/TWH'260QDF>+JK^J5! M0%#0_*#-GD31MFRE3T*]D)[_B-,U&6F2+!0'Q4TORVV?&&&NFO@&!0%FMSGZ MX?N#.2;X1 MYC2;\H:*,)@X$JV4>63ZBPEK [Y79(UT+G473M+4*)%?U.G"(.!XP)H!/*Q+H2OU=5T.RNJ"8*S4JV20W2F,ZH1?(&P] M$X04\"!H8B#IG'!&\(27X]'P8__]UO/!]NJC,[IE'5J0B M-%.U_("TL3&]UZ2U>M!>I!J!>;C;Q%6H?_-*I7( IEI W-O00':IK[%.%AUK MHNB6E3)#U)SL:\%GI 2QBH\\Y5B+C-7%&II5;K9GL*1+D+X%CZD7X#MO)W"# M1AH6EQLFT%N+#)6X\X'6'*.*2SD51QLN#]6I55Y;3+(1>C &6@'AC)6@1K^LU^(#ZS'*4;C%@6-: ^I05.7K__' MQ(M,*0@ E0T,-:"THA0PGG@R=%TT6EB5 "\"@QCK8QQD5P1G:P?_249BA;Q- MKFIAMRDI%0;#/!W"/L$J>=D&-A#7228P+%CI*DF%%NH?:1U5@E4"CC>M0TES M=6@K[_'0!S/7VJ,2S_B6K+?;9*8'-&GH\[S3\Y!9N@!O=O#O:3!*LBH404E* M<8M+;RWHUKI;*NO<\QD"'![AM<]+Y@\AFM?O/28+_[&]M0$4T?,RG A=,?+!@$U O7@\B\^FU&6;C;A2A,%< M\RGPWG-HJ(N;_18UKV*=+LT/7K=I750FP5^WW>%..3F4@U(@5O$+7U6I>:XYL92]5 M!,/4,6C5*_YPF+FG/+D\'J0$%&6;?75.>N^^#]4I[^>,7\5L0X[;:+8A<\\#-#2H&C@2\H[\C4.^+T^W\ _W"(1GE%O7?VS@CQ_<(Y#!*MT,TZ M"?)RE+]@](2?PYB^=TH'9/H!1^\JH2DLU@#,#3F/0?OS!I.OC!ECS^LNTV9'25:D^!%_RS\1F+\> MHEV$/_-J.I^BDF;KAX+?^,?HDG+#^KWS,XYQZD4P>E49UDZ3U1-S?8,$:PH% MJVG2M, [RF[(&9QG7KG)]:Q28/3<"WV:>2!\,Y M Y!]IE$5Q'102PF<'Q19IG-_&AW7;%,Z.Z4":+[I7%NS5KJ."<6*-9SCH<8* MFC>_R3-QCR,:2TE3Z6>N]20780=15,ZB'B(E]?%U': M(4[]PU30.;C4/P31.N2W@GBR2SI+QS&=HC?5H1D?1I9A]3QPBGF]Q^O,"P## MY"FH!X&?L9:U"X[F)M3W'/4JSIDU#N?@D(WEJ;KOY:FZ*_-4799Y MJ@[_"EUKK^URRTXBV-NS]WA#4[U7C]#*7-ZT(NP]]C[-N.:)]W'Z,"@Y#;1J M#Y87@W@Y+("B+@S= 0JE>"B>,OQ;@2O#=2_F2<6M'@EH0'<. 22RSHEG"'! MLEJ\XABT"6'?(.VADUS>):G41TLR8;"TTCFODDPM>CTFZ/$ ?DLRJ/X4>T40 MLG5_'-"!/&@" G PG"RPDZV=#\)[E.2?QC$;T>5Z7BORJ M6/I776YUT-](9LN5 RP[3>[$LYYIH0U M8 [/6X$KL0,YPJLB9B].>=%YD:9DW;PS<'4&2M:W2W/5C&MTFP_>2_X*"(>,J5UGXG2SO(-^2CYD%'E+]XY+L4HW6)@MXL M6]$(PBV+($QB5$.B[_6$0)9:E9ED5;#>1,D.XP><;D,?BY\A6D0,"[NI0-^^ M)O7R.P[XN,OB&+1[8(?[/:M[:(>NMLX>W*%^#$Q//K2%RL[-XFB2#<_4\4RS M*)'>2Q]63^)C7,(YU!JXO+!#\19>I#JTE4E:6^VJH=9+7+&8D7EBL2Y8Y-@%)H-2*#P-TFO9N@YNGG5U!&;! MA:5*% 5<]E A%SAOYW5;KE:8CNE)_5*N,!) KV0OX,+4@";>0J;PAQP M)PC":M>J3$;&"CE\4(7X]I-F(!BG[R*(DD:4 M+'-;YX/50A?(;GZ][O^T^^1%-,GIPPO&^>[/0;&"/=R M%'I@F#D"K/P6YA'-#EJJ(Z:/J@+0SZP(('%!C;4"6X?'^><>7WO>D+GO-?E( M=N"]?[%N>+U?)8@Y/ZU,@/UA+T-4?47<48Y$"7E053[ZF?X"8C^A[$MV_&'] MY[^%9"6>^B^[&[PE/_PMU+!#I6DY"]H6IT])AE7+WI&X%=?4:RVV/7V[^#OZ MF:HZ;\KK>$.F%LR4TR]X_8139?L-Q0$WF@)LOZ68$#I%/W,Y2,WR85RS?'A- MS=('*VZ6#Q";Y6QG:["][ M%VMU;C=3)73XO&>9<.9V\Q@B3P["3Z!A=(?6XX^"C">2&M(IV7ULWL2 [DOS M*@UHGM<(K?K5Q;67_HISNKY&&0UA /0BA[*OW33A&;.[9/.RP?CEL=5A[)Q- M"WX='GJD-7(WW8H. M996B::.VUC;2>$-S-)2&FU*C1_/@ZV=*N?[@\$. VW M7AYN#W?#0]#1#$XXC=3LW?(P-Z*YYZ'7<>X-1P(U2E8'[-F M9PT'SSAKHL:NXRK<1-+C1I9AT_U-,J_M!$<5X)RQ^Z 67/0H1=$S*0Y]1_QF M]I;& P*>[C9ADI*XR"9%7O9I-T@IMOCJI8'J='3&\MT$X\Y4+>+@VST+!]-] MYK9(%5S;3N38_HUV-L>,GNL*,S[27X)UM*NM,5F%W6@.=^ABHP3O\ M& -Z.$WANN6"K=8&=BI27LC @9CUI:V2^C%5MOH$R"B#.L^!&&F"<5.CX I3 MT)8NQF^[(LS58)"39OH)@]!+=P\>F_50U-KQ6*-D.V&3WH!^UB:Y!ACR&<$4 MY07C2D>(JK%I)KO#!6!<*R\-$5>_"-9A'-(M%+K#IAW9C!1_.;/[JBY.U2/; M.-"R"U9T:.OJMU)YB4-X,G)[))0PS17NW+\88TER[,-%R[BU&0S7- ME YMMW+RDF')PS<_L[W]ZYA?A/V<)MGLJTW5+[V*Y:>^JF99C\I_QGEW.KQM M_?YW6U ?3L?I\I;U$?K,KUG_8_2[JR1=X3!G3TK% 1F[PI254%?.@5K X'=? M4Y\TKL8Y>ZCV1_]A^JNII=K>2W,C;(AE+^2'Z+)O3492GD0!TT+!]&H*Z3K+ M"ASPY-3<2G9(X:L MH)KH+'6/HY7D.>M8#!;KUADW4M1Z$E%X.Z$ZH**G8FKGDC&-LHE@N!CAA=N* M:7=IZ./ZRZS\-CN5US#_I!,O)2#6VH'F!6\UG MU&$@T^[2\]_Z\$$2_H]XB[%:%7$ M 1F&OY:="$:W8",6Z]ZJ"7HI8'W=U0$V6""Q;\%09P!)>,3]BEUBW_O/TX6& MI0)VA[(JV,,9]HL$P^=Y[)"ONSMK[&KE'= 8#U@>LIU]JS2RFM_(NH!:Q6[V M=#WX;J9TN3P89AJ ')S*T8W<.@<:HI4T&\TDIW!5AWA,[DIRBTZ 1%+6SM?D M$.O#M*&(WLI3@6PFL2FK2]AM*P D;HW M'SXE9O-FI0BP1-!%ZLLA4%&ZRT8*1HNKH WF#SB?K>'GF1]4#F81!WSFT\I- M]XC3M600TZO9G">8&M&>*^ATG)-K)%#YR$%D#CQ)J++\+_+Z\H]JU!.*6Y\V M*$ /Y@\"6>?\, 0HY87X480#,84^GE=$-)?JXCG%6/VTDY&&-;Z80:\IHQ:' MP1HCC(*WU$LEY%5:1RAH]& ,:*T#QCN"7QWF+A.V?E@L!3PX$1Y(.J>4$3SQ MV2X_U#U(G+K$$?7.A%IC:7DHK7%+X_2M.:DI9M4N:XRR<[9-1:P^Y6.A-*U4 MRW50W(S^3<+(Z]A/R5",K^-Z>Y*=JB^V7AC1M<15DM(S>9KV1%07X_2M,7** M634CQRC#8.0$Q,,,3[P(FM\IKC>:RQ +KRH'K9*4!5S0D@Y)23J^>U$[KHT^ MXR.U729NEW!JT%U^B64!T4D)4,@>KM$=3WVB8YOXTPE M#YHW/9#&W"GG8K#VJCJ#_P7F3E.]>2)1<;!'I00OV)\2RCOGV@B0P]O30<$> MI&;/F<\::B7;"B\'Y.&A"WWA)67[:,DBSL,@C(KNX\1W:;(-,SH3%.[\SE.P MO:WV.2NBV9J?HU3GC)[=%'GHP%?!F1Y["IC] /V4?!L>5[^!O/I'Z-E!^2L' MVZ=;KT.>FG01!^<)>_X(QX;/8(W1MKA_-]:DUEZ>J2H,_H[&*]CC:U38)>!6 MD="N9M)T8PW@W:VWQLO57>2%Y*/52C)BZ91L3@G,#&A/"M0:SDDX"N8@R+3Z M'@7>VGO& />6>W9=,)S90U(\O^2B4Z\1>@YY)S=#0;VA$E3V29$.MJ0Q_I4. MP)Q^Q/VMZ?-_AYJ4>EG@_7;N;4*RZ/K"TAO2/4O.=O%L4Z-A;QII!+V9'RK% MG;/&'.-@1L>4D,^URAR5-G:,;^CRRO0<52%LC3%:P#59I)(P>**#-WPOA>Y$KP"".(.*]KCT2UIKG$LDFM8YI .>H]!,G%(_-%@E Q0<1(?V^5.ZQ7ERRU=.O)K MX/=XDZ1Y?1]\W+O:8PIR\<#V>$-%+VV;EP*#E_M 5[V]S0M#O#24OV!4%XEX MF6:[$0=<1S#-,QJQ*- :FP3@VW:)[O,E@&OD^4S2 MITXX5& KFS'11+SXMX+\^9B,GVZ/+\->@.M$\YH@UY$%P)A?3T0]&+SY=+HI MAYXR3Y]5SQ+M.C7*%5ATZZ2HUM<3S;I7%.M!8U?G2T3/NP3K(_(M+A,%VPGH MU<#[R>?%TLX)9PQ1E'2^]&9X.V9W_7"1)G/>% L2WUJ[D-]BCP5ZTV[CE5@' MKB GBY0-P4.;R!=<'VLWV+O#W3PD$\ \).[G C_ER[B7\+]GI436YFU#)=PV M>X2"X'BC0BF(/ZK$"3>>D6"UJN+P&LB23PU.<=I$UB[*;&YXBG =4".IB: MN!H;\\CJ;7?MC$$B:"_82@6T(89("A@I%! 'A"AE6=BZNRG$O*&1H%K#"*M1 MB"3KK:6>PU::*SX(8"MIL(Z/$W+83'.& @)L*BW:*2&!;IJK.>*SK0E!6E^*Z:9LPGYO$BR$];;L24\: MT\"6H8_-,E39SJ,* MOH4ZSH,^#Q!9?W@V@?[JW+JRY]A"+R ]0SUS_!EO%L MW8[:ZW8W%%&]TU1/ON^Q3X,CPE6(@\>$[](-.#*Y)%@DV=<,$4M85D7*BJ@J M@$9N526P2^"8E>&. D_]!^SN<42?'W],VL]*,FO)="/985Q>+Z8'.L*1?9YB M 9)C+IN,7VU/>?F4)M4+:,_$QASJA]A?L5O?L8)F:8E9 ?5R%)\HJX==U,Z MY-UG&)TT@;T\@*":;0+R_?,!.CH]L956#U0#3T ^0WH]=RT\0QX[>.VG!#HJ MGQVDAIF<,.XU-% /[.C$<8Y]Y-S!F?":S SQY"!--SN)@/.4@6+ G"8=.%^9 M(T?0;.^Q:QK)JB!UDV6B& 6Y+*Q&UP.5A_]T-RM3JGV<%N3+6;1BA@^?Y0!W?9$FI<@P9@4D>HE'-:R?1L4%?/C0RXJA9 D]5V M(^JTPN75#*YR-56*?K[ *Z^( 4D2VN'4@+ MBMJ+" 5A5K^!/^FT@'.GTD*CJ7J8%6Y2S8ZJEFW"OR11@--L>- EE_KECV J M6@%.>.10BOXS*L/O%WF>AD\%/\$F,_L[#P;5Z=&L4>OH=&!V"C549;!C')1M MYRP-3I8O5Y^3)&!6X'0;^C3;9A0LMSA]P9XD(XY."U!#C0 [O-"4Y4>H$G/4 M1-4-D54H'*U;7P.J=!$J\4NZ7,A1W=[C#!/Q%T*,"[S%4;*AJVO%(VY*!4#U M;X9S&!G%M9A?:NFA2_VK;@=L)1[;%<;/BH;IRP!J"RFT?O77@H[K^S..<>I% MA#N+8!W&(4U.0>.?%-6O40'4&J9(!]Z*Z[&NT=5TW%K+#:8X:GH)%Q8#(4 M M(L?6;X-:LJIR9VL-=NK2"E00+C7Z0I8S!BI7&E)L@X4&DR2SH$;64:57QU[5 M$T77,3TG*>)NT\X-K5OF+SAM< G= MEUX+= -*P1HV']-OM9TKMW>+\W,O>V&GCP%-I?93A@-B7N66%SX9#Z6;6^;: M@!IS FC1#1):!JH*04\[]!TMA[3M6]0,:DU9CMKWSMNQMX*NDK1]5Z8.JV\. M+X4-/$(=4 M/03W($UB6P:(OOKMK7Q=ZBQZ:B_ZMLAPW\6.R\'\KPA03L(2 M^8X^^DW3'-#M*+;H4[6P7AM@ X\ +6W?/$%E(:@JY0BQ.3)\<.9 "C[B;&V5?X2:G^9?TM&F_UE'H4P)*UA2'*$:&*J0(0H- M<6ROD?NS4QG09LT\=AR(:,[V$>J9])47INR2YT68^5&2%:ED&TBE <@1&0(= M[AW4:D>(*B*FB1I51TU5#J]>U#KY-FPS0U5 C3<6<;\5:WW4CA,P;<[V1S?D M+_)Q]1'Y'WI!E7SR_P%02P,$% @ $D@-4:7]W+[/'@ 4^H! !4 !M M>7-Z+3(P,C P-C,P7W!R92YX;6SM7=USXS:2?[^J^Q]XLW57N0>/OR:3S&QR M6_Z< E$1*!-"@" %RG(>,+:.A[OXU MOKH;C9_^\C))@AFB&2;IS^^.WQ^]"U :D1BGHY_?_?)T?>7__K7?PG8?S_]V\%!<(U1$G\.+DET<),.R9^#NW""/@=?4(IH MF!/ZY^"O85+P3\C?SQ]OV:_EUWT.OG__(0P.#@"=_16E,:&_/-XL.QOG^?3S MX>&W;]_>IV06?B/TM^Q]1&#=/9&"1FC9UV2>_?/?3RY/CDZ.CCZ>'KU_&3*F M+\.<_8E_QOYT]"/[W_'IX/CD\]$/GS^<_A_P>_(P+[+E]QR]'%7_E>0_)3C] M[3/_WW.8H8!!D6:?7S+\\[N:=-].WQ,Z.F2L'1_^_>OM4S1&D_ IQR2"+U; M4/%>VNB./WWZ="C^NFBZT?+EF2:+[S@]7+"S[)G]%2O:USC)\.=,L'=+HC 7 M%J7]FD#:@O]VL&AVP#\Z.#XY.#U^_Y+%[Q;*%QJD)$&/:!CP?YF-++^5X8K_ MB7#,[&)RR/]XR J)BC-S]+X*LUQ/N=HT8E@E@D@>AM3-/SY';>)@Y5%9/&? M(+3Y?,I&2(8GTX0IY+ CES=ICBB>G(<)5^S3&*$\TW&GHK''U4-(F4;&*,=1 MF'1AL;6#7OGE8Q!QW++[X0693"D:HS3#,W1+,JA607W8XWH\%,\$N_.M[2X @CK8I Q/WP>8U3-BOA,+EAZQD5$[V6 M/15-3]KCQGS.UK^83SMLS@&M5&JJ?CB[( (,MEED4+ ED7W3!.<@M0%(>[>] MJQGO_K*@[(L?T91084EL_)'8P @!O?3#>?E%3\5SAGXOV(\#8L@TN(,=C/)> M1OON1OT@?$[TS.HI;;8P=J!!#B'? )U*U)']9W $ 5PWO8Y7[ ?)* =[:CW0%0 M!--^5-RS,W'&NA!6=\L^:) P\T-IC):;#B[%EEX:]C'OH_*G'0<'P8*J_F.8 MQD'915#OH^)\P7M"H@:["7=?$:I3'__D5Q6O9\]LF@NC?-%1$CZC1'3_*Z>% MD1YV89:K-F.Z%1ZU#$7O1V1V&"-\R 7@/PA)#HZ.*W_:G]A'OY9,/*(1YM^= MYMR'V<(Z:]K>PPNF"24+Y,Q>OD?-%>!L-$4B,*Q?S!(I':"PQF3 M(N:27"?AJ%W_:TV >C_Q2>^M4CK1]T5!N8S7.(O"Y']12*_2F$=@VE4O;PU$ MX=0G%'2R.P%D(HT31"_8 M:!T1JMR=KC4$XO"C3S@H)':(P-,D3)+S(L,IRB3CH;4A$(%/_B'0*K%+!,8H M2;BO+4R50Z#9#GPZ\Q" %H$=ZO]J@N@(IZ,OE'S+QP @) 101#P\,"M5X-)] M41YHEL[$,@U.Z<604$#!\>I4#5&"0W1$W@GC',\0VW"'%9\J=&044'2\.FU# ME. 4G8A09C)"#)$;=,$#D'1^06*E-U9#",7*JP.Z@4H<[X;OBLDSHBI\ZJV@ M8'AU7)<)ZW*A(9,)*3/^GL9,[NR^R$6J.IMOE+A"6O#ZZ7!# MT%OV@;4 GS)9N1'8.PD.@F6&)/OY@K"O23,4\Y\RDN"8_2T.J@Z#JL>@ZK*K M.2ZL<1AFSP+#(CL8A>&T-$F4Y-GBDW7;K#[^=61)+^YKZ^T*CV,%!0-IH["QRJ-=P&@T14 M/]#@2=P\F87]P_//9V'"6,W.\HN0TCF;A\5E(#DZ0')GX480$*2+2#Z!^(B8 M1#AB:\N6F:'#91KL5%3.8N-=H ((K\?2#U0- UQ?/7"DTT1&_OW^1A1X& " M$3N+HW; S4 ;?L '!*H;)/T'4KL,)8WR&>]#Q/X8WY922SD4[.4D#Q/1TO&H M(U-$\_E#$I8N K;83OF)ADT3JN&FHG(6E379^$,$]V-DW4]YW0.VY[E%888> M\6C,CIN_L$F!BRG'2$/F+'!K A)(=#]0^AK2WU#.%]@G%!44YQAE=R2-=!.B MCLY=@-<$*)CT?B!5"@3!9K.EN^"NN5-#J?^]7*Q*N71XN8SRFJ/T6K"YQ>$S M3L3 9ZOI9M$$O1L1WH.[./'V?E]3/?DQ9]:X!KN%533NHL==89"BZ+7ON+F! M6G ]UQ[3='3N LYP %1;29DF_$!MX;1Y".=\2S6@88S /JM6(GYA\DA?'1TU&1T6FIH(B9Q^(',6Q\*W&B8/(8YO MTHMPBMF\7&-:<=X&T$+1VX5[I MZN'S_PE%=\AVQPX'CMPEG3S\;FM9PW=(KI'L4U2$CW%'6H M;GJU 1]NU+6_>]"X7G>ZS?6ZX+O&-_SGVW6['9QTF,KOJ6 X%AO_!T3%34_0 MX4=.O+\7\PQTX\9O4- 1D&C>$^)<$ MW_V2AD6,&8W+'4WI&U@RJ]_$2 F<.A!F*"U4,8]5"\<[$(V^-T[^3<%\F?DR M-D%\(206)QU$9SA"V1,[[-S/$!VC4+E]%O9_"BVOQ*W4(L=W MLZ7K"@.FD,IDW7\4JZ?EF*V>Q1.)%'+:A:0M?5"$PQ!FIB_R'?4(S! M NJ^HH$IK%)IMP5RX-FV:!4T#D:$HH& MXI65& M=C0?T##->%ES)E\:B]^2$JSX'T4YCRWUT,U^MOI"YX4>>C<0N/WU@)0?YM@B MGS[Q4TGDO#Z$9;, :&S?%[5%"N0BY>(\S'#$/48X*7)5F%Q+Z+STA&7C &K. MC['_-\2O(Z/X;,9.+:/J(8#[H6"\%E<&H]^U/^?U+"P;Q79Z]C2A+JKR5W=+N*!B)WFG=><3C@ M0P @2=5.-\HWK-W*4#>"9R/CO"E1_7SM R!LF*,;]J/"@]#6UC-@&F8E0Z#& M?KW4@ \HE*;$5Q.2BNNR+Q@"2#O9/F+3+DDMG<3ESK;)VR69A#A5[&?;FWN& MBLKBUO>G[0+50II^Y'I^19(7N%:'L/6FKO.9NL AE;C["9(M9LC]"5)R)U8' MJX;,=9I3%XA!FMA[N/478[70P[MPG1[5R0Q,-;3O)K%^G5:'OZR]ZP2K+F"K M9=]W9'=T\=C^0KUQ7K)_PWB**"8QXX#F'@ )OU#3_1:-_<58"R/@HHP3%/D# MH0*;HX^G1P(9_DDYOI[##,5\LF$KA%#I(TK*Q)[[*?\U^$K2O+?KR;3A,P1 MJNHR9462A^U)';SWOCKW9@V6HM^GM#YY[85,Y56]RX(RM>)S-MB*%&(UR *NQ,[_&Y#L")UG9_< MR_!KJ,%KU*HM0B?8&K2N$Y#[&7*] J?:Y4@,I_SXZ@71"&?H?EBKH/U T77! M0Y>+SU3[G%ZZ=YV!;+#3Z5&=NT6]7G_ !NQ=^G>=Y+P5[MT5ZF"X+XMQ/Z(H M";,,#['8C<.6=OY4[(1GQ4I$D2Z//HS$,!M?)^2;I/C<#UL--=9W(#KW M+Q-]*;?1N&FA%_]^S.4I:AO7LSN4;-^;(PMWZBW!%[/2)C=OW>:+KJX)IL-R".*2!KA M!#48'A"@9O0CW9,/ Q_X-M7NAV%=(@9#A 4(/[X2/%H_$@)TR*LRR3;IN->G"=O[(+$(V58AG@ M69@40L&K2-,EVRC/1*6RK#T7J_F>!UO59HCF^#EA&@K;1FPILX5O$QH/D!TPB8U7DQ=%B+NWIWKI!RG)F*@<$MV(([=*,OY M.^IU#@4?^8H/F=<%3.XZB6=7.)LJU/[X7A5HNTG+LJ;\PND3B@HJ>S5YS6#U M/;C.YW$PBJ%J]6//OBB7( M=.G2;J2[P'7F!S2,T4,XETP@Y4Y'3>0\HVAW6SZ(]GQ?,.1@:^=&8\A?@YL/ MK$D_@(='0?J(YGF0 K5#4S#7[;X7LY1(7)Z)#"-'7?KR)RUKZX@P0&=^S"", M\0BA.+MFNJBYJ9X5T"I(H A:<_QM 0>!"ND5?.%<3(;7A+9R#'J[P*@3*,36 M?'[]06RN.R]W^2N/U2.OGDJ&A3HZJ*2 PFO-Z;<]O%H9?1S W(6_5Y@BIC@ M;(>1SQ^2,.7^9IY9*%X>TX]?2!]0?*WY^GH?OG#-[;]O!ZZ\/G9F!IDZWEN+ MN>9>Z6Z^>D>[E]V\LB^H[=B_6+CU;AZ@,T]6D]H^YA%-JQFRBE.:[>P5Y%!D MK?D MX!)OLO7ZLL/B.&R]S&HO5AS$?9F+UVTY\<M,1'B5%+-[?7&FCU)#<[,]-PCN^WRWE=8L MF3'<*NV7*(-OA'O1I.NJH:_7J PNL9_8KZ"V([-Z15??JT?*E_(T[M;^&!P$ MESB+$I(5%+%?%JT=/L5)1V&*_RED7UWP+=]P?*CIY7Y8+75ALKKR"WBXM9_N M7;Y5NHT$*[ 'S([.&9N_6=)5ZSG#Z3L282X+*J@L9EDK8**," A]([ M'L9ZQ-8SL8WTXL&(6TX1-RD3K&@&ANL#[?AH?: M28,ZK3N;O XQ%77S5EP" M!IB:RN$0:V,,,+(T9(X'% 2CM2$%TH,'(TG.-18L3!X(Z:) [ MO#N_Y(]7]]EX/H$7_,G$Q1-Q6W01N-8/N&W[=5E. ,KZ>9UUP*#=NF/'P[H? M6UFO3M"/MCV8&LIJ+2.41HL+U),)SA5K[-'*K6< D:\:3^.!W@GG%M>NS17G0?#M[:IOYJ)0[0HYON( MIOQ-^$55W_:1?*HZGI:]!65W03Y&P;+/H.JTQZ3*.Y*SG1,Q0>O*5+)DKN0448912N'3YK#$%\?+(25R72=1@LN[6TN2I,8>\'9!+=4.NBY24?TN3"X*RJ2)YK"! M!*!S7<_3;*R %>'':'A@6S):;LQ63QA%I6Z7EZ$O4191/%57_S'OR7E]3],1 MU559?D!]A[[5)*8D93]&Y=&F-%']B%WF(9KVY+P*J"G4797EP?:S+9 X:%:3 M:>PY/X+"B<%W91\N]YFO-:XH+HYF7U'(>8OOTSN24EX3CKL0SL,,9W]=%) ; MH&B<8G;^,0I ;MG_'D]&L!V.Z/:2I&M4_0 .;/@SLMPCGII,G&J.X2/@6 M?C)-R!RAZG6Z]A*#9XG@122;\<(UHY194%SN5828$">1O:]\C5%1ZPAY,.]4 MN<&7* ]Q(IEI9 G%P7<5F<. MY?7[W_=#QA43@@PU+Z<#Z)QYQ. ( B7Q9J%3QFR4RY]IVKL7RZ+/$1MMYK9^ M63/K8J]B,5VTX\>Z=L$=ILMW+.ZI*)P%>F573^ET3>L$"3&4T)N9LLV]J)H@ M3V#7%;R8%E^K@_%\?AXF_'G8IS%"^1=*BBDSJH&Z=C.,6C?R-NS6.Q^A4KSZ M0P5>(-G"ZN89Z"(4\:?L=OW];Q7*77OVS ( MBZUA*XJJ!>J\\)*YLL?_QNS MW3J-QO-;-$/)V0L&V8*:_A4AKA:TMFWP =8JCE&6E=W@^Y),V&D9@"ZL&^] M!IBT#&:8Q*M]O@]@WZ13MO\3(AY_19-G1 '0MA&Y3ESJ9+XR).5:Z5RU8X;H M,\F0^U(P;4*>=('^Q!!Z:ZE3MJ _^2- ?]H%^E-#Z*TE5]F"_O350=]RGEY^ M5N8OM&UO(.?2K7OV)?-CRU//NEGUI'$_W&JU=P1:3L%RZ]#1.=\V](72^A-, M$'6]\FFE]HJTC;D%WKTW&Y0=SC"FRO=CFFECWVB^ 7?@?.?2*W@2PX!IL>=I MR*-00146:8\8;!1E44<,@JJSM\B!XGY.6U(X*)8*HO1EHPAP_X-E\FGV_<(. M2?SUP?MT=81"\0AEJTS"FW21)B.W-\-NG$9533 BVTCI362U/6DN> MQ(RU'X=OJ.H,ZIJPD^F.8 M@%(%?H28)2SJ0LH:,C_@!9@M##"OXL2/3)4\@G*6QI<\+D+$6Y17+]QJD2YR M!")V[0 &V>3&C0&P5O;?Q?N$DH2_^I/&7T/Z&\K%XSL@_/64KAVS7<"'ZF/_ MD:_N8#!)S^()3C'?V>9XAH#P \E=.V*[V("19O;?$*I+I2ANW[E44LLM 4KO MNDA<;T>9-7,QTY_O/B*E4WVS_JG.5>2#7_W-9?3F,GIS&>W,M(KG#,CX#/&\6BCL@B'/R :#EKS-L[4#N[K7[I*Y^!=Z'" MFM?*.].\"R=(YV_74_IA)#L8?""SJ6O&"Z_]LE(8WQK>BV12G;-.0>+:20LU MY#6LM$KP8P5Y"W?:"W>>OH4[W\*=>Q;K^N13G*-#K.LM7E6=I_Z :L<41_" M5:T>,O6"JB#Q8[YUXE5L+*8?'$_-*[;XUN]^.& "9V$$65$AM)[ K#/===@ MDMGQ1ST4SPF.%M46E3ZI]J;0>?0':^%>L$75_5$JN2V]>B,IRPZK40BC=1UY M!T6$&@4*373BQ_;$LRP*2U4*C7#I.4UBG]+?2X]$]D64J+U)RPKM7RC);.3# MJ[[,:9G?;&2R;%A<>:;S6[>D$TPAE2695Y5\Z>]-K:2KJJS0_4^>/M M)!6,"F/.2E'DV$H)@ A^[QV"&A7L?UIO:SGHA3T^4!RAY1^SZJ_9L<("NG4' MM(^/_MG'-NKS9)2WB7!7\#,M.X0M8VT789*@^'Q^%4;C9EM#:S#K&F@9_3L( MK%A&%[7Z825B]A,&K=DP5FV N/WH'6Z;@OH!@*$]K4\ZO0W2S8Z=!;5V/$1E M*O7#/NKOWU2<+M8A!?AJ*K 7R3MH(=JPY*E=F,F /!0T&H>M[CS>LJTA5.,> M.>YDHEA5LO#45"!+U-ML E6L1RZN32&LJK3VAM8CBA">22[NK+VW56_K+BR^ ME9*5DOLQNR\&V%D:EXM/[<6> :(3^0ROIX2BYI]_!:H5RS/]XM'GLWQ9!4PS MY;=20''PR$NBEHBRB6'C5)!#HB* H>.2+@(CETV16 M'5@"F5D74,@\.LR;"VD?,C[]ADE= M"'[O6X60C (HG)D M:P\X$BHH;AZ=^T%RV74%5)/HIEN'OSI+Q?&*K*YD,4W&_RC*IR[807J&,[Y* MREP'_?0-Q=4W5T.?FO6@2! [=O S!TK%8](I5\<$Y_J7>C^LEP@*&CT%;+\5 MU/KRHJ9TC1\A:8W?E2CZ>D"&W?1[8)9^-2R3V*0#Q^G$G=!JGJA-E>7'*LKK MT:^XG9=I[>R4B=E'PZ'<+G5T3E.*.X!!C*3S&,'+)X\HCU?<; M55=7?09EIT'9:Y"/4;#L.BC[WO*()3-(DC.@R.;[AJK"J0(Y *'3$%;%CJZ\ MZ5H[QS>,H9J5!*V:LOA22719! %0/;2EK2>7OEL-2H; [5NISYWI_JU>IR?E M$=[J=;[5ZWPK#;/-\J&M[^*X7.5;?9=6V%Y]?1=K9;+VI[P+Z/P'+/?2K2_7 MY5^DV_A&R9=M].3'\K/S6]664E*V0F(WMZRWKD7G\(J/I824/E"S>^/G#WBO MW5*22I\CM*=[[CNODK#C^V.6[LCT-6I?Y74R2_=A^M(Y]';9GA80\>!FFJ6K M.#U.GQTNJNVI.;Q5$W&W'F]9761/+6Z_*I/T: .@2B6[#F274G$7%_J]X/Y( M8A+#_K@>PZ[BUJO^@IS8"%_WYUDNV2SYUB<#RRE\B*CN5W!;J]*WJ+:?88F= M1;6W'= #]GWZ0%$KP3[A(9/!2KR[#TRTL2$YB2>XJ.U,#Y!?+^@T^=,^F]/> MW)EW6Z]E""H[B'R#4D4>>45B>6).[<^># 5=,DZ-8RM1:[A6I8:]X!)JRI8U MVU1:NT(7K-J80$ :_8I3/"DF*IVN-7$62%G7V89&6V5Q-P5\#5^TJFTV<1:W MT*NV319;!5-T9UE8/-Z\F[T(Q7?5CO52*5N42.FC-(H5OU%G9;<62;%?',7* M1E)]E:5]&];E)HN=T/NV$ +DZ^ %K/["__?,;(-]\O]02P$"% ,4 " 2 M2 U1D0ZFYX-9 #;W0, $0 @ $ ;7ES>BTR,#(P,#8S M,"YX;6Q02P$"% ,4 " 22 U1%T8 5E8- !8AP $0 M@ &R60 ;7ES>BTR,#(P,#8S,"YXBTR,#(P,#8S,%]C86PN>&UL M4$L! A0#% @ $D@-4=TJ\LW'$ )/P !4 ( !^7( M &UYZQF%3 M +J8 @ 5 " ?.# !M>7-Z+3(P,C P-C,P7VQA8BYX;6Q0 M2P$"% ,4 " 22 U1I?W !3Z@$ %0 @ $[M K;7ES>BTR,#(P,#8S,%]P&UL4$L%!@ & 8 B@$ #W3 $! end